

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (I-18)

Report of Reference Committee on Amendments to Constitution and Bylaws

Todd M. Hertzberg, MD, Chair

1
2 Your Reference Committee recommends the following consent calendar for acceptance:

3
4 **RECOMMENDED FOR ADOPTION**

5
6 1. Board of Trustees Report 15 – Specialty Society Representation in the House of
7 Delegates – Five-Year Review
8 2. Council on Ethical and Judicial Affairs Report 1 – Competence, Self-Assessment
9 and Self-Awareness
10 3. Council on Ethical and Judicial Affairs Report 3 – Amendment to E-2.2.1,
11 “Pediatric Decision Making”
12 4. Council on Ethical and Judicial Affairs Report 5 – Physicians’ Freedom of Speech
13 5. Resolution 002 – Protecting the Integrity of Public Health Data Collection

14
15 **RECOMMENDED FOR ADOPTION AS AMENDED**

16
17 6. Board of Trustees Report 14 – Protection of Physician Freedom of Speech
18 7. Resolution 001 – Support of a National Registry for Advance Directives
19 8. Resolution 003 – Mental Health Issues and Use of Psychotropic Drugs for
20 Undocumented Immigrant Children
21 9. Resolution 004 – Opposing the Detention of Migrant Children
22 10. Resolution 005 (Late Resolution 1001) – Affirming the Medical Spectrum of
23 Gender

24
25 **RECOMMENDED FOR REFERRAL**

26
27 11. Council on Ethical and Judicial Affairs Report 2 – Study Aid-in-Dying as End-of-
28 Life Option / The Need to Distinguish “Physician-Assisted Suicide” and “Aid-in-
29 Dying”

30
31 **RECOMMENDED FOR NOT ADOPTION**

32
33 12. Council on Ethical and Judicial Affairs Report 4 – CEJA Role in Implementing H-
34 140.837, “Anti-Harassment Policy”

1 (1) BOARD OF TRUSTEES REPORT 15 – SPECIALTY
2 SOCIETY REPRESENTATION IN THE HOUSE OF
3 DELEGATES – FIVE-YEAR REVIEW

4
5 RECOMMENDATION:

6
7 Madam Speaker, your Reference Committee recommends
8 that the recommendations in Board of Trustees Report 15
9 be adopted and the remainder of the report be filed.

10
11 Board of Trustees Report 15 presents the completed review of the specialty organizations
12 seated in the House of Delegates (HOD) that were scheduled to submit information and
13 materials for the 2018 American Medical Association (AMA) Interim Meeting in compliance
14 with the five-year review process established by the House of Delegates in Policy G-
15 600.020, “Summary of Guidelines for Admission to the House of Delegates for Specialty
16 Societies,” and AMA Bylaw 8.5, “Periodic Review Process.” The Board of Trustees
17 recommends that the following be adopted and the remainder of this report be filed: That
18 the American Academy of Allergy, Asthma & Immunology, American Academy of
19 Ophthalmology, Inc., American Academy of Orthopaedic Surgeons, American Academy
20 of Otolaryngology-Head and Neck Surgery, American Academy of Pain Medicine,
21 American Academy of Pediatrics, American Academy of Physical Medicine &
22 Rehabilitation, American Association of Neurological Surgeons, and the Society of
23 Nuclear Medicine and Molecular Imaging retain representation in the American Medical
24 Association House of Delegates.

25
26 Board of Trustees Report 15 was introduced by the Board of Trustees, and no further
27 testimony was offered. Your Reference Committee recommends that Board of Trustees
28 Report 15 be adopted.

29
30 (2) COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS
31 REPORT 1 – COMPETENCE, SELF-ASSESSMENT AND
32 SELF-AWARENESS

33
34 RECOMMENDATION:

35
36 Madam Speaker, your Reference Committee recommends
37 that the recommendations in Council on Ethical and Judicial
38 Affairs Report 1 be adopted and the remainder of the report
39 be filed.

40
41 Council on Ethical and Judicial Affairs Report 1 examines physicians’ ethical responsibility
42 of commitment to competence and is concerned with a broader notion of competence that
43 deals with a physician’s wisdom and judgment about their own ability to provide safe, high-
44 quality care “in the moment.” The report notes certain influences on clinical reasoning such
45 as heuristics, habits of perception and overconfidence can lead to problems in effective
46 reasoning. Hence, it is important for physicians to develop an informed self-assessment
47 that leads to self-awareness of a physician’s own ability to practice safely in the moment
48 and develop a “mindful practice” over the course of their lifetime to ethically maintain
49 competence. The report proposes guidance to this end.

1 Your Reference Committee heard testimony that was largely supportive of Council on
2 Ethical and Judicial Affairs Report 1. Hesitations were raised regarding circumstances in
3 which physicians no longer possess the self-awareness to accurately assess their own
4 competence, such as in the case of impairment. Testimony argued that impaired
5 physicians should not be considered to be acting unethically. While your Reference
6 Committee is sensitive to these concerns, its judgment is that these issues are duly
7 addressed both by section (f) in the recommendations of this report as well as Opinion E-
8 9.3.2 "Physician Responsibilities to Impaired Colleagues". Therefore, your Reference
9 Committee recommends that Council on Ethical and Judicial Affairs Report 1 be adopted
10 as written.

11
12 (3) COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS
13 REPORT 3 – AMENDMENT TO E-2.2., "PEDIATRIC
14 DECISION MAKING"

15 RECOMMENDATION:

16 Madam Speaker, your Reference Committee recommends
17 that the recommendations in Council on Ethical and Judicial
18 Affairs Report 3 be adopted and the remainder of the report
19 be filed.

20 This report provides ethics guidance for physicians in relation to the concerns expressed
21 in Resolution 3-A-16, "Supporting Autonomy for Patients with Differences in Sex
22 Development (DSD)," responding to Board of Trustees Report 7-I-16 of the same title, and
23 Resolution 13-A-18, "Opposing Surgical Sex Assignment of Infants with Differences of
24 Sex Development. Council on Ethical and Judicial Affairs Report 3 recommends that
25 Opinion E-2.2.1, "Pediatric Decision Making," be amended in lieu of Resolution 3-A-16
26 and 13-A-18, and provides guidance to physicians on providing compassionate, humane
27 care to all pediatric patients, while negotiating with parents/guardians to develop a shared
28 understanding of the patient's medical and psychosocial needs and interests in the context
29 of family relationships and resources. The report considers the continuum of pediatric
30 decision-making between interventions about which there is consensus in the professional
31 community, whose benefits are significant and significantly outweigh the risks they pose,
32 and decisions that carry significant risks of harm or about which currently available
33 evidence suggests offer little prospect of clinical benefit or cannot be reasonably expected
34 to achieve the intended goal. The report also considers whether decisions about DSD
35 should be different from other decisions, and advises seeking a shared understanding of
36 goals for care in creating treatment plans that respect the unique needs, values and
37 preferences of pediatric patients and their families.

38 Testimony on Council on Ethical and Judicial Affairs Report 3 was largely supportive.
39 Critical testimony noted that much of the language of the report was satisfactory, but felt
40 that it lacked adequate language addressing the care of intersex patients. Testimony
41 suggested that the bulleted points on pages 5 and 6 of the report on the topic of decision-
42 making in these circumstances would assuage concerns if it was adopted in the
43 recommendation. All other groups and individuals who testified were satisfied with this
44 report. Additionally, there were several personal testimonies of individuals and families
45 directly affected by congenital adrenal hyperplasia (CAH). These individuals felt that their
46 experiences with shared decision-making were the right choice for them and that surgical

1 treatment decisions were created together with their medical team in contrast to
2 considering such surgeries to be “medically sanctioned violence.” Your Reference
3 Committee noted the majority of testimony was in support of this report and that the report
4 created a very balanced and appropriately broad view of pediatric decision making, one
5 that is applicable beyond those issues related only to intersex and DSD. Therefore, your
6 Reference Committee recommends that Council on Ethical and Judicial Affairs Report 3
7 be adopted and the remainder of the report be filed.

8
9 (4) COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS
10 REPORT 5 – PHYSICIANS’ FREEDOM OF SPEECH

11 RECOMMENDATION:

12
13 Madam Speaker, your Reference Committee recommends
14 that the recommendations in Council on Ethical and Judicial
15 Affairs Report 5 be adopted and the remainder of the report
16 be filed.

17
18 Council on Ethical and Judicial Affairs Report 5 responds to referred Resolution 6-I-17,
19 “Physician’s Freedom of Speech,” which asks the AMA to amend Opinion E-1.2.10,
20 “Political Action by Physicians.” This report references Opinions within the *Code of*
21 *Medical Ethics* that provide guidance with respect to physicians’ rights to express
22 themselves on matters of social and political importance and underscores physicians’
23 rights to due process when their conduct is subjected to disciplinary review. The report
24 also notes that constitutional protection for “freedom of speech” does not apply to private
25 places of employment, and that private employers generally have the power to terminate
26 an employee because of the employee’s speech. The Council views the situation of
27 physicians who express personal views on political and social issues online like that of
28 physicians who participate professionally in the media; physicians should recognize that
29 even when they speak personally, they are likely to be viewed by the public through the
30 lens of their professional status and relationships with health care institutions. The report
31 recommends that Resolution 6-I-17 not be adopted.

32
33 The only testimony heard on Council on Ethical and Judicial Affairs Report 5 was given
34 by the authors of the original resolution, who suggested referral. Your Reference
35 Committee concluded that resolution 6-I-17 is calling for an amendment to ethics policy
36 by making an argument grounded on concerns of First Amendment constitutional rights,
37 which your Reference Committee believes to be a constitutional issue rather than an
38 ethical issue. Further, the resolution’s recommendation is one framed as a constitutional
39 issue of “Freedom of Speech,” but more accurately reflects employment law as the
40 grievance described is one between physicians and their employers and not one of
41 government restrictions of physician speech. Therefore, your Reference Committee
42 recommends that CEJA Report 3 be adopted, but if the authors of Resolution 6-I-17 wish
43 to create House policy, they may submit a new resolution.

1 (5) RESOLUTION 002 – PROTECTING THE INTEGRITY OF
2 PUBLIC HEALTH DATA COLLECTION

3 RECOMMENDATION:

4
5 Madam Speaker, your Reference Committee recommends
6 that Resolution 002 be adopted.7
8 Resolution 002 asks that our AMA advocate for the inclusion of demographic data
9 inclusive of sexual orientation and gender identity in national and state surveys,
10 surveillance systems and health registries. The resolution also asks that our AMA
11 advocate against the removal of such demographic data from these registries without
12 plans for updating measures of these data.13
14 Your Reference Committee heard testimony that unanimously supported Resolution 002.
15 Speakers noted that such data collection is essential to providing high-quality care
16 according to evidence-based medicine, and that efforts to develop guidelines and
17 determine best practices depend on the availability of data about the populations being
18 treated. Your Reference Committee recommends that Resolution 002 be adopted.19
20 (6) BOARD OF TRUSTEES REPORT 14 – PROTECTION OF
21 PHYSICIAN FREEDOM OF SPEECH

22 RECOMMENDATION A:

23
24 Madam Speaker, your Reference Committee recommends
25 that recommendation 1 in Board of Trustees Report 14 be
26 amended by addition and deletion to read as follows:27
28 1. That our American Medical Association ~~strongly oppose support~~ litigation challenging the exercise of a physician's
29 First Amendment right to express opinions ~~regarding relating to~~ medical issues (New HOD Policy)30
31 RECOMMENDATION B:32
33 Madam Speaker, your Reference Committee recommends
34 that Board of Trustees Report 14 be adopted as amended
35 and the remainder of the report be filed.36
37 Board of Trustees Report 14 responds to Resolution 5-I-17, "Protection of Physician
38 Freedom of Speech," which asks that our AMA strongly oppose litigation challenging the
39 exercise of a physician's First Amendment right to express opinions regarding medical
40 issues. The report recommends that AMA policy H-460.895, "Free Speech Applies to
41 Scientific Knowledge," be reaffirmed. The report recommends against the use of the term
42 "good faith" in AMA policy regarding physician opinions on medical issues, as there is no
43 simple test as to whether an opinion has been made in good faith or bad faith. Additionally,
44 the report notes that the AMA Litigation Center is already aware of the possibility that
45 physician members of medical societies may be sued for expressing opinions on medical
46 issues.

1 issues and is committed to taking appropriate steps to assist these societies and their
2 members in the event of litigation.

3
4 Limited testimony supported the premise of the recommendations in Board of Trustees
5 Report 14. Some concern was expressed about the inclusion of the phrase, "regarding
6 medical issues," in Recommendation 1 as it could be seen as unnecessarily restrictive or
7 confusing. Your Reference Committee agrees that our AMA should support physicians'
8 right to express opinions relating to medical issues, but believes that the positive
9 framework as amended, as opposed to opposition of litigation, more appropriately
10 expresses the AMA's role in these matters. Therefore, your Reference Committee
11 recommends that Board of Trustees Report 14 be adopted as amended.

12
13 (7) RESOLUTION 001 – SUPPORT OF A NATIONAL
14 REGISTRY FOR ADVANCE DIRECTIVES

15 RECOMMENDATION A:

16
17 Madam Speaker, your Reference Committee recommends
18 that Resolution 001 be amended by addition to read as
19 follows:

20
21 RESOLVED, that our American Medical Association
22 advocate for the development of model legislation and the
23 establishment and maintenance of a national, no-charge,
24 confidential and secure method for the storage and retrieval
25 of advance directive documents by authorized agents. (New
26 HOD Policy)

27
28 RECOMMENDATION B:

29
30 Madam Speaker, your Reference Committee recommends
31 that Resolution 001 be adopted as amended.

32
33 Resolution 001 asks that our AMA advocate for the establishment and maintenance of a
34 national, no-charge, confidential and secure method for the storage and retrieval of
35 advance directive documents by authorized agents. The resolution notes that Advanced
36 Care Planning (ACP) improves the respect of end-of-life wishes, improves patient and
37 family satisfaction, and is cost-effective, but also that ACP documentation varies by state
38 and region and is often difficult to locate, as no central database for such documentation
39 is readily available for health care providers.

40
41 Your Reference Committee heard testimony that largely supported Resolution 001.
42 Speakers emphasized the importance of honoring patients' preferences for end of life
43 care, and the difficulty often faced when attempting to access this documentation across
44 state lines or even between systems in the same geographic area. It was noted that while
45 a number of states currently have advance directive registries, electronic health record
46 interoperability would be essential for an effective national directory. Some concerns were
47 raised concerning financial and legal challenges involved in creating such a directory,
48 safeguarding the security and integrity of information within it, and ensuring that patients
49 would be given the opportunity, if at all possible, to confirm or change advance directives

1 at the point of care. Your Reference Committee agreed that the development of model
2 legislation would aid in accomplishing the goal of the resolution. Thus, your Reference
3 Committee recommends that Resolution 001 be adopted as amended.

4

5 (8) RESOLUTION 003 – MENTAL HEALTH ISSUES AND USE
6 OF PSYCHOTROPIC DRUGS FOR UNDOCUMENTED
7 IMMIGRANT CHILDREN

8 RECOMMENDATION A:

9

10 Madam Speaker, your Reference Committee recommends
11 that the first Resolve in Resolution 003 be amended by
12 addition and deletion to read as follows:

13

14 RESOLVED, That our American Medical Association
15 officially object to policies separating undocumented
16 immigrant parents ~~and/or~~ guardians from children, as well
17 as ~~allowing policies that prohibit~~ unaccompanied
18 undocumented minors access to the U.S. (New HOD
19 Policy); and be it further

20

21 RECOMMENDATION B:

22

23 Madam Speaker, your Reference Committee recommends
24 that the second Resolve in Resolution 003 be amended by
25 addition and deletion to read as follows:

26

27 RESOLVED, That our AMA ~~condemn only support~~ the
28 practice of administering psychotropic drugs to immigrant
29 children ~~without when there has been evaluation by~~
30 ~~appropriate medical personnel, and with~~ parental or
31 guardian consent or court order except in the case of
32 imminent danger to self or others (New HOD Policy); and be
33 it further

34

35 RECOMMENDATION C:

36

37 Madam Speaker, your Reference Committee recommends
38 that the third Resolve in Resolution 003 be amended by
39 addition and deletion to read as follows:

40

41 RESOLVED, That our AMA support a position ~~whereby~~
42 ~~federal immigration officials would become more aware of~~
43 ~~the emotional decompensation in this immigrant population,~~
44 ~~with the establishment of policies designed to decrease~~
45 ~~stress and emotional trauma.~~ (New HOD Policy)

46

47 RESOLVED, That our AMA (1) support education for
48 immigration officials regarding increased risk of sexual
49 assault and sexual trauma amongst unaccompanied minor

1 immigrant children, as well as the emotional
2 decompensation in this immigrant population due to these
3 abuses and other traumas, and (2) encourage policies
4 designed to decrease incidence of sexual assault, increase
5 reporting and timely access to treatment services, and
6 decrease stress and emotional trauma.

7

8 RECOMMENDATION D:

9

10 Madam Speaker, you Reference Committee recommends
11 that Resolution 003 be adopted as amended.

12

13 Resolution 003 asks that our AMA officially object to policies separating undocumented
14 immigrant parents/guardians from their children, as well as allowing unaccompanied
15 minors access to the United States. The resolution also urges our AMA to condemn the
16 practice of administering psychotropic drugs to immigrant children without parental or
17 guardian consent or court order, except in cases of imminent danger to self or others. In
18 addition, the resolution asks our AMA to support a position whereby federal immigration
19 officials become more aware of emotional decompensation in this immigrant population
20 with the establishment of policies designed to decrease stress and emotional trauma.

21

22 Testimony reflected almost unanimous support of the spirit of Resolution 003, with
23 speakers emphasizing the trauma experienced by both parents and children when the
24 family is separated. Amendments were offered to clarify the intent of the first and second
25 Resolve clauses, particularly regarding the necessity of medical evaluation in cases when
26 immigrant children are administered psychotropic drugs. Your Reference Committee also
27 heard significant testimony regarding sexual trauma and felt that combining this into the
28 third Resolve clause effectively addressed

29

30 the intent of the original third Resolve as well as these additional concerns. Your
31 Reference Committee recommends that Resolution 003 be adopted as amended.

32

33 (9) RESOLUTION 004 – OPPOSING THE DETENTION OF
34 MIGRANT CHILDREN

35

36 RECOMMENDATION:

37

38 Madam Speaker, your Reference Committee recommends
39 that the third Resolve in Resolution 004 be amended by
40 addition and deletion to read as follows:

41

42 RESOLVED, That our AMA urge that continuity of care for
43 all migrant children released from such detention facilities.
44 ~~be provided with indicated follow-up health care to ensure~~
45 ~~their welfare following these experiences.~~ (New HOD
46 Policy)

47

48 Resolution 004 asks that our AMA oppose the separation of migrant children from their
49 families and any effort to end or weaken the Flores Settlement, which requires the U.S.
50 government to release undocumented children “without unnecessary delay” when

1 detention is not required for the protection and safety of that child, and that those children
2 that remain in custody must be placed in the “least restrictive setting” possible. The
3 resolution also asks our AMA to support the humane treatment of all undocumented
4 children by advocating for regular, unannounced auditing of the medical conditions and
5 services at all detention facilities by a non-governmental third party with medical expertise
6 in the care of vulnerable children. Additionally, the resolution requests that our AMA urge
7 that all children released from such detention be provided with indicated follow-up health
8 care to ensure their welfare following these experiences.
9

10 Your Reference Committee heard widespread support for Resolution 004, focusing on the
11 goal of ensuring quality health care for all patients in confined settings and the scrutiny of
12 detention centers in general. A suggestion for referral was made in light of the complexity
13 of the treatment of migrant children. However, due to the urgent nature of the Flores
14 Settlement currently being threatened, your Reference Committee developed amended
15 language in lieu of referral. Therefore, your Reference Committee recommends that
16 Resolution 004 be adopted as amended.
17

18 (10) RESOLUTION 005 (LATE RESOLUTION 1001) –
19 AFFIRMING THE MEDICAL SPECTRUM OF GENDER

20 RECOMMENDATION A:

21 Madam Speaker, your Reference Committee recommends
22 that the second resolve in Resolution 005 be amended by
23 addition and deletion to read as follows:
24

25 ~~RESOLVED, That our AMA oppose any effort to prohibit the
reassignment of an individual's sex. (New HOD Policy)~~

26 ~~RESOLVED, That our AMA oppose any efforts to deny an
individual's right to determine their stated sex marker or
gender identity. (New HOD Policy)~~

27 RECOMMENDATION B:

28 Madam Speaker, your Reference Committee recommends
29 that Resolution 005 be adopted as amended.

30 Resolution 005 asks that AMA Policy D-295.312, “Medical Spectrum of Gender,” be
31 amended. The resolution asks our AMA to educate state and federal policymakers and
32 legislators on and advocate for policies addressing the medical spectrum of gender
33 identity to ensure access to quality health care. The resolution also asks that our AMA
34 affirm that an individual’s genotypic sex, phenotypic sex, sexual orientation, gender and
35 gender identity are not always aligned or indicative of the other, and that gender for many
36 individuals may differ from the sex assigned at birth.
37

38 Testimony for Resolution 005 offered nearly unanimous support, with speakers noting the
39 ongoing difficulties faced by transgender individuals and how an improved social and
40 structural support system might ameliorate some of those difficulties. Testimony
41 suggested that any proposal to limit or narrow the definition of sex would lead to public
42

1 health consequences, and that it is essential to acknowledge that gender is fluid and that
2 gender identity does not always match sex at birth. Some speakers noted that the original
3 phrasing of the second resolve may have been problematic, and the above amendments
4 were offered and supported by subsequent speakers. Your Reference Committee
5 recommends that Resolution 005 be adopted as amended.

6

7 (11) COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS
8 REPORT 2 – STUDY AID-IN-DYING AS END-OF-LIFE
9 OPTION / THE NEED TO DISTINGUISH “PHYSICIAN-
10 ASSISTED SUICIDE” AND “AID-IN-DYING”

11 RECOMMENDATION:

12

13 Madam Speaker, your Reference Committee recommends
14 that Council on Ethical and Judicial Affairs Report 2 be
15 referred.

16

17 Council on Ethical and Judicial Affairs Report 2 responds to Resolution 15-A-15, “Study
18 Aid-in-Dying as End-of-Life Option,” and Resolution 14- A-17, “The Need to Distinguish
19 between ‘Physician-Assisted Suicide’ and ‘Aid in Dying’.” Resolution 15-A-15 asks that the
20 Council on Ethical and Judicial Affairs study medical aid-in-dying and make a
21 recommendation regarding the AMA taking a neutral stance; Resolution 14-A-17 asks that
22 AMA define and clearly distinguish “physician assisted suicide” and “aid in dying” for use
23 in all AMA policy and position statements. This report holds that the terms ‘aid in dying’
24 and ‘physician-assisted suicide’ reflect different ethical perspectives. The Council finds
25 “physician assisted suicide” to be the most precise term and urges that it be used by the
26 AMA. Importantly, the report explains that there are irreducible differences in moral
27 perspectives regarding the issue of physician-assisted suicide, such that both sides share
28 common commitment to “compassion and respect for human dignity and rights” (see
29 Principle I of the AMA Principles of Medical Ethics), but draw different moral conclusions
30 from these shared commitments. The report considers the risks of unintended
31 consequences of physician-assisted suicide, noting that there is debate about the
32 available data. The report argues that where physician-assisted suicide is legal,
33 safeguards can and should be improved to mitigate risk. The report further notes that too
34 often physicians and patients do not have the conversations they should about death and
35 dying and that physicians should be skillful in engaging in these difficult conversations and
36 knowledgeable about the options available to terminally ill patients. The report concludes
37 that in existing opinions on physician-assisted suicide and the exercise of conscience, the
38 *Code of Medical Ethics* offers sufficient guidance to support physicians and the patients
39 they serve in making well-considered, mutually respectful decisions about legally available
40 options for care at the end of life while respecting the intimacy of a patient-physician
41 relationship. Thus, the report recommends that the *Code* not be amended, and that
42 Resolutions 15-A-16 and 14-A-17 not be adopted.

43

44 Your Reference Committee heard extensive mixed testimony regarding Council on Ethical
45 and Judicial Affairs Report 2. There was broad agreement that the Council had written a
46 strong report that thoroughly examines the issues under consideration, including focusing
47 on the shared values of care, compassion, respect, and dignity. Testimony offered a great
48 deal of support for keeping the current *Code* unchanged. However, your Reference
49 Committee also heard a significant amount of testimony questioning whether the

1 conclusions of the report were supported by its body, specifically urging reexamination of
2 opinion E-5.7, which states that, "physician-assisted suicide is fundamentally incompatible
3 with the physician's role as healer" in order to acknowledge that physicians have other
4 roles beyond healer that may be incongruent with each other. Your Reference Committee
5 therefore recommends that Council on Ethical and Judicial Affairs Report 2 be referred.

6

7 (12) COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS
8 REPORT 4 – CEJA ROLE IN IMPLEMENTING H-140.837,
9 "ANTI-HARASSMENT POLICY"

10

11 RECOMMENDATION:

12

13 Madam Speaker, your Reference Committee recommends
14 that the recommendations in Council on Ethical and Judicial
15 Affairs Report 4 not be adopted.

16

17 Council on Ethical and Judicial Affairs Report 4 recommends that provision (3) of AMA
18 Policy H-140.837, "Anti-Harassment Policy," be rescinded and that the process for
19 implementing the AMA's anti-harassment policy be referred to the Board of Trustees for
20 further study. At the 2018 Annual Meeting, the House of Delegates adopted with
21 amendment Board of Trustees Report 20-A-18, "Anti-Harassment Policy," giving the
22 Council on Ethical and Judicial Affairs the authority and responsibility to take disciplinary
23 action regarding allegations of harassment during meetings associated with the AMA. The
24 report notes that the Council on Ethical and Judicial Affairs believes promoting safe
25 engagement among all attendees during professional meetings affiliated with the AMA is
26 an urgent organizational responsibility. However, the responsibility to adjudicate
27 allegations of harassment is qualitatively different from the Council on Ethical and Judicial
28 Affairs' normal judicial function and demands a different set of skills. The Council also
29 expressed doubt that it possessed the resources or flexibility necessary to carry out this
30 new role effectively, and is concerned that such a role could undermine confidence in the
31 Council, to the detriment of both its judicial and policy work.

32

33 Your Reference Committee heard generally negative testimony on Council on Ethical and
34 Judicial Affairs Report 3. Speakers suggested that the judicial function assigned to the
35 Council on Ethical and Judicial Affairs in AMA Policy H-140.837 is not unreasonable given
36 the Council's role as outlined in AMA Bylaws. Testimony also questioned the Council's
37 concern about a potential investigatory role, noting that such activities would be conducted
38 by the Human Resources of the AMA, with adjudication appropriately being handled by
39 the Council. Your Reference Committee acknowledges the Council on Ethical and Judicial
40 Affairs' significant concerns about their ability and resources to effectively carry out the
41 role outlined in AMA policy as written, and strongly urges our Board of Trustees to further
42 examine the process. However, since adoption of this report would eliminate the only
43 current AMA process regarding adjudication of harassment claims at AMA meetings, your
44 Reference Committee recommends that Council on Ethical and Judicial Affairs Report 4
45 not be adopted.

1
1 Madam Speaker, this concludes the report of Reference Committee on Amendments to
2 Constitution and Bylaws. I would like to thank Mark Ard, MD, Jayne Courts, MD, Keith
3 E. Davis, MD, Sean Figy, MD, Dionne Hart, MD, Spiro Spanakis, DO, and all those who
4 testified before the Committee.

Mark Ard, MD
California

Sean Figy, MD
Resident & Fellow Section

Jayne E. Courts, MD (Alternate)
Michigan

Dionne Hart, MD
Minority Affairs Section

Keith E. Davis, MD (Alternate)
Idaho

Spiro Spanakis, DO (Alternate)
Massachusetts

Todd M. Hertzberg, MD
Pennsylvania
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (I-18)

Report of Reference Committee B

Francis P. MacMillan, Jr., MD, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:

2 **RECOMMENDED FOR ADOPTION**

3

4 1. Board of Trustees Report 4 – Increased Use of Body-Worn Cameras by Law
5 Enforcement Officers (Resolution 208-I-17)

6 2. Board of Trustees Report 8 – 340B Drug Discount Program (Resolution 225-A-18
7 Resolve 3)

8 3. Resolution 201 – Reimbursement for Services Rendered During Pendency of
9 Physician's Credentialing Application

10 4. Resolution 207 – Defense of Affirmative Action

11 5. Resolution 209 – Sexual Assault Education and Prevention in Public Schools

12 6. Resolution 217 – Opposition to Medicare Part B to Part D Changes

13 7. Resolution 226 – Support for Interoperability of Clinical Data

14 8. Resolution 229 – Addressing Surgery Performed by Optometrists

15

16 **RECOMMENDED FOR ADOPTION AS AMENDED**

17

18 9. Board of Trustees Report 5 – Exclusive State Control of Methadone Clinics
19 (Resolution 211-I-17)

20 10. Board of Trustees Report 7 – Advocacy for Seamless Interface Between
21 Physicians Electronic Health Records (EHRs), Pharmacies and Prescription Drug
22 Monitoring Programs (PDMPs) (Resolution 212-A-17; BOT Report 12-A-18)

23 11. Board of Trustees Report 11 – Violence Prevention (Resolution 419-A-18,
24 Resolves 1 and 3)
25 Resolution 214 – A Public Health Case for Firearm Regulation
26 Resolution 233 – Opposing Unregulated, Non-Commercial Firearm
27 Manufacturing

28 12. Resolution 205 – Legalization of the Deferred Action for Legal Childhood Arrival
29 (DALCA)

30 13. Resolution 208 – Increasing Access to Broadband Internet to Reduce Health
31 Disparities

32 14. Resolution 211 – Eliminating Barriers to Automated External Defibrillator Use

33 15. Resolution 212 – Development and Implementation of Guidelines for
34 Responsible Media Coverage of Mass Shootings

35 16. Resolution 216 – Medicare Part B Competitive Acquisition Program (CAP)

36 17. Resolution 220 – Supporting Mental Health Training Programs for Corrections
37 Officers and Crisis Intervention Teams for Law Enforcement

38 18. Resolution 224 – Fairness in the Centers for Medicare & Medicaid Services
39 Authorized Quality Improvement Organization's (QIO) Medical Care Review
40 Process

41 19. Resolution 232 – Opposition to Mandatory Licensing Requirements for Qualified
42 Clinical Data Registries

43

1 20. Resolution 235 – Inappropriate Use Of CDC Guidelines For Prescribing Opioids
2

3 **RECOMMENDED FOR REFERRAL**

4
5 21. Resolution 202 – Enabling Methadone Treatment of Opioid Use Disorder in
6 Primary Care Settings

7 22. Resolution 204 – Restriction on IMG Moonlighting

8 23. Resolution 206 – Repealing Potential Penalties Associated with MIPS
9 Resolution 231 – Reducing the Regulatory Burden in Health Care

10
11 **RECOMMENDED FOR REFERRAL FOR DECISION**

12
13 24. Resolution 210 – Forced Organ Harvesting for Transplantation

14
15 **RECOMMENDED FOR NOT ADOPTION**

16
17 25. Resolution 215 – Extending the Medical Home to Meet Families Wherever They
18 Go

19 26. Resolution 230 – Nonprofit Hospitals and Network Health Systems

20 27. Resolution 234 – Negligent Credentialing Actions Against Hospitals

21
22 **RECOMMENDED FOR REAFFIRMATION IN LIEU OF**

23
24 28. Resolution 218 – Alternatives to Tort for Medical Liability

25 29. Resolution 225 – “Surprise” Out of Network Bills

26 30. Resolution 228 – Medication Assisted Treatment

27
28 Resolutions handled via the Reaffirmation Consent Calendar:

29
30 Resolution 203 – Support for the Development and Distribution of HIPAA-
31 Compliant Communication Technologies

32 Resolution 213 – Increasing Firearm Safety to Prevent Accidental Child Deaths

33 Resolution 219 – Promotion and Education of Breastfeeding

34 Resolution 221 – Regulatory Relief from Burdensome CMS "HPI" EHR
35 Requirements

36 Resolution 222 – Patient Privacy Invasion by the Submission of Fully Identified
37 Quality Measure Data to CMS

38 Resolution 223 – Permanent Reauthorization of the State Children’s Health
39 Insurance Program

1 (1) BOARD OF TRUSTEES REPORT 4 – INCREASED USE OF
2 BODY-WORN CAMERAS BY LAW ENFORCEMENT
3 OFFICERS (RESOLUTION 208-I-17)

4
5 RECOMMENDATION:
6

7 Madam Speaker, your Reference Committee recommends that
8 the Recommendation in Board of Trustees Report 4 be adopted
9 and the remainder of the report be filed.

10
11 The Board of Trustees recommends that the following be adopted in lieu of Resolution 208-
12 1-17, and that the remainder of the report be filed. That our American Medical Association
13 work with interested state and national medical specialty societies to support state legislation
14 and/or regulation that would encourage the use of body-worn camera programs for law
15 enforcement officers and fund the purchase of body-worn cameras, training for officers and
16 technical assistance for law enforcement agencies.

17
18 Your Reference Committee commends the Board of Trustees for an excellent and thorough
19 board report. Your Reference Committee heard testimony largely in support of Board of
20 Trustees Report 4. There was some testimony questioning whether the issues being raised
21 were outside the expertise and scope of our AMA. The majority of the testimony, however,
22 emphasized that the use of body-worn cameras by law enforcement was a matter of public
23 health and directly related to existing AMA policy. The issues raised by this report are critical
24 and very timely. Your Reference Committee agrees with testimony urging adoption,
25 recognizing that there are nuances that will need to be addressed as our AMA works with
26 interested state and specialty societies during any given state legislative and/or regulatory
27 process. Your Reference Committee, therefore, recommends that Board of Trustees Report
28 4 be adopted.

29
30 (2) BOARD OF TRUSTEES REPORT 8 – 340B DRUG
31 DISCOUNT PROGRAM (RESOLUTION 225-A-18 RESOLVE
32 3)

33
34 RECOMMENDATION:

35
36 Madam Speaker, your Reference Committee recommends that
37 the Recommendation in Board of Trustees Report 4 be adopted
38 and the remainder of the report be filed.

39
40 The Board of Trustees recommends that the following recommendations be adopted in lieu
41 of the third resolve Resolution 225-A-18 and the remainder of this report be filed 1. That our
42 American Medical Association support a revised 340B drug discount program covered entity
43 eligibility formula, which appropriately captures the level of outpatient charity care provided by
44 hospitals, as well as standalone community practices. (New HOD Policy) 2. Our AMA will
45 confer with national medical specialty societies on providing policymakers with specific
46 recommended covered entity criteria for the 340B drug discount program. (Directive to Take
47 Action)

48
49 Your Reference Committee heard overwhelmingly supportive testimony on Board of Trustees
50 Report 8. Your Reference Committee heard testimony that there should be equity in payment
51 between community practice providers and those affiliated with hospitals. Your Reference

1 Committee also heard testimony that the 340B rebate program should ultimately benefit
2 patients who are underinsured or uninsured by providing rebates to those providers who
3 actually provide medical care and treatment to them. Additionally, your Reference Committee
4 heard testimony encouraging the collaboration with appropriate stakeholders when crafting
5 and providing recommendations on covered entity criteria in the 340B discount program to
6 policymakers. Accordingly, your Reference Committee recommends that Board of Trustees
7 Report 8 be adopted.

8
9 (3) RESOLUTION 201 – REIMBURSEMENT FOR SERVICES
10 RENDERED DURING PENDENCY OF PHYSICIAN'S
11 CREDENTIALING APPLICATION

12 RECOMMENDATION:

13 Madam Speaker, your Reference Committee recommends that
14 Resolution 201 be adopted.

15 Resolution 201 asks that our American Medical Association develop model state legislation
16 for physicians being credentialed by a health plan to treat patients and retroactively receive
17 payments if they are ultimately credentialed. (Directive to Take Action)

18 Your Reference Committee heard strong testimony in support of the issues raised related to
19 Resolution 201 and therefore recommends adoption.

20
21 (4) RESOLUTION 207 – DEFENSE OF AFFIRMATIVE ACTION

22 RECOMMENDATION:

23 Madam Speaker, your Reference Committee recommends that
24 Resolution 207 be adopted.

25 Resolution 207 asks that our American Medical Association oppose legislation that would
26 undermine institutions' ability to properly employ affirmative action to promote a diverse
27 student population. (New HOD Policy)

28 Your Reference Committee heard supportive testimony for Resolution 207. Your Reference
29 Committee heard testimony that our AMA does have existing policy in support of creating a
30 diverse student population. Your Reference Committee heard testimony that our AMA filed
31 amicus briefs in *Fisher v. University of Texas at Austin*, and argued that racial diversity is a
32 vital component of a successful medical education and that medical school admission officers
33 should be allowed to consider applicants' race in order to achieve the schools' educational
34 goals. Your Reference Committee also heard testimony that existing AMA policy falls short in
35 addressing the necessity of affirmative action as mechanism for equality at the undergraduate
36 level, which is necessary to bolster the pool of minority students able to apply to a medical
37 program. Your Reference Committee agrees with this testimony and recommends adoption.

1 (5) RESOLUTION 209 – SEXUAL ASSAULT EDUCATION AND
2 PREVENTION IN PUBLIC SCHOOLS

3 RECOMMENDATION:

4 Madam Speaker, your Reference Committee recommends that
5 Resolution 209 be adopted.

6 Resolution 209 asks that our American Medical Association support state legislation
7 mandating that public middle and high school health education programs include age
8 appropriate information on sexual assault education and prevention, including but not limited
9 to topics of consent and sexual bullying. (Directive to Take Action)

10 Your Reference Committee heard overwhelming testimony in support of Resolution 209. The
11 issues raised by Resolution 209 are both urgent and timely. Your Reference Committee,
12 therefore, recommends adoption.

13 (6) RESOLUTION 217 – OPPOSITION TO MEDICARE PART B
14 TO PART D CHANGES

15 RECOMMENDATION:

16 Madam Speaker, your Reference Committee recommends that
17 Resolution 217 be adopted.

18 Resolution 217 asks that our American Medical Association advocate against Medicare
19 changes which would recategorize Medicare Part B drugs into Part D. (New HOD Policy)

20 Your Reference Committee heard overwhelmingly supportive testimony on Resolution 217.
21 Your Reference Committee heard testimony that Congress and the Administration must do
22 more to address the high cost of physician administered drugs and access challenges. Your
23 Reference Committee also heard testimony that the Administration's proposal to move some
24 drugs from the Medicare Part B benefit to the Part D benefit will not result in lower costs to
25 Medicare beneficiaries and may disrupt the chain of custody needed to ensure that physician
26 administered drugs have not been adulterated or subjected to conditions that degrade the
27 efficacy or undermine the safety of the treatment. Accordingly, your Reference Committee
28 recommends adoption of Resolution 217.

29 (7) RESOLUTION 226 – SUPPORT FOR INTEROPERABILITY
30 OF CLINICAL DATA

31 RECOMMENDATION:

32 Madam Speaker, your Reference Committee recommends that
33 Resolution 226 be adopted.

34 Resolution 226 asks that our American Medical Association review and advocate for the
35 implementation of appropriate recommendations from the "Consensus Statement: Feature
36 and Function Recommendations to Optimize Clinician Usability of Direct Interoperability to
37 Enhance Patient Care," a physician-directed set of recommendations, to EHR vendors and

1 relevant federal offices such as, but not limited to, the Office of the National Coordinator, and
2 the Centers for Medicare and Medicaid Services. (Directive to Take Action)

3

4 Your Reference Committee heard supportive testimony on Resolution 226. Your Reference
5 Committee heard testimony that our AMA has strong policy regarding the development and
6 adoption of universal Electronic Health Records interoperability standards. Your Reference
7 Committee also heard testimony that our AMA is working to eliminate unjustified information
8 blocking and excessive costs which prevent data exchange. Your Reference Committee
9 further heard testimony that Resolution 226 would complement this existing AMA policy. You
10 Reference Committee also heard testimony in support of referral because Resolution 226
11 references a document outside our AMA's control. Your Reference Committee understands
12 these concerns but would note that the Resolution 226 explicitly state that our AMA only
13 advocate for appropriate recommendations in the document. Your Reference Committee
14 believes that it is a better use of our AMA resources to have our AMA advocate directly to
15 Office of the National Coordinator to promote interoperability on the appropriate
16 recommendations rather than drafting a report on interoperability. Accordingly, your
17 Reference Committee recommends that Resolution 226 be adopted.

18

19 (8) RESOLUTION 229 – ADDRESSING SURGERY
20 PERFORMED BY OPTOMETRISTS

21

22 RECOMMENDATION:

23

24 Madam Speaker, your Reference Committee recommends that
25 Resolution 229 be adopted.

26

27 Resolution 229 asks that our American Medical Association support legislation prohibiting
28 optometrists from performing surgical procedures as defined by AMA policies H-475.983,
29 "Definition of Surgery," and H-475.988, "Laser Surgery" (New HOD Policy); and be it further
30 that our AMA encourage state medical associations to support state legislation and
31 rulemaking prohibiting optometrists from performing surgical procedures as defined by AMA
32 policies H-475.983, "Definition of Surgery," and H-475.988, "Laser Surgery". (New HOD
33 Policy).

34

35 Your Reference Committee heard overwhelming supportive testimony on Resolution 229 and
36 therefore recommends adoption.

1 (9) BOARD OF TRUSTEES REPORT 5 – EXCLUSIVE STATE
2 CONTROL OF METHADONE CLINICS (RESOLUTION 211-I-
3 17)

4
5 RECOMMENDATION A:

6
7 Madam Speaker, your Reference Committee recommends that
8 the Recommendation 1 of Board of Trustees Report 5 be
9 amended by deletion to read as follows:

10
11 1. That our American Medical Association (AMA) support the
12 right of federally certified Opioid Treatment Programs (OTPs) to
13 be located ~~within residential, commercial and any other areas~~
14 where there is a demonstrated medical need; (New HOD Policy)

15
16 RECOMMENDATION B:

17
18 Madam Speaker, your Reference Committee recommends that
19 the Recommendation in Board of Trustee Report 5 be adopted
20 as amended and the remainder of the report be filed.

21
22 The Board of Trustees recommends that the following recommendation be adopted in lieu of
23 Resolution 211-1-17, and that the remainder of the report be filed. 1. That our American
24 Medical Association (AMA) support the right of federally certified Opioid Treatment Programs
25 (OTPs) to be located within residential, commercial and any other areas where there is a
26 demonstrated medical need; (New HOD Policy) 2. That our AMA encourage state
27 governments to collaborate with health insurance companies and other payers, state medical
28 societies, national medical specialty societies, OTPs and other health care organizations to
29 develop and disseminate resources that identify where OTP providers operate in a state and
30 take part in surveillance efforts to obtain timely and comprehensive data to inform treatment
31 opportunities; and (New HOD Policy) 3. That our AMA advocate for the federal agencies
32 responsible for approving opioid treatment programs to consider the views of state and local
33 stakeholders when making decisions about OTP locations and policies. (New HOD Policy)

34
35 Your Reference Committee heard supportive testimony on Board of Trustees Report 5. While
36 there was some testimony suggesting that states should be the sole arbiter of how Opioid
37 Treatment Programs (OTPs) should operate, your Reference Committee heard testimony that
38 strong data exists suggesting that OTPs are providing high-quality, evidence-based care to
39 hundreds of thousands of patients under a federal structure. Your Reference Committee
40 heard additional testimony that this federal structure appears to provide consistency while
41 also leaving many areas governing medical practice to state control. This information in the
42 Board Report and the testimony provided by proponents of the recommendations strongly
43 suggests that OTPs are one area where state and federal efforts are working well together.
44 Your Reference Committee heard further testimony that improvements to this structure can
45 be made. Your Reference Committee agrees with the Board that all stakeholders must work
46 together to an even greater extent to ensure that OTPs can prosper to an even greater extent
47 so that patients with an opioid use disorder have greater access to care. Your Reference
48 Committee heard testimony concerning retaining local control over placement of OTPs in
49 residential and commercial areas.

1 Your Reference Committee heard testimony that an additional Recommendation should be
2 added to the Board of Trustees Report 5 that our AMA support aligning 42 CFR Part 2 privacy
3 protections with current HIPAA regulations in an effort to promote improved coordination of
4 care for patients being treated for substance use disorder (SUD). Others testifying against
5 alignment stated that our AMA has strong policy protecting the confidentiality of patient
6 records and privacy rights of patients with SUD and that our AMA shares the goal of ensuring
7 that physicians have a patient's entire medical record to review and care for their patients.
8 Furthermore, your Reference Committee heard that 113 patient and provider groups oppose
9 alignment stating that federal SUD confidentiality rules must be maintained to protect patient
10 privacy and to encourage those with opioid and other substance use disorders to enter
11 treatment.

12
13 Testimony stated that our AMA encourages patients to consent to share SUD information to
14 help clinicians provide coordinated and holistic care. Your Reference Committee heard
15 testimony that our AMA believes that to balance privacy with access to information, and to
16 have truly coordinated care, patients must be willing and active participants. Testimony further
17 indicated that patients who refuse to sign a consent are the very patients who would be
18 deterred from seeking treatment if the laws were aligned, and, consequently, those patients
19 would be kept out of the treatment system without even providing them a chance to better
20 understand the benefits of providing consent.

21
22 Your Reference Committee heard further testimony that harmonization could negatively
23 impact privacy of a vulnerable population. SUDs are widely stigmatized and disclosure of
24 SUD-related information can have serious consequences for the patient. Testimony noted that
25 there exists significant confusion and misunderstanding of how Part 2 allows information to
26 be shared among clinicians and other parties, including payers, Accountable Care
27 Organizations, and Health Information Exchanges. Clarifying guidance and regulations would
28 be a meaningful step to help providers, payers, and patients understand rights and obligations
29 under the current law as well as existing opportunities for information sharing. Your Reference
30 Committee heard testimony that while Part 2 will not give SUD information to a hospital in
31 emergency, HIPAA is also permissive, so alignment of Part 2 and HIPAA will not compel a
32 Part 2 program to give SUD information to an emergency room physician. Your Reference
33 Committee also heard testimony that there are workable solutions to electronically track
34 patient consent through EHRs that would be more effective in providing physicians with
35 access to sensitive medical records while maintaining robust patient privacy protections.

36
37 Your Reference Committee heard testimony raising concerns that alignment of the two laws
38 may not actually accomplish the goals of a professional being fully informed including:

- 39 • The current state of interoperability doesn't allow a physician to electronically access
40 all of a patient's information, often requiring physicians to resort to fax or paper
41 records. Many Part 2 facilities do not have EHRs. In most cases, alignment would not
42 change the availability of SUD information.
- 43 • Many states have adopted their own laws restricting disclosure of sensitive medical
44 information. Alignment will not preempt these more restrictive laws, which will further
45 confuse patients and clinicians about how SUD information can be shared.
- 46 • If a patient's medical record needs to be shared for any reason other than for
47 treatment, payment, or health care operations, a physician must remove all mentions
48 of SUD information, which will be highly burdensome and time-consuming for a
49 physician, likely needing to be done by hand.

1 Therefore, given the complexity and the differing views, your Reference Committee believes
2 that adding an additional Recommendation about aligning Part 2 with HIPAA to a Board of
3 Trustees Report regarding the exclusive state control of methadone clinics would not allow
4 our AMA and other interested physician groups the opportunity to fully consider this important
5 issue that directly implicates the access to appropriate treatment as well as strong patient
6 privacy protections. Accordingly, your Reference Committee recommends that Board of
7 Trustees Report 7 be adopted as amended.

8

9 (10) BOARD OF TRUSTEES REPORT 7 – ADVOCACY FOR
10 SEAMLESS INTERFACE BETWEEN PHYSICIANS
11 ELECTRONIC HEALTH RECORDS (EHRs), PHARMACIES
12 AND PRESCRIPTION DRUG MONITORING PROGRAMS
13 (PDMPs) (RESOLUTION 212-A-17; BOT REPORT 12-A-18)

14

15 RECOMMENDATION A:

16

17 Madam Speaker, your Reference Committee recommends that
18 the second Recommendation of Board of Trustees Report 7 be
19 amended by addition to read as follows:

20

21 2. That our AMA urge EHR vendors and Health Information
22 Exchanges (HIEs) to increase transparency of custom
23 connections and costs for physicians to integrate their products
24 in their practices. (Directive to Take Action)

25

26 RECOMMENDATION B:

27

28 Madam Speaker, your Reference Committee recommends that
29 the third Recommendation of Board of Trustees Report 7 be
30 amended by addition to read as follows

31

32 3. That our AMA support state-based pilot studies of best
33 practices to integrate EHRs, HIEs, EPSCs, and PDMPs as well
34 as efforts to identify burdensome state and federal regulations
35 that prevent such integration from occurring. (New HOD policy)

36

37 RECOMMENDATION C:

38

39 Madam Speaker, your Reference Committee recommends that
40 Board of Trustees Report 7 be amended by addition of a new
41 Recommendation to read as follows:

42

43 That our AMA support initiatives to improve the functionality of
44 state PDMPs, including; (1) lessening the time delay between
45 when a prescription is dispensed and when the prescription
46 would be available to physicians through a PDMP; and (2)
47 directing state-based PDMP's to support improved integrated
48 EHR interfaces. (Directive to Take Action)

49

50 RECOMMENDATION D:

1 Madam Speaker, your Reference Committee recommends that
2 the recommendations in Board of Trustee Report 7 be adopted
3 as amended and the remainder of the report be filed.
4

5 The Board of Trustees recommends that the following recommendations be adopted in lieu
6 of Resolution 212-A-17, and the remainder of the report be filed 1. That our American Medical
7 Association (AMA) advocate for a federal study to evaluate the use of PDMPs to improve pain
8 care as well as treatment for substance use disorders. This would include identifying whether
9 PDMPs can distinguish team-based care from uncoordinated care, misuse, or "doctor
10 shopping," as well as help coordinate care for a patient with a substance use disorder or other
11 condition requiring specialty care. (Directive to Take Action) 2. That our AMA urge EHR
12 vendors to increase transparency of custom connections and costs for physicians to integrate
13 their products in their practice. (Directive to Take Action) 3. That our AMA support state-based
14 pilot studies of best practices to integrate EHRs, EPSCs and PDMPs as well as efforts to
15 identify burdensome state and federal regulations that prevent such integration from
16 occurring. (New HOD Policy)
17

18 Your Reference Committee heard supportive testimony on Board of Trustees Report 7.
19 Concern was raised, however, that the report did not go far enough. Several testified that the
20 issues raised are time sensitive and that our AMA needs to take a vocal and public stance on
21 the issues raised in the report. Your Reference Committee acknowledges the aggressive
22 advocacy our AMA is engaged in on the issues raised in this report as well as the extensive
23 work done by nearly all state medical societies in negotiating the political pressures associated
24 with rising mortality and the limited evidence showing PDMPs can help improve pain care.
25 Your Reference Committee agrees that physicians need to be aware of the importance of
26 checking PDMPs and that PDMP data needs to be incorporated into the EHR to truly improve
27 clinical decision making at the point of care. Despite progress being made in data integration,
28 your Reference Committee is concerned that each state is only in the initial stages of such
29 integration and reaching agreements with PDMP vendors may not take into account how
30 those agreements may ultimately pass costs along to physicians. While state PDMPs do not
31 charge physicians to access the PDMP, health systems and others do incur costs for
32 integrating HIE and PDMP data into EHRs. Each state does this differently. Further
33 complicating this is that there are some state laws that may limit PDMP funding. Your
34 Reference Committee received information that physicians have contacted our AMA and
35 reported that access to a PDMP via an EHR has resulted in compounding fees where the
36 EHR vendor, PDMP vendor, and additional third-party intermediaries separately charge
37 physicians, health systems or hospitals. Furthermore, your Reference Committee heard that
38 some states prohibit the use of certain sources of funding, or they rely predominantly on
39 federal grants, thus limiting the potential range of funding mechanisms. For instance, Florida
40 law specifically prohibits the use of state funds to support the PDMP—further tying PDMP
41 financing to physician-bound fees. Because of the need to be very careful and cognizant of
42 unintended consequences arising out of incredibly well intentioned proffered amendments,
43 your Reference Committee recommends that Board of Trustees Report 7 be adopted as
44 amended.

45 (11) BOARD OF TRUSTEES REPORT 11 – VIOLENCE
46 PREVENTION (RESOLUTION 419-A-18, RESOLVES 1 AND
47 3)
48 RESOLUTION 213 – INCREASING FIREARM SAFETY TO
49 PREVENT ACCIDENTAL CHILD DEATHS

1 RESOLUTION 233 – OPPOSING UNREGULATED, NON-
2 COMMERCIAL FIREARM MANUFACTURING

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends that
7 the recommendation of Board of Trustees Report 11 **be**
8 **Recommendation 1 be** amended by addition and deletion to
9 read as follows:

10
11 1. That Policy H-145.996, “Firearm Availability” be amended by
12 addition and deletion to read as follows:

13
14 H-145.996 Firearm Availability

15 1. Our AMA: (a) Advocates a waiting period and background
16 check for all firearm purchasers; (b) encourages legislation
17 that enforces a waiting period and background check for all
18 firearm purchasers; and (c) urges legislation to prohibit the
19 manufacture, sale or import of lethal and non-lethal guns
20 made of plastic, ceramics, or other non-metallic materials
21 that cannot be detected by airport and weapon detection
22 devices.

23
24 2. Our AMA policy is to supports requiring require the
25 licensing/permitting of owners of firearms-owners and
26 purchasers, including the completion of a required safety
27 course, and registration of all firearms.

28
29 3. Our AMA supports granting local law enforcement
30 discretion over whether to issue concealed carry permits, in
31 the permitting process in such that local police chiefs are
32 empowered to make permitting decisions regarding
33 “concealed carry”, by supporting “gun violence restraining
34 orders” for individuals arrested or convicted of domestic
35 violence or stalking, and by supporting “red flag” laws for
36 individuals who have demonstrated significant signs of
37 potential violence. In supporting local law enforcement, we
38 also support as well the importance of “due process” so that
39 decisions could be reversible by individuals can petition
40 petitioning in court for their rights to be restored. (Modify
41 Current HOD Policy)

42
43 3. Our AMA supports “gun violence restraining orders” for
44 individuals arrested or convicted of domestic violence or
45 stalking, and supports extreme risk protection orders,
46 commonly known as “red-flag” laws, for individuals who have
47 demonstrated significant signs of potential violence. In
48 supporting restraining orders and “red-flag” laws, we also
49 support the importance of due process so that individuals
50 can petition for their rights to be restored. (Modify Current
51 HOD Policy)

1
2 RECOMMENDATION B:
3

4 Madam Speaker, your Reference Committee recommends that
5 recommendations of Board of Trustees Report 11 be amended
6 by addition of new Recommendations 4 and 5 to read as
7 follows.

8
9 4. That Policy H-145.990, "Prevention of Firearm Accidents in
10 Children" be amended by addition and deletion to read as
11 follows:

12 H-145.990, "Prevention of Firearm Accidents in Children"

13
14 Our AMA (1) supports increasing efforts to reduce pediatric
15 firearm morbidity and mortality by encouraging its members to
16 (a) inquire as to the presence of household firearms as a part of
17 childproofing the home; (b) educate patients to the dangers of
18 firearms to children; (c) encourage patients to educate their
19 children and neighbors as to the dangers of firearms; and (d)
20 routinely remind patients to obtain firearm safety locks, to store
21 firearms under lock and key, and to store ammunition
22 separately from firearms;(2) encourages state medical societies
23 to work with other organizations to increase public education
24 about firearm safety; and (3) encourages organized medical
25 staffs and other physician organizations, including state and
26 local medical societies, to recommend programs for teaching
27 firearm safety to children; and (4) support enactment of Child
28 Access Prevention laws that are consistent with AMA policy.

29
30 5. That Policy H-145.994, "Control of Non-Detectable Firearms"
31 be amended by addition to read as follows:

32
33 H-145.994, "Control of Non-Detectable Firearms"
34 The AMA supports a ban on the (1) manufacture, importation,
35 and sale of any firearm which cannot be detected by ordinary
36 airport screening devices, including 3D printed firearms and (2)
37 production and distribution of 3D firearm digital blueprints.

38
39 RECOMMENDATION C:
40

41 Madam Speaker, your Reference Committee recommends that
42 Board of Trustees Report 11 be adopted as amended in lieu of
43 Resolutions 213 and 233 and the remainder of the report be
44 filed.

45 The Board of Trustees recommends that the following recommendations be adopted in lieu
46 of the first and third resolves of Resolution 419-A-18 and the remainder of the report be filed.

47 1. That Policy H-145.996, "Firearm Availability" be amended by addition and deletion to read
48 as follows: H-145.996 Firearm Availability - 1. Our AMA: (a) Advocates a waiting period and
49 background check for all firearm purchasers; (b) encourages legislation that enforces a
50 waiting period and background check for all firearm purchasers; and (c) urges legislation to
51 prohibit the manufacture, sale or import of lethal and non-lethal guns made of plastic,

1 ceramics, or other non-metallic materials that cannot be detected by airport and weapon
2 detection devices. 2. Our AMA policy is to supports requiring ~~require~~ the licensing/permitting
3 of ~~owners of firearms~~owners and purchasers, including the completion of a required safety
4 course, and registration of all firearms. 3. Our AMA supports granting local law enforcement
5 discretion over whether to issue concealed carry permits, ~~in the permitting process in such~~
6 that local police chiefs are empowered to make permitting decisions regarding "concealed
7 carry", by supporting "gun violence restraining orders" for individuals arrested or convicted of
8 domestic violence or stalking, and by supporting "red flag" laws for individuals who have
9 demonstrated significant signs of potential violence. In supporting local law enforcement, we
10 also support as well the importance of "due process" so that decisions could be reversible by
11 individuals can petition ~~petitioning~~ in court for their rights to be restored. (Modify Current HOD
12 Policy) 2. That Policy H-145.972, "Firearms and High-Risk Individuals" be reaffirmed. Our
13 AMA supports: (1) the establishment of laws allowing family members, intimate partners,
14 household members, and law enforcement personnel to petition a court for the removal of a
15 firearm when there is a high or imminent risk for violence; (2) prohibiting persons who are
16 under domestic violence restraining orders, convicted of misdemeanor domestic violence
17 crimes or stalking, from possessing or purchasing firearms; (3) expanding domestic violence
18 restricting orders to include dating partners; (4) requiring states to have protocols or
19 processes in place for requiring the removal of firearms by prohibited persons; (5) requiring
20 domestic violence restraining orders and gun violence restraining orders to be entered into
21 the National Instant Criminal Background Check System; and (6) efforts to ensure the public
22 is aware of the existence of laws that allow for the removal of firearms from high-
23 risk individuals. (Reaffirm HOD Policy) 3. That our American Medical Association: (1)
24 encourages the enactment of state laws requiring the reporting of relevant mental health
25 records, as defined by state and federal law, to the National Instant Criminal Background
26 Check System (NICS); (2) supports federal funding to provide grants to states to improve
27 NICS reporting; and (3) encourages states to automate the reporting of mental health records
28 to NICS to improve the quality and timeliness of the data. (New HOD Policy). Resolution 213
29 asks that our American Medical Association advocate for enactment of Child Access
30 Prevention laws in all 50 states or as federal law. (New HOD Policy). Resolution 233 asks that
31 our AMA support legislation that opposes: a) unregulated, non-commercial firearm
32 manufacturing, such as via 3-D printing, regardless of the material composition or detectability
33 of such weapons; b) production and distribution of 3-D firearm blueprints; and be it further that
34 our AMA issue a statement of concern to Congress and the Bureau of Alcohol, Tobacco,
35 Firearms and Explosives regarding the manufacturing of firearms using 3-D printers and the
36 online dissemination of 3-D firearm blueprints as a public health issue.

37
38 Your Reference Committee heard mixed testimony on Board of Trustees Report 11. Your
39 Reference Committee heard that our AMA has extensive policy on firearm safety and violence
40 prevention including policy that supports requiring the licensing of firearm owners, including
41 completion of a required safety course and registration of all firearms. Your Reference
42 Committee heard testimony expressing concerns surrounding granting local law enforcement
43 discretion over whether to issue concealed carry permits and that these decisions may be
44 made arbitrarily and without just cause. However, testimony also indicated that our AMA
45 should support gun violence restraining orders and extreme risk protection orders, commonly
46 known as "red flag" laws, as currently stated in AMA policy H-145.996. Accordingly, your
47 Reference Committee recommends that Board of Trustees 11 be adopted with amendment.

48
49 Your Reference Committee heard generally supportive testimony on Resolution 213. Your
50 Reference Committee heard testimony that our AMA already has strong policy regarding the
51 prevention of unintentional shooting deaths among children and firearm accidents in children

1 including supporting efforts to reduce pediatric firearm morbidity and mortality. Your
2 Reference Committee also heard testimony in support of the intent behind Resolution 213 in
3 supporting Child Access Prevention (CAP) laws; however, the testimony raised concerns that
4 supporting all Child Access Prevention laws could be problematic because an individual
5 state's CAP law may be contrary to existing AMA policy. Accordingly, given the strong existing
6 AMA policy, your Reference Committee recommends adding a fourth recommendation to
7 Board of Trustees Report 11 to amend existing policy by incorporating the intent of Resolution
8 213 where the CAP law is consistent with AMA policy.
9

10 Your Reference Committee heard generally supportive testimony on Resolution 233. Your
11 Reference Committee heard testimony expressing concern regarding the accessibility of 3D
12 printers and the ability to easily fabricate 3D printed firearms. Your Reference Committee
13 heard testimony that using digital blueprints to a 3D printed firearms will increase access to
14 guns in an unregulated manner. Your Reference Committee also heard testimony that our
15 AMA already has policy supporting a ban on the manufacture, importation, and sale of any
16 firearm which cannot be detected by ordinary airport screening devices and that this policy
17 would cover 3D printed firearms. Testimony also indicated that a ban on all unregulated or
18 non-commercial firearms is too broad and does not take into account how states vary in
19 interpreting what are unregulated firearms. Accordingly, given the potential unintended
20 consequences and the focus of the Resolution 233 is on 3D firearms and digital blueprints,
21 your Reference Committee recommends adding a Fifth recommendation to Board of Trustees
22 Report 11 that existing policy be amended to specifically reference 3D printed firearms and
23 3D digital blueprints.
24

25 Therefore, your Reference Committee recommends that Board of Trustees Report 11 be
26 adopted as amended in lieu of Resolutions 213 and 233 and the remainder of the report be
27 filed.
28

29 (12) RESOLUTION 205 – LEGALIZATION OF THE DEFERRED
30 ACTION FOR LEGAL CHILDHOOD ARRIVAL (DALCA)
31

32 RECOMMENDATION A:
33

34 Madam Speaker, your Reference Committee recommends that
35 Policy D-255.979 be amended by addition as follows:
36

37 Our AMA will work with all relevant stakeholders to clear the
38 backlog for conversion from H1-B visas for physicians to
39 permanent resident status, and support dependents of
40 physicians on H-1B visas, who are admitted to the U.S. under
41 the H-4 nonimmigrant classification to remain in the U.S. legally
42 while their green card applications are pending.
43 RECOMMENDATION B:
44

45 Madam Speaker, your Reference Committee recommends that
46 Policy D-255.979 be adopted as amended in lieu of Resolution
47 205.
48

49 Resolution 205 asks that our American Medical Association support legalization of the
50 Deferred Action for Legal Childhood Arrival (DALCA) (New HOD Policy); and be it further; that
51 our AMA work with the appropriate agencies to allow DALCA children to start and finish

1 medical school and/or residency training until these DALCA children have officially become
2 legal. (Directive to Take Action)

3

4 Your Reference Committee heard mixed testimony on Resolution 205. Your Reference
5 Committee heard testimony that there are thousands of children who arrive in our country with
6 their H-1B physician parents legally. Your Reference Committee heard testimony that
7 physicians with H-1B visas may bring their immediate dependents, such as their children, to
8 the U.S. through the H-4 visa process; however, once their children turn 21 years of age they
9 are at risk for deportation because they have aged out and are no longer dependents admitted
10 to the U.S. under the H-4 non-immigration classification while their families' green cards are
11 caught in the H-1B visa backlog. Your Reference Committee heard testimony that Deferred
12 Action for Legal Childhood Arrival (DALCA), is a newly developed term used to draw a
13 distinction from Deferred Action for Childhood Arrivals (DACA) students and is not widely-
14 used by either immigration attorneys or public officials at the federal level. Your Reference
15 Committee also heard testimony that many of these H-4 visa children are in medical schools
16 or have already graduated from U.S. medical schools, but are subject to deportation because
17 they have reached the age of 21. Your Reference Committee further heard testimony that our
18 AMA already has strong policy regarding permanent residence status for physicians and that
19 Resolution 205 should be incorporated into this existing policy. Accordingly, your Reference
20 Committee recommends that current AMA policy D-255.979 be amended and adopted in lieu
21 of Resolution 205.

22

23 (13) RESOLUTION 208 – INCREASING ACCESS TO
24 BROADBAND INTERNET TO REDUCE HEALTH
25 DISPARITIES

26

27 RECOMMENDATION A:

28

29 Madam Speaker, your Reference Committee recommends that
30 Resolution 208 amended by addition to read as follows:

31

32 RESOLVED, That our AMA advocate for the expansion of
33 broadband and wireless connectivity to all rural and
34 underserved areas of the United States. (New HOD Policy)

35

36 RECOMMENDATION B:

37

38 Madam Speaker, your Reference Committee recommends that
39 Resolution 208 be adopted as amended.

40 Resolution 208 asks that our American Medical Association advocate for the expansion of
41 broadband connectivity to all rural areas of the United States. (New HOD Policy)

42

43 Your Reference Committee heard overwhelmingly supportive testimony on Resolution 208.
44 Your Reference Committee heard testimony that to address the access challenges in rural
45 and other underserved areas that lack broadband and wireless connectivity, it is essential to
46 advocate adequate federal support so that residents have access to digital health modalities.
47 Your Reference Committee also heard testimony that innovations in health care delivery will
48 increasingly rely on connectivity that is reliable, adequate, and affordable. In line with our
49 AMA's effort to develop, support, and implement digital health technology across the United
50 States, your Reference Committee recommends adoption of Resolution 208 with an

1 amendment to include wireless in addition to broadband and underserved communities as
2 well as rural.

3
4 (14) RESOLUTION 211 – ELIMINATING BARRIERS TO
5 AUTOMATED EXTERNAL DEFIBRILLATOR USE

6
7 RECOMMENDATION A:

8
9 Madam Speaker, your Reference Committee recommends that
10 third Resolve of Resolution 211 be amended by addition and
11 deletion to be read as follows:

12
13 RESOLVED That our AMA support consistent and uniform
14 legislation across states for the legal protection of untrained
15 personnel those who use AEDs in the course of attempting to
16 aid a sudden cardiac arrest victim. (Directive to Take Action)

17
18 RECOMMENDATION B:

19
20 Madam Speaker, your Reference Committee recommends that
21 Resolution 211 be adopted as amended.

22
23 Resolution 211 asks that our American Medical Association update its policy on
24 cardiopulmonary resuscitation and automated external defibrillators (AEDs) by endorsing
25 efforts to promote the importance of AED use and public awareness of AED locations, by
26 using solutions such as integrating AED sites into widely accessible mobile maps and
27 applications (New HOD Policy); and be it further that our AMA urge AED vendors to remove
28 labeling from AED stations that stipulate that only trained medical professionals can use the
29 defibrillators (Directive to Take Action); and be it further that our AMA support consistent and
30 uniform legislation across states for the legal protection of untrained personnel who use AEDs
31 in the course of attempting to aid a sudden cardiac arrest victim. (Directive to Take Action)

32
33 Your Reference Committee heard strong testimony in support of Resolution 211. Your
34 Reference Committee heard testimony that Resolution 211 will help increase use of AEDs in
35 public sudden cardiac arrest events. Your Reference Committee agrees with testimony that
36 the term “untrained personnel” should to be deleted as it is confusing and ambiguous. Your
37 Reference Committee heard testimony that by deleting this term, resulting policy will be
38 unambiguous and consistent with the reasonable person standard that currently underlies
39 Good Samaritan laws across the country. Accordingly, your Reference Committee
40 recommends that Resolution 211 be adopted as amended.

41
42 (15) RESOLUTION 212 – DEVELOPMENT AND
43 IMPLEMENTATION OF GUIDELINES FOR RESPONSIBLE
44 MEDIA COVERAGE OF MASS SHOOTINGS

45
46 RECOMMENDATION:

47
48 Madam Speaker, your Reference Committee recommends that
49 the following alternate resolution be adopted in lieu of
50 Resolution 212:

1 DEVELOPMENT AND IMPLEMENTATION OF
2 RECOMMENDATIONS FOR RESPONSIBLE MEDIA
3 COVERAGE OF MASS SHOOTINGS
4

5 RESOLVED, that our AMA encourage the Centers for Disease
6 Control and Prevention, in collaboration with other public and
7 private organizations, to develop recommendations or best
8 practices for media coverage of mass shootings. (New HOD
9 Policy)

10
11 Resolution 212 asks that our American Medical Association encourage the Centers for
12 Disease Control and Prevention, the National Institute of Mental Health, the Associated Press
13 Managing Editors, the National Press Photographers Association, and other relevant
14 organizations to develop guidelines for media coverage of mass shootings in a manner that
15 is unlikely to provoke additional incidents. (New HOD Policy)

16
17 Your Reference Committee heard supportive testimony on Resolution 212. Testimony was
18 provided that research suggests that an incident of a mass shooting increases the probability
19 of another mass shooting in the immediate future, and the contagion effect was demonstrated
20 in the mid-1990's with suicides, which led to the development of media coverage guidelines
21 by the Centers for Disease Control and Prevention (CDC), the World Health Organization,
22 and media organizations. Your Reference Committee also heard testimony that
23 recommended that the resolution be amended to encourage the development of
24 recommendations or best practices by the CDC, in collaboration with other public and private
25 organizations, rather than "guidelines," for media coverage of mass shootings, and that the
26 following language in the resolved clause should be deleted since it is too vague: "in a manner
27 that is unlikely to provoke additional incidents." Accordingly, your Reference Committee
28 recommends that an alternate resolution be adopted in lieu of Resolution 212.

29 (16) RESOLUTION 216 – MEDICARE PART B COMPETITIVE
30 ACQUISITION PROGRAM (CAP)

31
32 RECOMMENDATION A:

33
34 Madam Speaker, your Reference Committee recommends that
35 Resolution 216 be amended by addition and deletion to read as
36 follows:

37
38 RESOLVED, That our AMA advocate that any revised Medicare
39 Part B Competitive Acquisition Program meet the following
40 standards to improve the value of the program by lowering the
41 cost of drugs without undermining quality of care:
42 (1) it must be genuinely voluntary and not penalize practices
43 which that choose not to participate;

1 (2) it should provide supplemental payments to support complex
2 care coordination and management for cancer patients,
3 including reimbursement for costs associated with the
4 administration of anticancer drugs such as special handling and
5 storage for Part B hazardous drugs
6 (3) it must not reduce reimbursement for services related to
7 provision/administration of Part B drugs, and reimbursement
8 should be indexed to an appropriate healthcare inflation rate;
9 (3)(4) it should permit flexibility such as allowing for variation in
10 orders that may occur on the day of treatment, and allow for the
11 use of CAP-acquired drugs at multiple office locations;
12 (4)(5) it should allow practices to choose from multiple vendors
13 to ensure competition, and should also ensure that vendors
14 meet appropriate safety and quality standards;
15 (5)(6) it should include robust and comprehensive patient
16 protections which include preventing delays in treatment,
17 helping patients find assistance or alternative payment
18 arrangements if they cannot meet the cost-sharing
19 responsibility, and vendors should bear the risk of non-payment
20 of patient copayments in a way that does not penalize the
21 physician;
22 (6) it should not be tied to negotiated discounts (7) it should not
23 allow vendors to restrict patient access using utilization
24 management policies such as step therapy; and
25 (7)(8) it should not force disruption of current systems which
26 have evolved to ensure patient access to necessary
27 medications.

28
29 RECOMMENDATION B:
30

31 Madam Speaker, your Reference Committee recommends that
32 Resolution 216 be adopted as amended.
33

34 Resolution 216 asks that our American Medical Association advocate that any revised
35 Medicare Part B Competitive Acquisition Program meet the following standards to improve
36 the value of the program by lowering the cost of drugs without undermining quality of care: (1) it
37 must be genuinely voluntary and not penalize practices which choose not to participate; (2) it
38 should provide supplemental payments to support complex care coordination and
39 management for cancer patients, including reimbursement for costs associated with the
40 administration of anticancer drugs such as special handling and storage for hazardous drugs;
41 (3) it should permit flexibility such as allowing for variation in orders that may occur on the day
42 of treatment, and allow for the use of CAP-acquired drugs at multiple office locations; (4) it
43 should allow practices to choose from multiple vendors to ensure competition, and should also
44 ensure that vendors meet appropriate safety and quality standards; (5) it should include robust
45 and comprehensive patient protections which include preventing delays in treatment, helping
46 patients find assistance or alternative payment arrangements if they cannot meet the cost-
47 sharing responsibility, and vendors should bear the risk of non-payment of patient copayments
48 in a way that does not penalize the physician; and (6) it should not be tied to negotiated
49 discounts such as rebates to pharmacy benefit managers given in exchange for implementing
50 utilization management policies like step therapy. (New HOD Policy)

1 Your Reference Committee heard supportive testimony on Resolution 216. Your Reference
2 Committee heard testimony that the physicians in community practice must have access to
3 affordable Part B drugs and the payment should cover actual costs. Your Reference
4 Committee also heard testimony that a new competitive acquisition program should account
5 for all of the issues raised in the resolved of this resolution. Your Reference Committee heard
6 testimony of an amendment that included a provision that our AMA oppose models that do
7 not meet the criteria set out in Resolution 216. Your Reference Committee believes that this
8 language could hamper our AMA's efforts to advocate and negotiate on this important issue
9 because future alternatives may be offered and our AMA may not be able to support
10 potentially beneficial options. Therefore, your Reference Committee recommends adoption of
11 Resolution 216 as amended.

12

13 (17) RESOLUTION 220 – SUPPORTING MENTAL HEALTH
14 TRAINING PROGRAMS FOR CORRECTIONS OFFICERS
15 AND CRISIS INTERVENTION TEAMS FOR LAW
16 ENFORCEMENT

17

18 RECOMMENDATION A:

19

20 Madam Speaker, your Reference Committee recommends that
21 Resolution 220 be amended by addition and deletion to read as
22 follows.

23

24 RESOLVED, That our American Medical Association support
25 legislation and federal funding for evidence-based training
26 programs by qualified professionals aimed at educating
27 corrections officers in effectively interacting with mentally ill
28 populations people with mental health diagnoses in federal
29 prisons all detention and correction facilities. (New HOD Policy)

30

31 RECOMMENDATION B:

32

33 Madam Speaker, your Reference Committee recommends that
34 Resolution 220 be adopted as amended.

35 Resolution 220 asks that our American Medical Association support legislation and federal
36 funding for evidence-based training programs aimed at educating corrections officers in
37 effectively interacting with mentally ill populations in federal prisons. (New HOD Policy)

38

39 Your Reference Committee heard supportive testimony on Resolution 220, which addresses
40 the important issues of mental health training programs for corrections officers and crisis
41 intervention teams for law enforcement. Your Reference Committee heard further testimony
42 that corrections officers can play a vital role in the proper treatment of offenders with mental
43 illness but generally receive very little training in mental health issues, making violence
44 between inmates and officers commonplace.

45

46 Your Reference Committee also heard testimony that our AMA already has strong policy
47 supporting mental health crisis interventions, H-345.972, "Mental Health Crisis Interventions",
48 as a means for jail diversion and community-based treatment options for those with severe
49 mental illness. Testimony further indicated that AMA policy also supports federal funding to
50 encourage increased community and law enforcement participation training including
51 evidence-based crisis intervention training programs, as they have been shown efficacious in

1 promoting jail diversion for individuals experiencing a mental-health related crisis. However,
2 this policy does not specifically apply to educating and supporting law enforcement officials in
3 federal or state prisons. Your Reference Committee heard testimony (1) that evidence-based
4 training programs should be conducted by qualified professionals; (2) to change “mentally ill
5 populations” to “people with mental health diagnoses”; and (3) to change “federal prisons” to
6 be more expansive and cover “all detention and correction facilities.” Accordingly, your
7 Reference Committee agrees with these changes and recommends that Resolution 220 be
8 adopted as amended.

9

10 (18) RESOLUTION 224 – FAIRNESS IN THE CENTERS FOR
11 MEDICARE & MEDICAID SERVICES AUTHORIZED
12 QUALITY IMPROVEMENT ORGANIZATION’S (QIO)
13 MEDICAL CARE REVIEW PROCESS

14 RECOMMENDATION A:

15 Madam Speaker, your Reference Committee recommends that
16 Resolution 224 be amended by addition and deletion to read as
17 follows:

18 RESOLVED, that our American Medical Association advocate
19 ~~seek by regulation and/or legislation to change amend~~ the
20 Centers for Medicare and Medicaid Services (CMS) quality
21 improvement organization (QIO) process to mandate an
22 opportunity for practitioners and/or providers to request an
23 additional review when the QIO initial determination peer review
24 and the QIO reconsideration peer review are in conflict
25 (Directive to Take Action)

26 RESOLVED, that our AMA advocate seek by regulation and/or
27 ~~legislation~~ to require CMS authorized QIOs to disclose to
28 practitioners and/or providers when the QIO peer reviewer is not
29 a peer match and is reviewing a case outside of their area of
30 expertise (Directive to Take Action);

31 RESOLVED, that our AMA advocate seek by regulation and/or
32 ~~legislation~~ to require CMS authorized QIOs to disclose in their
33 annual report, the number of peer reviews performed by
34 reviewers without the same expertise as the physician being
35 reviewed. (Directive to Take Action)

36 RECOMMENDATION B:

37 Madam Speaker, your Reference Committee recommends that
38 Resolution 224 be adopted as amended.

39 Resolution 224 asks that our American Medical Association seek by regulation and/or
40 legislation to amend the Centers for Medicare and Medicaid Services (CMS) quality
41 improvement organization (QIO) process to mandate an opportunity for practitioners and/or
42 providers to request an additional review when the QIO initial determination peer review and
43 the QIO reconsideration peer review are in conflict (Directive to Take Action); and be it further,

1 that our AMA seek by regulation and/or legislation to require CMS authorized QIOs to disclose
2 to practitioners and/or providers when the QIO peer reviewer is not a peer match and is
3 reviewing a case outside of their area of expertise (Directive to Take Action); and be it further,
4 that our AMA seek by regulation and/or legislation to require CMS authorized QIOs to disclose
5 in their annual report, the number of peer reviews performed by reviewers without the same
6 expertise as the physician being reviewed. (Directive to Take Action)

7
8 Your Reference Committee heard supportive testimony on Resolution 224. Your Reference
9 Committee heard testimony that our AMA has existing policy regarding Quality Improvement
10 Organization (QIO), including offering due process and fairness for physicians, requiring
11 physician consent before disclosure of QIO review determinations, mandating the utilization
12 of specialty-specific physician reviewers, and to annually publish the names of physician
13 reviewers with credentials and specialties. Your Reference Committee heard further testimony
14 that our AMA submitted to CMS a letter in October that implements the Resolves of Resolution
15 224. This letter includes advocating for similar due process procedures for physicians and
16 patients, allowing for physician-to-physician conversations at the second level of review,
17 notifying physicians when a peer reviewer does not have similar expertise or specialty as the
18 physician subject to the QIO process, and to disclose the number of peer reviews performed
19 by reviewers without the same expertise. However, your Reference Committee also heard
20 testimony that existing AMA policy does not specifically address the issues identified in
21 Resolution 224. Your Reference Committee believes that Resolution 224 should be amended
22 to provide flexibility to our AMA in its advocacy activities to include potentially resolving the
23 issues with CMS through subregulatory actions or other activities that are not explicitly
24 regulation or legislation. Accordingly, your Reference Committee recommends that Resolution
25 224 be adopted as amended.

26 (19) RESOLUTION 232 – OPPOSITION TO MANDATORY
27 LICENSING REQUIREMENTS FOR QUALIFIED CLINICAL
28 DATA REGISTRIES

29 RECOMMENDATION:

30
31
32 Madam Speaker, your Reference Committee recommends that
33 the following alternate resolution be adopted in lieu of
34 Resolution 232.

35
36 RESOLVED, that our American Medical Association (AMA)
37 oppose any Centers for Medicare and Medicaid Services (CMS)
38 proposal that would require Qualified Clinical Data Registries
39 (QCDR) measure owners, as a condition of measure approval
40 for reporting in Merit-based Incentive Payment System (MIPS)
41 and other Medicare quality payment programs, to enter into a
42 free license agreement with CMS that would allow other QCDRs
43 to use the owner's measures without a direct license with the
44 measure owner; and be it further (Directive to Take Action)

45
46 RESOLVED, that our AMA oppose any CMS proposal that
47 would require inclusion of CMS as a party in a QCDR measure

1 licensing agreement between the QCDR measure owner and
2 another; and be it further (Directive to Take Action)

3
4 RESOLVED, that our AMA support in situations where QCDR
5 measures are shared between the original measure owner and
6 another QCDR, that the latter QCDR:

7
8 1. Must adhere to certain standards and terms set out by the
9 QCDR measure owner on measure implementation and data
10 capture, including data validity and reliability, plus fair
11 remuneration for measure development and ongoing measure
12 stewardship.

13
14 2. Must have demonstrated clinical expertise in medicine,
15 quality measure development and improvement by providing
16 methods to ensure data quality, routine metric reporting, and
quality improvement consultation. (New HOD Policy)

17
18 Resolution 232 asks that our American Medical Association actively oppose any Centers for
19 Medicare & Medicaid Services (CMS) proposal that would require qualified clinical data
20 registry (QCDR) measure owners, as a condition of measure approval for reporting in the
21 Merit-based Incentive Payment System and other Medicare quality payment programs, to
22 enter into a license agreement with CMS that would allow other QCDRs to use the owner's
23 measures without a fee or without a direct license with the measure owner. (Directive to Take
24 Action)

25
26 Your Reference Committee heard generally supportive testimony for Resolution 232. Your
27 Reference Committee heard testimony that our AMA opposed the CMS proposal to
28 undermine QCDR measure ownership and development in the physician fee schedule. Your
29 Reference Committee also heard testimony that CMS did not finalize the proposal. Your
30 Reference Committee heard further testimony that even though CMS did not finalize the
31 proposal, this issue may come up again in future rulemaking. An amendment was offered to
32 address the concerns of Resolution 232 through adherence to and implementation of
33 standards and terms set by a specialty's QCDR including demonstrating clinical expertise and
34 providing methods to ensure data quality. Your Reference Committee understands that the
35 first Resolve means that our AMA would oppose CMS requiring QCDR measure owners as a
36 condition of measure approval to enter into a free license agreement. Your Reference
37 Committee further understands that Resolution 232 does not prevent QCDR measure owners
38 from providing to CMS the QCDR measures for free. Accordingly, your Reference Committee
39 recommends that an alternate resolution that reflects these amendments be adopted in lieu
40 of Resolution 232.

41
42 (20) RESOLUTION 235 – INAPPROPRIATE USE OF CDC
43 GUIDELINES FOR PRESCRIBING OPIOIDS

44
45 RECOMMENDATION:

46
47 Madam Speaker, your Reference Committee recommends that
48 the following alternate resolution be adopted in lieu of
49 Resolution 235:

1 RESOLVED, that our American Medical Association (AMA)
2 applaud the Centers for Disease Control and Prevention (CDC)
3 for its efforts to prevent the incidence of new cases of opioid
4 misuse, addiction, and overdose deaths (Directive To Take
5 Action)

6
7 RESOLVED, that our AMA continue to communicate with the
8 nation's largest pharmacy chains, pharmacy benefit managers,
9 National Association of Insurance Commissioners, Federation
10 of State Medical Boards, and National Association of Boards of
11 Pharmacy opposing communications being sent to physicians
12 that include a blanket proscription against filing prescriptions for
13 opioids that exceed numerical thresholds without taking into
14 account the diagnosis and previous response to treatment for a
15 patient and any clinical nuances that would support such
16 prescribing as falling within standards of good quality patient
17 care. (Directive To Take Action)

18
19 RESOLVED, that Policies H-120.924, D-95.987, D-160.981, H-
20 265.998, and H-220.951 be reaffirmed. (Reaffirm Existing HOD
21 Policy)

22
23 Resolution 235 asks that our American Medical Association applaud the Centers for Disease
24 Control and Prevention (CDC) for its efforts to prevent the incidence of new cases of opioid
25 misuse, addiction, and overdose deaths; and be it further, that no entity should use MME
26 (morphine milligram equivalents) thresholds as anything more than guidance and that MME
27 thresholds should not be used to completely prohibit the prescribing of, or the filling of
28 prescriptions for, medications used in oncology care, palliative medicine care, and addiction
29 medicine care (New HOD Policy); and be it further, that our AMA communicate with the
30 nation's largest pharmacy chains and pharmacy benefit managers to recommend that they
31 cease and desist with writing threatening letters to physicians and cease and desist with
32 presenting policies, procedures and directives to retail pharmacists that include a blanket
33 proscription against filling prescriptions for opioids that exceed certain numerical thresholds
34 without taking into account the diagnosis and previous response to treatment for a patient and
35 any clinical nuances that would support such prescribing as falling within standards of good
36 quality patient care (New HOD Policy); and be it further, that AMA Policy opposing the
37 legislating of numerical limits on medication dosage, duration of therapy, numbers of
38 pills/tablets, etc., be reaffirmed (Reaffirm HOD Policy); and be it further, that physicians should
39 not be subject to professional discipline or loss of board certification or loss of clinical
40 privileges simply for prescribing opioids at a quantitative level that exceeds the MME
41 thresholds found in the CDC Guidelines (New HOD Policy); and be it further, that our AMA
42 encourage the Federation of State Medical Boards and its member boards, medical specialty
43 societies, and other entities (including, possibly, the CDC) to develop improved guidance on
44 management of pain and management of potential withdrawal syndromes and other aspects
45 of patient care for "legacy patients" who may have been treated for extended periods of time
46 with high-dose opioid therapy for chronic non-malignant pain. (New HOD Policy)

47
48 Your Reference Committee heard supportive testimony of the intent of Resolution 235. Your
49 Reference Committee heard testimony that the third resolve should be amended to reflect that
50 our AMA is already working with national pharmacy chains regarding physicians who have
51 received letters about exceeding numerical thresholds. Your Reference Committee also heard

1 testimony that our AMA already has strong policy regarding many of the resolves in Resolution
2 235, including opposing specific doses or durations limits on pharmacologic therapy not
3 supported by medical evidence and protecting due process for medical staff, professional
4 discipline, and board certifications that covers physicians being subject to professional actions
5 for prescribing opioids at a quantitative level that exceeds CDC guidelines. Further testimony
6 indicated that it would redundant to ask FSMB to develop improved guidance because our
7 AMA's "End the Epidemic" website has more than 400 state- and specialty-specific resources.
8 Accordingly, your Reference Committee recommends that an alternate resolution be adopted
9 in lieu of Resolution 235, including reaffirming existing policy.

10
11 Evaluating Actions by Pharmacy Benefit Manager and Payer Policies on Patient Care
12 H-120.924

13 Our AMA will: (1) urge the National Association of Boards of Pharmacy, Federation of
14 State Medical Boards (FSMB), and National Association of Insurance Commissioners
15 (NAIC) to support having national pharmacy chains, health insurance companies, and
16 pharmacy benefits managers (PBMs) testify at state-level public hearings by state
17 medical/pharmacy boards and state departments of insurance, on whether the
18 pharmacy chains, health insurance companies, and PBMs' policies to restrict the
19 prescribing/dispensing of opioid analgesics are in conflict with state insurance laws or
20 state laws governing the practice of medicine and pharmacy; and (2) oppose specific
21 dose or duration limits on pharmacologic therapy that are not supported by medical
22 evidence and clinical practice.

23 BOT Rep. 17, A-18

24
25 Prevention of Opioid Overdose D-95.987

26 1. Our AMA: (A) recognizes the great burden that opioid addiction and prescription
27 drug abuse places on patients and society alike and reaffirms its support for the
28 compassionate treatment of such patients; (B) urges that community-based programs
29 offering naloxone and other opioid overdose prevention services continue to be
30 implemented in order to further develop best practices in this area; and (C) encourages
31 the education of health care workers and opioid users about the use of naloxone in
32 preventing opioid overdose fatalities; and (D) will continue to monitor the progress of
33 such initiatives and respond as appropriate. 2. Our AMA will: (A) advocate for the
34 appropriate education of at-risk patients and their caregivers in the signs and
35 symptoms of opioid overdose; and (B) encourage the continued study and
36 implementation of appropriate treatments and risk mitigation methods for patients at
37 risk for opioid overdose. 3. Our AMA will support the development and implementation
38 of appropriate education programs for persons in recovery from opioid addiction and
39 their friends/families that address how a return to opioid use after a period of
40 abstinence can, due to reduced opioid tolerance, result in overdose and death. (Res.
41 526, A-06 Modified in lieu of Res. 503, A-12 Appended: Res. 909, I-12 Reaffirmed:
42 BOT Rep. 22, A-16 Modified: Res. 511, A-18)

43
44 Promotion of Better Pain Care D-160.981

45 1. Our AMA: (a) will express its strong commitment to better access and delivery of
46 quality pain care through the promotion of enhanced research, education and clinical
47 practice in the field of pain medicine; and (b) encourages relevant specialties to
48 collaborate in studying the following: (i) the scope of practice and body of knowledge
49 encompassed by the field of pain medicine; (ii) the adequacy of undergraduate,
50 graduate and post graduate education in the principles and practice of the field of pain
51 medicine, considering the current and anticipated medical need for the delivery of

1 quality pain care; (iii) appropriate training and credentialing criteria for this
2 multidisciplinary field of medical practice; and (iv) convening a meeting of interested
3 parties to review all pertinent matters scientific and socioeconomic. 2. Our AMA
4 encourages relevant stakeholders to research the overall effects of opioid production
5 cuts. 3. Our AMA strongly urges the US Drug Enforcement Administration to base any
6 future reductions in aggregate production quotas for opioids on actual data from
7 multiple sources, including prescribing data, and to proactively monitor opioid quotas
8 and supply to prevent any shortages that might develop and to take immediate action
9 to correct any shortages. 4. Our AMA encourages the US Drug Enforcement
10 Administration to be more transparent when developing medication production
11 guidelines. 5. Our AMA and the physician community reaffirm their commitment to
12 delivering compassionate and ethical pain management, promoting safe opioid
13 prescribing, reducing opioid-related harm and the diversion of controlled substances,
14 improving access to treatment for substance use disorders, and fostering a public
15 health based-approach to addressing opioid-related morbidity and mortality. (Res.
16 321, A-08 Appended: Res. 522, A-10 Reaffirmed in lieu of Res. 518, A-12 Reaffirmed:
17 BOT Rep. 19, A-16 Reaffirmed in lieu of Res. 117, A-16 Appended: Res. 927, I-16
18 Appended: Res. 526, A-17 Modified: BOT Action in response to referred for decision
19 Res. 927, I-16)

20
21 Guidelines for Due Process H-265.998

22 While it is not possible to develop universal guidelines for due process, voluntary
23 utilization of the following general guidelines for due process, adapted in each instance
24 to suit the circumstances and conditions of the health care organization and within the
25 requirements of the applicable laws of the jurisdiction, should assist in providing the
26 type of hearing which the law in each jurisdiction requires: (1) The physician should
27 be provided with a statement, or a specific listing, of the charges made against him or
28 her. (2) The physician is entitled to adequate notice of the right to a hearing and a
29 reasonable opportunity of no less than 30 days to prepare for the hearing. (3) It is the
30 duty and responsibility of the hearing officer to conduct a fair, objective, expeditious
31 and independent hearing pursuant to established rules. (4) The rules of procedure
32 should clearly define the extent to which attorneys may participate in the hearing. (5)
33 The physician against whom the charges are made should have the opportunity to be
34 present at the hearing and hear all of the evidence against him or her. (6) The
35 physician is entitled to the opportunity to present a defense to the charges against him
36 or her. (7) To the extent feasible, the hearing panel should evaluate the issues and
37 evidence presented related to the proposed corrective action while blinded to the
38 patient outcome. (8) The hearing panel should render a decision based on the
39 evidence produced at the hearing. (9) The hearing panel should include in its decision
40 the conclusions reached and actions recommended and, as an important focus if
41 feasible, remedial steps for the physician and for the health care facility itself. When
42 feasible, the hearing panel should include terms that permit measurement and
43 validation of the completed remediation process. (10) The hearing panel should
44 endeavor to state its findings, the clinical basis and support for its findings, its
45 recommendations, and actions as clearly as possible. (11) Within 10 days of the
46 receipt of the hearing panel's decision, the physician, medical executive committee or
47 health care organization, if it brought the correction action, has the right to request an
48 appellate review. The written request for an appellate review shall include an
49 identification of the grounds for appeal and a clear and concise statement of the facts
50 and/or evidence in support of the appeal. The grounds for an appeal of the decision
51 shall be: (a) substantial non-compliance with the procedures required in the medical

1 staff bylaws; or (b) the decision is against the manifest weight of the evidence. If an
2 appellate review is to be conducted, the appeal board shall schedule the appellate
3 review and provide notice to the physician, medical executive committee and the
4 health care organization. The MEC shall appoint an appeal board consisting of
5 members of the medical staff who did not sit on the original hearing panel, or, at the
6 request of the MEC, the governing body or at least three members thereof may sit as
7 the appeal board. The appeal board shall consider the record of the hearing before
8 the hearing panel. If the appeal board determines that significant relevant evidence,
9 which could bear on the outcome of the proceeding, was not entertained by the hearing
10 panel, it may refer the matter back to the hearing panel for further deliberation or, at
11 the appeal board's discretion, it may receive and consider the new evidence. Similarly,
12 if the appeals board determines that there was not substantial compliance with the
13 hearing procedures in the medical staff bylaws, the appeal board may refer the matter
14 back to the hearing body or, at the appeal board's discretion, it may convene additional
15 hearings to correct any defect in the process. Upon completion of the appeal board's
16 deliberations, the appeal board shall present its recommendation(s) to the governing
17 body as to whether the recommendations(s) of the hearing body should be affirmed,
18 modified, or reversed. (12) In any hearing, the interest of patients and the public must
19 be protected. (BOT Rep. II, A-80 Reaffirmed: Sunset Report, I-98 Amended: BOT
20 Action in response to referred for decision BOT Rep. 23, A-05 Reaffirmed: Res. 12, A-
21 06 Reaffirmed: BOT Rep. 06, A-16)

22

23

Medical Staff Membership H-220.951

24

25

26

27

28

29

30

31

32

(21) RESOLUTION 202 – ENABLING METHADONE TREATMENT OF OPIOID USE DISORDER IN PRIMARY CARE SETTINGS

33

34

35

36

RECOMMENDATION:

37

38

Madam Speaker, your Reference Committee recommends that
Resolution 202 be referred.

39

40

41

42

43

44

45

46

Resolution 202 asks that our American Medical Association study the implications of removing those administrative and/or legal barriers that hamper the ability of primary care physician practices to dispense methadone, as part of medication assisted treatment (Directive to Take Action); and be it further, that our AMA study the implications of working with other Federation stakeholders to identify the appropriate educational tools that would support primary care practices in dispensing ongoing methadone for appropriate patients as part of medication-assisted treatment. (Directive to Take Action)

47

48

49

50

51

Your Reference Committee heard supportive testimony on Resolution 202. Your Reference Committee heard testimony that our AMA should study the implications of removing barriers that hamper the ability of physician practices to dispense methadone. Your Reference Committee also heard testimony that our AMA does not need to study working with the state

1 and specialty societies regarding these issues but instead should work directly with the
2 Federation members on enabling methadone treatment. However, your Reference Committee
3 also heard that no appropriate educational tools that would support primary care practices in
4 dispensing ongoing methadone exist at this moment and that this also needs study. Your
5 Reference Committee heard testimony on the need for the physician community to continue
6 reducing the stigma associated with methadone use and medication assisted treatment. Of
7 note, your Reference Committee heard concerns about providing access to methadone to
8 primary care physicians without sufficient training, and only for the singular indication of opioid
9 use disorder. Given the nature of the testimony, your Reference Committee recommends
10 referral.

11
12 (22) RESOLUTION 204 – RESTRICTION ON IMG
13 MOONLIGHTING

14 RECOMMENDATION:

15 Madam Speaker, your Reference Committee recommends that
16 Resolution 204 be referred.

17 Resolution 204 asks that our American Medical Association advocate for changes to federal
18 legislation allowing physicians with a J-1 visa in fellowship training programs the ability to
19 moonlight. (New HOD Policy)

20 Your Reference Committee heard supportive but mixed testimony on Resolution 204. Your
21 Reference Committee heard testimony that our AMA has strong policy regarding limiting duty
22 hours for residents/fellows. Your Reference Committee heard testimony that International
23 Medical Graduates moonlighting will improve access to care for underserved populations in
24 certain areas around the U.S. facing a physician shortage. Your Reference Committee also
25 heard testimony that J-1 visa classifications are explicitly reserved for educational and cultural
26 exchange. Further testimony indicated that J-1 visa classifications are not a work visa and,
27 therefore, J-1 physician participants are not permitted to engage in any work outside of their
28 approved program of graduate medical education. Your Reference Committee also heard
29 testimony that more research needs to be done on the impact of a potential shift of AMA Policy
30 including policies related to patient safety, fatigue/stress on the fellow, professional licensing,
31 payment, and liability. As a result, your Reference Committee believes that Resolution 204
32 should be referred.

33
34 (23) RESOLUTION 206 – REPEALING POTENTIAL PENALTIES
35 ASSOCIATED WITH MIPS
36 RESOLUTION 231 – REDUCING THE REGULATORY
37 BURDEN IN HEALTH CARE

38 RECOMMENDATION:

39 Madam Speaker, your Reference Committee recommends that
40 Resolutions 206 and 231 be referred.

41 Resolution 206 asks that our American Medical Association advocate to repeal all potential
42 penalties associated with the MIPS program. (Directive to Take Action) Resolution 231 asks
43 that our American Medical Association work to support the repeal of the Merit-Based Incentive
44 Payment System (MIPS) (Directive to Take Action); and be it further, that upon repeal of MIPS,

1 our AMA oppose any federal efforts to implement any pay-for-performance programs unless
2 such programs add no significant regulatory or paperwork burdens to the practice of medicine
3 and have been shown, by evidence-based research, to improve the quality of care for those
4 served. (Directive to Take Action)

5
6 Your Reference Committee heard mixed testimony on Resolutions 206 and 231. Your
7 Reference Committee heard testimony that a similar resolution was debated in June at our
8 Annual Meeting, and that the House of Delegates voted against adoption. Your Reference
9 Committee heard testimony that Congress passed the Bipartisan Budget Act of 2018 and
10 included five key MACRA improvements supported by our AMA. These improvements will
11 allow CMS and physicians three additional years to gradually transition into the MIPS
12 program. Your Reference Committee also heard testimony that our AMA continues to work
13 closely with CMS to recommend a variety of improvements to the MIPS program including
14 simplified scoring methodology, reduced reporting burden, and the ability for physicians to
15 report data across multiple performance categories. Your Reference Committee heard further
16 testimony that the cost of repealing MIPS penalties would need to be offset and would
17 potentially come at the expense of bonuses or across the board cuts in physician payments;
18 and that would impact even the physicians who are currently exempt from MIPS, such as
19 small practices. Testimony also indicated that the second Resolve in Resolution 231 would
20 effectively disallow our AMA to continue its support for the Administration's and Congress'
21 efforts to advance successful, innovative payment models as well as the technologies needed
22 to support the models. Your Reference Committee also heard testimony that our AMA should
23 continue to work to simplify and improve the MIPS program, and work with state and specialty
24 societies to help develop more opportunities for physicians to participate in Alternative
25 Payment Models, which would allow them to be exempt from the MIPS program. Your
26 Reference Committee has concerns that repealing penalties associated with MIPS or
27 repealing the entire program could result in an alternative program that may be less desirable.
28 Your Reference Committee understands the continued efforts made by our AMA and
29 specialties to improve MIPS; however, given the Board of Trustees interest in evaluating this
30 issue further, your Reference Committee recommend that Resolutions 206 and 231 be
31 referred.

32
33 (24) RESOLUTION 210 – FORCED ORGAN HARVESTING FOR
34 TRANSPLANTATION

35
36 RECOMMENDATION:

37
38 Madam Speaker, your Reference Committee recommends that
39 Resolution 210 be referred for decision.
40

1 Resolution 210 asks that our American Medical Association reaffirm Ethical Opinion E-6.1.1,
2 "Transplantation of Organs from Living Donors,", and believes that transplant surgeons,
3 especially those who come to the United States for training in transplant surgery, must agree
4 to these guidelines, and that American medical and hospital institutions not be complicit in
5 any ethical violations or conflicts of interest (New HOD Policy); and be it further, that our AMA
6 representatives to the World Medical Association request an independent, interdisciplinary
7 (not restricted to transplant surgeons), transparent investigation into the Chinese practices of
8 organ transplantation including (but not limited to): the source of the organs as well as the
9 guidelines followed; and to report back on these issues as well as the status of Prisoners of
10 Conscience as sources of transplantable organs (Directive to Take Action); and be it further
11 that our AMA call upon the U.S. Government to protect the large number of transplant tourists
12 by implementing legislation to regulate the evolving, ethical challenges by initiating a
13 Reciprocal Transplant Transparency Act which would blacklist countries that do not meet the
14 same transparency and ethical standards practiced in the U.S. (such as the public listing of
15 annual transplant numbers by every transplant center to permit scrutiny). (Directive to Take
16 Action)

17

18 Your Reference Committee heard mixed testimony on Resolution 210. Testimony was
19 presented by the sponsor and supporters of the resolution that according to the Executive
20 Director and founder of Doctors Against Forced Organ Harvesting, a medical non-
21 governmental organization, there are substantiated allegations of "state-sponsored domestic
22 organ trafficking and harvesting" in China from executed prisoners, and from prisoners of
23 conscience, including Uighurs, House Christians, Tibetans and Falun Gong practitioners.
24 There was further testimony that although the Chinese Medical Association has stated that
25 the practice of harvesting organs from the deceased prisoners was outlawed as of January 1,
26 2015, and that organ tourism is prohibited by Chinese law, there have been reports of dramatic
27 increases in transplant tourism and evidence suggesting that the supply of organs in China
28 could not realistically come from legitimate organ donation programs. Your Reference
29 Committee also heard that transplant tourism has become a lucrative source of income in
30 China, leading to a rapid expansion of the transplant infrastructure in China, and China has
31 declared the Hainan Islands to be a special economic zone for medical tourism.

32

33 Testimony was also presented that ethical guidelines for transplantation are set forth by our
34 AMA, the World Medical Association (WMA), and the World Health Organization, and the U.S.
35 Congress passed House Resolution 343 in 2016, calling for an end to forced organ harvesting
36 from Falun Gong prisoners of conscience in China; that a Resolution was introduced in the
37 U.S. Senate in 2017; and the European Parliament also passed Written Declaration 48 in
38 2016, calling for investigations and an end to forced organ harvesting from Falun Gong
39 prisoners of conscience in China.

40

41 Testimony was presented that the first Resolve clause of Resolution 210 is problematic and
42 should not be adopted because technically, opinions in the Code of Medical Ethics, such as
43 E-6.1.1, are not reaffirmed—they are AMA ethics policy in perpetuity until or unless CEJA
44 proposes a revision at its own initiative or in response to a request from the HOD or the Board.
45 Testimony was further presented that the ask in the second Resolve clause, for the WMA to
46 conduct an investigation, is not within the scope of WMA's activity. While the WMA can
47 conduct, and has conducted, fact-finding missions, the organization does not engage in
48 investigations of member nations. Your Reference Committee also heard testimony that third
49 Resolved clause is also problematic because it would require our AMA to call upon the federal
50 government to initiate a treaty process to regulate the evolving, ethical challenges of
transplant tourism. Your Reference Committee heard testimony that this is beyond our AMA's

1 resources, and it is generally our AMA's practice to work through the WMA on international
2 issues such as those raised in Resolution 210.

3
4 Accordingly, given the complicated and serious issue of forced organ harvesting and the
5 concerns raised by the Resolve clauses of Resolution 210, your Reference Committee
6 recommends that Resolution 210 be referred for decision.

7
8 (25) RESOLUTION 215 – EXTENDING THE MEDICAL HOME TO
9 MEET FAMILIES WHEREVER THEY GO

10
11 RECOMMENDATION:

12
13 Madam Speaker, your Reference Committee recommends that
14 Resolution 215 not be adopted.

15
16 Resolution 215 asks that our American Medical Association develop model legislation to
17 permit primary care physicians, who work in medical homes/primary care practices that satisfy
18 the National Committee for Quality Assurance (NCQA) Patient-Centered Medical Home
19 Recognition Program guidelines, and who have documented a face-to-face patient-care
20 relationship, to provide telehealth services for the patient when the patient travels to any of
21 the fifty states. (Directive to Take Action)

22
23 Your Reference Committee heard mixed testimony on Resolution 215. Your Reference
24 Committee also heard testimony that our AMA has strongly advocated to protect the long-
25 standing position of licensure being state based including that state laws where the patient is
26 located should apply including licensure, medical practice, and liability laws. Your Reference
27 Committee heard additional testimony that state-based exceptions and carve outs will further
28 complicate oversight and regulation, patient protections, and spawn challenging conflicts of
29 laws problems. Furthermore, your Reference Committee heard testimony that our AMA
30 already has strong policy promoting quality telemedicine. Accordingly, your Reference
31 Committee recommends that Resolution 215 not be adopted.

32 (26) RESOLUTION 230 – NONPROFIT HOSPITALS AND
33 NETWORK HEALTH SYSTEMS

34
35 RECOMMENDATION:

36
37 Madam Speaker, your Reference Committee recommends that
38 Resolution 230 not be adopted.

39
40 Resolution 230 asks that our American Medical Association lobby federal legislators, the
41 Internal Revenue Service, and/or other appropriate federal officials to investigate and review
42 whether non-profit hospitals and other applicable health systems are meeting the provisions
43 of Internal Revenue Code relating to their tax-exempt status when they restrict or otherwise
44 limit medical staff privileges or maintain closed medical staffs, and take appropriate action to
45 ensure that non-profit hospitals and other applicable health systems continue to meet
46 charitable purposes as required under applicable sections of the Internal Revenue Code.
47 (Directive to Take Action)

48
49 Your Reference Committee heard mixed testimony on Resolution 230. Your Reference
50 Committee heard testimony that the Internal Revenue Service does not strictly say that limiting
51 or closing a medical staff will cost a hospital its 501(c)(3) status and that this policy is long-

1 standing. Your Reference Committee heard testimony that an effort to change this would likely
2 be strenuously opposed by the hospital industry. Your Reference Committee heard testimony
3 that existing AMA policy does not support this resolution—our AMA policy does not say that
4 hospitals cannot close or limit their medical staffs or enter into exclusive contracts with select
5 physicians; it says that the medical staff should be consulted before such actions are taken
6 and that physicians who are not included on the medical staff need to be given due process
7 before being excluded in support of referral. Accordingly, your Reference Committee
8 recommends that Resolution 230 be not adopted.
9

10 (27) RESOLUTION 234 – NEGLIGENT CREDENTIALING
11 ACTIONS AGAINST HOSPITALS

12 RECOMMENDATION:

13 Madam Speaker, your Reference Committee recommends that
14 Resolution 234 not be adopted.

15 Resolution 234 asks that our American Medical Association recognize that “negligent
16 credentialing” lawsuits undermine the overall integrity of the credentialing process, potentially
17 resulting in adverse impacts to patient access and quality of care (New HOD Policy); and be
18 it further, that our AMA actively oppose state legislation and court action recognizing
19 “negligent credentialing” as a cause of action that would allow for patients to sue a hospital
20 and medical staff (Directive to Take Action); and be it further, that our AMA work with state
21 medical societies and medical specialty associations in those states that recognize the tort of
22 negligent credentialing to advocate that such claims should place the highest standard of proof
23 on the plaintiff. (Direct to Take Action)

24 Your Reference Committee heard mixed testimony on Resolution 234. Your Reference
25 Committee heard testimony that patients are already protected under various medical liability
26 or medical malpractice laws and that the threat of liability for negligent credentialing may result
27 in hospitals and health plans adopting more stringent criteria to credential licensed physicians.
28 Your Reference Committee also heard testimony that negligent credentialing is an action that
29 is taken against a hospital and not a physician. Testimony further indicated that our AMA
30 should focus our resources on protecting physicians from liability. Your Reference Committee
31 also heard testimony that removing the hospital from a liability action could be at the expense
32 of the physician and leave the physician with having greater liability. Your Reference Committee
33 heard further testimony that asking our AMA to argue for the highest standard of
34 proof (which is reasonable doubt) for a negligence case weakens AMA’s advocacy efforts
35 because proof beyond reasonable doubt is only meant for criminal cases. Accordingly, your
36 Reference Committee recommends that Resolution 234 not be adopted.

37 (28) RESOLUTION 218 – ALTERNATIVES TO TORT FOR
38 MEDICAL LIABILITY

39 RECOMMENDATION:

40 Madam Speaker, your Reference Committee recommends that
41 Policies H-435.943, H-435.978, H-435.993, D-435.974, and D-
42 43 44 45 46 47 48 49 435.992 be reaffirmed in lieu of Resolution 218.

1 That our American Medical Association study and/or develop options for alternatives to the
2 tort system that will: assure fair compensation to individuals harmed as a result of systems or
3 clinician error in the process of receiving medical care and separately; identify and hold
4 accountable physicians, other practitioners and health care delivery systems for questionable
5 practice through professional review and quality management as well as identify opportunities
6 for improving systems to maximize the safety of medical care (as in New Zealand and other
7 countries or the Candor strategy). (Directive to Take Action)

8
9 Your Reference Committee heard mixed testimony on Resolution 218. Your Reference
10 Committee heard testimony that our AMA remains on the forefront on the medical liability
11 issue by advocating at both the federal and state levels and conducting research to improve
12 the liability system. Our AMA remains committed to advocate for proven reforms—such as
13 caps on non-economic damages—to resolve this problem. Your Reference Committee also
14 heard testimony that based on existing AMA policy our AMA will continue advocating for
15 innovative reforms, such as health courts and early disclosure models, to complement
16 traditional reforms. Your Reference Committee also heard testimony that a fair or no-fault
17 compensation system as proposed in Resolution 218 runs contrary to AMA policy by lowering
18 the standard of proof required for a judgment against a physician, lacks requirements that
19 medical experts have the same or similar expertise as the defendant, and could increase
20 National Practitioner Databank Reporting. Accordingly, given the strong AMA policy on
21 medical liability, your Reference Committee recommends reaffirming policy in lieu of
22 Resolution 218.

23
24 AMA Support for State Medical Societies' Efforts to Implement MICRA-Type
25 Legislation H-435.943

26 Our AMA supports state medical associations in their opposition to proposals to
27 replace a state medical liability system with a no-fault liability or Patient Compensation
28 System, unless those proposals are consistent with AMA policy. (BOT Rep. 02, I-16)

29
30 Federal Medical Liability Reform H-435.978
31 Our AMA: (1) supports federal legislative initiatives implementing the following medical
32 liability reforms: (a) limitation of \$250,000 or lower on recovery of non-economic
33 damages; (b) the mandatory offset of collateral sources of plaintiff compensation; (c)
34 decreasing sliding scale regulation of attorney contingency fees; and (d) periodic
35 payment for future awards of damages; (2) reaffirms its support for the additional
36 reforms identified in Report L (A-89) as appropriate for a federal reform vehicle. These
37 are: (a) a certificate of merit requirement as a prelude to filing medical liability cases;
38 and (b) basic medical expert witness criteria; (3) supports for any federal initiative
39 incorporating provisions of this type would be expressly conditional. Under no
40 circumstances would support for federal preemptive legislation be extended or
41 maintained if it would undermine effective tort reform provisions already in place in the
42 states or the ability of the states in the future to enact tort reform tailored to local needs.
43 Federal preemptive legislation that endangers state-based reform will be actively
44 opposed. Federal initiatives incorporating extended or ill-advised regulation of the
45 practice of medicine also will not be supported. Effective medical liability reform, based
46 on the California Medical Injury Compensation Reform Act (MICRA) model, is integral
47 to health system reform. (BOT Rep. S, I-89, BOT Rep. I-93-53, Reaffirmed: BOT Rep.
48 8, I-98, Reaffirmation A-00, Reaffirmation I-03, Reaffirmed: Sub. Res. 910, I-03,
49 Reaffirmed: Res. 206, I-09, Reaffirmation A-10, Reaffirmed: Sub. Res. 222, I-10,
50 Reaffirmed: Res. 206, A-11, Reaffirmed in lieu of Res. 205, I-11, Reaffirmed in lieu of
51 first resolve of Res. 214, I-15)

1 Tort Liability Reform H-435.993
2

3 Our AMA: (1) supports the efforts of state medical societies to form coalitions
4 supporting tort reform in each state and representing the numerous interests adversely
5 affected by present escalating tort liability costs; and (2) believes these coalitions
6 should address such issues as reform of laws governing product and professional
7 liability, and development of appropriate public education programs regarding the
8 impact and cost to consumers of present liability laws. (Sub. Res. 6, A-84, Reaffirmed
9 by CLRPD Rep. 3 - I-94, Reaffirmation A-00, Reaffirmation I-08, Reaffirmed: BOT Rep.
09, A-18)

10
11 Health System and Litigation Reform D-435.974
12

13 Our AMA will: (1) press vigorously and creatively for inclusion of effective medical
14 litigation reforms as part of the comprehensive federal health system/insurance reform
15 debate now underway in Washington, DC; and (2) consider and, as necessary,
16 negotiate with federal policymakers on a wide range of litigation reform policy options
17 to gain inclusion of a remedy in the health system reform package. These options
18 might include traditional tort reforms, recovery limitations similar to those of the
19 Veterans Administration (VA) system, demonstration/pilot programs on alternate
20 dispute resolution systems such as the VA model and health courts, and/or other
21 effective options to preserve patient access to care. (Res. 209, A-09, Reaffirmed: Sub.
22 Res. 222, I-10)

23 Liability Reform D-435.992
24

25 Our AMA: (1) in concert with a coalition for civil liability reform, shall develop a broad-
26 based and sustained grassroots member mobilization campaign to communicate its
27 call for immediate legislative relief from the current tort system to our congressional
28 representatives and senators; (2) will work for passage of significant legislation in both
29 houses of the US Congress on liability reform in this congressional year; and (3) will
30 work with state and national medical specialty societies to develop and implement a
31 comprehensive strategic plan that will address all aspects of the growing medical
32 liability crisis to ensure that federal medical liability reform legislation continues to
33 move forward through the legislative process. (Sub. Res. 215, A-02, Reaffirmation I-
03, Appended: Sub. Res. 910, I-03, Modified: BOT Rep. 28, A-13)

34
35 (29) RESOLUTION 225 – “SURPRISE” OUT OF NETWORK BILLS
36

37 RECOMMENDATION:

38
39 Madam Speaker, your Reference Committee recommends that
40 Policy H-285.904 be reaffirmed in lieu of Resolution 225.

41
42 Resolution 225 asks that our American Medical Association advocate that any federal
43 legislation on “surprise” out of network medical bills be consistent with AMA Policy H-285.904,
44 “Out-of-Network Care,” and apply to ERISA plans not subject to state regulation (New HOD
45 Policy); and be it further, that our AMA advocate that such federal legislation protect state
46 laws that do not limit surprise out of network medical bills to a percentage of Medicare or
47 health insurance fee schedules. (New HOD Policy)

48
49 Your Reference Committee heard testimony that our AMA is committed to developing patient-
50 centered solutions to unanticipated out-of-network care and addressing the financial burden
51 patients may face when they incur unexpected expenses for care not covered by their health

1 insurance company. Your Reference Committee heard that concepts addressed in Resolution
2 225 already addressed in existing out-of-network policy H-285-904, which was recently
3 adopted after substantial conversation with state and specialty societies. Testimony also
4 stated that this policy clearly outlines both a fair payment standard and requires that advocacy
5 around our out-of-network policy should be directed at all health plans, including ERISA-
6 regulated plans.

7
8 Your Reference Committee heard testimony for and against the addition of a recommendation
9 that our AMA develop model federal legislation consistent with existing policy relative to this
10 subject. Testimony for adoption suggested that our AMA develop model federal legislation
11 consistent with existing policy. Testimony against adding this language raised concerns that
12 drafting a federal model bill could limit our AMA's and other physician groups' flexibility to work
13 with Congress to craft a workable solution. Your Reference Committee heard that if our AMA
14 drafted a federal bill, and then Congress uses different language or a different statutory
15 pathway than what our AMA proposed, our AMA would potentially be in a position of having
16 to oppose or not support the bill that would otherwise achieve the same result, while other
17 physician groups and other stakeholders would not be under the same constraint. Your
18 Reference Committee agrees with these concerns, and notes that our current AMA Policy H-
19 285.904 was just amended at our 2018 Annual Meeting with language that is very clear—our
20 AMA will advocate for Policy H-285.904 "for all health plans, including ERISA plans." Your
21 Reference Committee heard testimony that this means our AMA will continue to advocate for
22 federal legislation, whether it is achieved through the Public Health Service Act, the Social
23 Security Act, the Internal Revenue Code, ERISA, or other federal statutes, as long as it meets
24 the criteria of our policy. Furthermore, your Reference Committee heard testimony that our
25 AMA is currently engaged in discussions with Members of Congress who are attempting to
26 draft a federal solution to balance billing. These discussions include working with other
27 physician groups, and that these physician groups have all been largely aligned around
28 current AMA policy as the basis for negotiations. Your Reference Committee agrees with the
29 concerns raised that altering course now could impact not just our AMA's progress, but that
30 of other physician groups engaged in this advocacy activity. Accordingly, your Reference
31 Committee recommends that Policy H-285.904 be reaffirmed in lieu of Resolution 225.

32
33 Out-of-Network Care H-285.904
34 1. Our AMA adopts the following principles related to unanticipated out-of-network
35 care: A. Patients must not be financially penalized for receiving unanticipated care
36 from an out-of-network provider. B. Insurers must meet appropriate network adequacy
37 standards that include adequate patient access to care, including access to hospital-
38 based physician specialties. State regulators should enforce such standards through
39 active regulation of health insurance company plans. C. Insurers must be transparent
40 and proactive in informing enrollees about all deductibles, copayments and other out-
41 of-pocket costs that enrollees may incur. D. Prior to scheduled procedures, insurers
42 must provide enrollees with reasonable and timely access to in-network physicians. E.
43 Patients who are seeking emergency care should be protected under the "prudent
44 layperson" legal standard as established in state and federal law, without regard to
45 prior authorization or retrospective denial for services after emergency care is
46 rendered. F. Out-of-network payments must not be based on a contrived percentage
47 of the Medicare rate or rates determined by the insurance company. G. Minimum
48 coverage standards for unanticipated out-of-network services should be identified.
49 Minimum coverage standards should pay out-of-network providers at the usual and
50 customary out-of-network charges for services, with the definition of usual and
51 customary based upon a percentile of all out-of-network charges for the particular

1 health care service performed by a provider in the same or similar specialty and
2 provided in the same geographical area as reported by a benchmarking database.
3 Such a benchmarking database must be independently recognized and verifiable,
4 completely transparent, independent of the control of either payers or providers and
5 maintained by a non-profit organization. The non-profit organization shall not be
6 affiliated with an insurer, a municipal cooperative health benefit plan or health
7 management organization. H. Mediation should be permitted in those instances where
8 a physicians unique background or skills (e.g. the Gould Criteria) are not accounted
9 for within a minimum coverage standard. 2. Our AMA will advocate for the principles
10 delineated in Policy H-285.904 for all health plans, including ERISA plans. (Res. 108,
11 A-17; Reaffirmation: A-18; Appended: Res. 104, A-18)

12
13 (30) RESOLUTION 228 – MEDICATION ASSISTED TREATMENT

14
15 RECOMMENDATION:

16
17 Madam Speaker, your Reference Committee recommends that
18 Policies H-185.931, H-95.944, and D-160.981 be reaffirmed in
19 lieu of Resolution 228.

20
21 Resolution 228 asks that our American Medical Association advocate for all insurance plans
22 (public and private payers) to provide coverage for medication assisted treatment of opioid
23 use disorder by all qualified physicians. (New HOD Policy)

24
25 Your Reference Committee heard mixed testimony on Resolution 228. Your Reference
26 Committee heard testimony that all insurance plans should provide coverage for medication
27 assisted treatment (MAT) of opioid use disorder. Testimony also indicated that our AMA
28 already has existing policy that our AMA advocate for all payers to provide coverage for MAT.
29 Further testimony stated that our AMA is also already advocating for all forms of MAT to be
30 on the lowest cost-sharing tier of a plan formulary and also to remove prior authorization and
31 other health plan barriers to MAT. Accordingly, your Reference Committee recommends
32 reaffirming Policies H-185.931, H-95.944, and D-160.981.

33
34 Workforce and Coverage for Pain Management H-185.931

35 1. Our AMA supports efforts to improve the quality of care for patients with pain,
36 ensuring access to multiple analgesic strategies, including non-opioid options and
37 interventional approaches when appropriate, with a focus on achieving improvement
38 in function and activities of daily living. 2. Our AMA supports guidance on pain
39 management for different clinical indications developed by the specialties who manage
40 those conditions and disseminated the same way other clinical guidelines are
41 promoted, such as through medical journals, medical societies, and other appropriate
42 outlets. 3. Our AMA will advocate for an increased focus on comprehensive,
43 multidisciplinary pain management approaches that include the ability to assess co-
44 occurring mental health or substance use conditions, are physician led, and recognize
45 the interdependency of treatment methods in addressing chronic pain. 4. Our AMA
46 supports health insurance coverage that gives patients access to the full range of
47 evidence-based chronic pain management modalities, and that coverage for these
48 services be equivalent to coverage provided for medical or surgical benefits. 5. Our
49 AMA supports efforts to expand the capacity of practitioners and programs capable of
50 providing physician-led interdisciplinary pain management services, as well as an
51 expanded behavioral health workforce to improve the availability of services to

1 address the psychological, behavioral, and social aspects of pain and pain
2 management within multidisciplinary pain clinics. Patients and their caregivers should
3 be involved in the decision-making process. 6. Our AMA supports an expanded
4 availability of comprehensive multidisciplinary pain medicine clinics for patients in both
5 urban and rural areas, and an improvement in payment models for comprehensive
6 multidisciplinary pain clinics services such that such services can become more
7 financially viable. (CMS/CSAPH Rep. 1, A-15 Reaffirmed: BOT Rep. 5, I-15
8 Reaffirmed: BOT Rep. 19, A-16 Reaffirmed in lieu of Res. 117, A-16 Modified: BOT
9 Rep. 38, A-18)

10
11 Third-Party Payer Policies on Opioid Use Disorder Pharmacotherapy H-95.944
12 Our AMA opposes federal, state, third-party and other laws, policies, rules and
13 procedures, including those imposed by Pharmacy Benefit Managers working for
14 Medicaid, Medicare, TriCare, and commercial health plans, that would limit a patient's
15 access to medically necessary pharmacological therapies for opioid use disorder,
16 whether administered in an office-based opioid treatment setting or in a federal
17 regulated Opioid Treatment Program, by imposing limitations on the duration of
18 treatment, medication dosage or level of care. (Res. 710, A-13)

19
20 Promotion of Better Pain Care D-160.981

21 1. Our AMA: (a) will express its strong commitment to better access and delivery of
22 quality pain care through the promotion of enhanced research, education and clinical
23 practice in the field of pain medicine; and (b) encourages relevant specialties to
24 collaborate in studying the following: (i) the scope of practice and body of knowledge
25 encompassed by the field of pain medicine; (ii) the adequacy of undergraduate,
26 graduate and post graduate education in the principles and practice of the field of pain
27 medicine, considering the current and anticipated medical need for the delivery of
28 quality pain care; (iii) appropriate training and credentialing criteria for this
29 multidisciplinary field of medical practice; and (iv) convening a meeting of interested
30 parties to review all pertinent matters scientific and socioeconomic. 2. Our AMA
31 encourages relevant stakeholders to research the overall effects of opioid production
32 cuts. 3. Our AMA strongly urges the US Drug Enforcement Administration to base any
33 future reductions in aggregate production quotas for opioids on actual data from
34 multiple sources, including prescribing data, and to proactively monitor opioid quotas
35 and supply to prevent any shortages that might develop and to take immediate action
36 to correct any shortages. 4. Our AMA encourages the US Drug Enforcement
37 Administration to be more transparent when developing medication production
38 guidelines. 5. Our AMA and the physician community reaffirm their commitment to
39 delivering compassionate and ethical pain management, promoting safe opioid
40 prescribing, reducing opioid-related harm and the diversion of controlled substances,
41 improving access to treatment for substance use disorders, and fostering a public
42 health based-approach to addressing opioid-related morbidity and mortality. (Res.
43 321, A-08 Appended: Res. 522, A-10 Reaffirmed in lieu of Res. 518, A-12 Reaffirmed:
44 BOT Rep. 19, A-16 Reaffirmed in lieu of Res. 117, A-16)

1 Madam Speaker, this concludes the report of Reference Committee B. I would like to thank
2 Sue Bornstein, MD, Tilden Childs, MD, Daniel P. Edney, MD, Ross F. Goldberg, MD,
3 Raymond Lorenzoni, MD, Bruce A. MacLeod, MD, and all those who testified before the
4 Committee.

Sue Bornstein, MD
American College of Physicians

Ross F. Goldberg, MD (Alternate)
Arizona

Tilden L. Childs, MD
American College of Radiology

Raymond Lorenzoni, MD
Medical Society of the State of New York
(Resident and Fellow Delegate)

Daniel P. Edney, MD (Alternate)
Mississippi

Bruce A. MacLeod, MD (Alternate)
Pennsylvania

Francis P. MacMillan, Jr., MD
Massachusetts
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (I-18)

Report of Reference Committee C

Peter C. Amadio, MD, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:

2 **RECOMMENDED FOR ADOPTION**

3 1. Council on Medical Education Report 5 – Reconciliation of AMA Policy on
4 Medical Student Debt
5 2. Council on Medical Education Report 6 – Reconciliation of AMA Policy on
6 Resident/Fellow Contracts and Duty Hours
7 3. Resolution 951 – Prevention of Physician and Medical Student Suicide
8 4. Resolution 953 – Support for the Income-Driven Repayment Plans
9 5. Resolution 954 – VHA GME Funding
10 6. Resolution 955 – Equality for COMLEX and USMLE

11 **RECOMMENDED FOR ADOPTION AS AMENDED**

12 7. Council on Medical Education Report 1 – Competency of Senior Physicians
13 8. Council on Medical Education Report 3 – Developing Physician-Led Public
14 Health/Population Health Capacity in Rural Communities
15 9. Council on Medical Education Report 4 – Reconciliation of AMA Policy on
16 Primary Care Workforce
17 10. Resolution 956 – Increasing Rural Rotations During Residency
18 11. Resolution 957 – Board Certifying Bodies
19 12. Resolution 961 – Protect Physician-Led Medical Education

20 **RECOMMENDED FOR REFERRAL**

21 13. Resolution 959 – Physician and Medical Student Mental Health and Suicide

22 **RECOMMENDED FOR REAFFIRMATION IN LIEU OF**

23 14. Resolution 960 – Inadequate Residency Slots

24 Existing policy was reaffirmed in lieu of the following resolutions via the Reaffirmation
25 Consent Calendar:

26 Resolution 958 – National Health Service Corps Eligibility

27 Note: The following two items were withdrawn and not considered.

28 Resolution 952 – IMG Section Member Representation on Committees/Task
29 Forces/Councils

30 Resolution 962 – Improve Physician Health Programs

1 (1) COUNCIL ON MEDICAL EDUCATION REPORT 5 -
2 RECONCILIATION OF AMA POLICY ON MEDICAL
3 STUDENT DEBT

4
5 RECOMMENDATION:

6
7 Madam Speaker, your Reference Committee recommends
8 that the recommendations in Council on Medical Education
9 Report 5 be adopted and the remainder of the report be
10 filed.

11 Council on Medical Education Report 5 asks:

12 1. That our American Medical Association (AMA) adopt as policy "Principles of and Actions
13 to Address Medical Education Costs and Student Debt" the language shown in column 1
14 of Appendix A of this report; and

15 2. That our AMA rescind the following policies, as shown in Appendix C:

- 16 • D-305.956, "AMA Participation in Reducing Medical Student Debt"
- 17 • D-305.957, "Update on Financial Aid Programs"
- 18 • D-305.962, "Tax Deductibility of Student Loan Payments"
- 19 • D-305.966, "Reinstatement of Economic Hardship Loan Deferment"
- 20 • D-305.970, "Proposed Revisions to AMA Policy on Medical Student Debt"
- 21 • D-305.975, "Long-Term Solutions to Medical Student Debt"
- 22 • D-305.977, "Deductibility of Medical Student Loan Interest"
- 23 • D-305.978, "Mechanisms to Reduce Medical Student Debt"
- 24 • D-305.979, "State and Local Advocacy on Medical Student Debt"
- 25 • D-305.980, "Immediate Legislative Solutions to Medical Student Debt"
- 26 • D-305.981, "Financing Federal Consolidation Loans"
- 27 • D-305.993, "Medical School Financing, Tuition, and Student Debt"
- 28 • D-405.986, "Student Loans and Medicare / Medicaid Participation"
- 29 • H-305.926, "Supporting Legislation to Create Student Loan Savings Accounts"
- 30 • H-305.928, "Proposed Revisions to AMA Policy on Medical Student Debt"
- 31 • H-305.932, "State and Local Advocacy on Medical Student Debt"
- 32 • H-305.948, "Direct Loan Consolidation Program"
- 33 • H-305.954, "Repayment of Medical School Loans"
- 34 • H-305.965, "Student Loans"
- 35 • H-305.980, "Student Loan Repayment Grace Period"
- 36 • H-305.991, "Repayment of Educational Loans"

37
38 Your Reference Committee heard testimony uniformly in favor of the Council on Medical
39 Education's work on consolidating and reconciling multiple AMA policies on this important
40 topic. Limited testimony was received requesting addition of the word "service" to item 5
41 of the proposed new policy ("Encourage the National Health Service Corps to have service
42 repayment policies that are consistent with other federal loan forgiveness programs"), but
43 your Reference Committee believes this addition is not currently reflected in existing
44 policy, and therefore would be outside the permissible parameters of a reconciliation
45 report. (See AMA Policy G-600.111, "Consolidation and Reconciliation of AMA Policy,"
46 which states: "(4) The consolidation process permits editorial amendments for the sake of
47 clarity, so long as the proposed changes are transparent to the House and do not change
48

1 the meaning.") Therefore, your Reference Committee recommends that Council on
2 Medical Education Report 5 be adopted and the remainder of the report be filed.
3

4 (2) COUNCIL ON MEDICAL EDUCATION REPORT 6 -
5 RECONCILIATION OF AMA POLICY ON RESIDENT/
6 FELLOW CONTRACTS AND DUTY HOURS
7

8 RECOMMENDATION:
9

10 Madam Speaker, your Reference Committee recommends
11 that the recommendations in Council on Medical Education
12 Report 6 be adopted and the remainder of the report be
13 filed.
14

15 Council on Medical Education Report 6 asks:

16 1. That our American Medical Association (AMA) adopt the proposed revisions shown in
17 Appendix A, column 1, for the following three policies:

- 18 • H-310.907, "AMA Duty Hours Policy" (with revised title: "Resident/Fellow Clinical and
19 Educational Work Hours")
- 20 • H-310.912, "Residents and Fellows' Bill of Rights"
- 21 • H-310.929, "Principles for Graduate Medical Education"

22 2. That our AMA rescind the following seven policies, as shown in Appendix C, and
23 incorporate relevant portions of four of these policies into existing AMA policy:

- 24 • D-310.987, "Impact of ACGME Resident Duty Hour Limits on Physician Well-Being
25 and Patient Safety"
- 26 • H-310.922, "Determining Residents' Salaries"
- 27 • H-310.932, "Annual Contracts for Continuing Residents"
- 28 • H-310.947, "Revision of the 'General Requirements' of the Essentials of Accredited
29 Residency Programs"
- 30 • H-310.979, "Resident Physician Working Hours and Supervision"
- 31 • H-310.988, "Adequate Resident Compensation"
- 32 • H-310.999, "Guidelines for Housestaff Contracts or Agreements"

33 Your Reference Committee heard testimony uniformly in favor of the Council on Medical
34 Education's work on consolidating and reconciling multiple AMA policies on this important
35 topic. Limited testimony was provided that a revision to H-310.912, "Residents and
36 Fellows' Bill of Rights," section E.(3), to replace "maternity and paternity leave" with "family
37 and medical leave," could be problematic for PGY-1 resident physicians, if interpreted as
38 referring to the federal Family Medical Leave Act (FMLA). The Council on Medical
39 Education clarified the intent of the policy to be broader than the FMLA; your Reference
40 Committee therefore recommends adoption of Council on Medical Education Report 6.
41

1 (3) RESOLUTION 951 - PREVENTION OF PHYSICIAN AND
2 MEDICAL STUDENT SUICIDE

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 951 be adopted.

8
9 Resolution 951 asks: That our American Medical Association request that the Liaison
10 Committee on Medical Education and the Accreditation Council for Graduate Medical
11 Education collect data on medical student, resident and fellow suicides to identify patterns
12 that could predict such events.

13
14 Online testimony regarding this item was supportive of the resolution's intent, although
15 some testimony noted that the Council on Medical Education is currently writing a report
16 related to this topic, and suggested referral. Your Reference Committee heard
17 impassioned in-person testimony regarding the devastating effects of burnout and
18 depression, and all who spoke were in agreement regarding the urgency of this issue.
19 Additional testimony agreed that collection of data by the bodies named in this resolution
20 is an important step, but also highlighted that those named groups work only with medical
21 students and residents, and that these data are also needed for physicians who have
22 completed their training. Your Reference Committee agrees, and encourages the Council
23 on Medical Education to consider this data gap when presenting their related report to the
24 HOD at the 2019 Annual Meeting. Overall, however, this resolution commanded
25 widespread support. Therefore, your Reference Committee recommends that Resolution
26 951 be adopted.

27
28 (4) RESOLUTION 953 - SUPPORT FOR THE INCOME-
29 DRIVEN REPAYMENT PLANS

30
31 RECOMMENDATION:

32
33 Madam Speaker, your Reference Committee recommends
34 that Resolution 953 be adopted.

35
36 Resolution 953 asks: That our American Medical Association advocate for continued
37 funding of programs including Income-Driven Repayment plans for the benefit of reducing
38 medical student loan burden.

39
40 Your Reference Committee heard uniformly positive testimony on this item. Our AMA
41 policy supports maintaining and expanding both state and federal programs that minimize
42 the impact of student loan debt on the pursuit of a career in medicine. As such, income-
43 driven repayment plans are critical programs that enable a diverse range of students the
44 ability to specialize in their desired discipline within the profession's workforce. These
45 plans relieve the burden of medical student loan debt by setting loan payments as a
46 percentage of the new physician's income. Payments become more manageable with the
47 repayment period extended from the standard 10 years to up to 25 years, and the
48 remaining balance can be forgiven at the end of that period. Lifting the burden of medical
49 student debt through the evaluation and development of feasible and effective loan

1 forgiveness programs is a laudable goal for our AMA; your Reference Committee believes
2 this resolution provides our AMA the means to this end. Therefore, your Reference
3 Committee recommends that Resolution 953 be adopted.

4

5 (5) RESOLUTION 954 - VHA GME FUNDING

6

7 RECOMMENDATION A:

8

9 Madam Speaker, your Reference Committee recommends
10 that Resolves 1 and 2 of Resolution 954 be adopted.

11

12 RECOMMENDATION B:

13

14 Madam Speaker, your Reference Committee recommends
15 that Resolve 3 in Resolution 954 be referred.

16

17 Resolution 954 asks: That our American Medical Association continue to support the
18 mission of the Department of Veterans Affairs Office of Academic Affiliations for expansion
19 of graduate medical education (GME) residency positions; That our AMA collaborate with
20 appropriate stakeholder organizations to advocate for preservation of Veterans Health
21 Administration (VHA) funding for GME and support its efforts to expand GME residency
22 positions in the federal budget and appropriations process; and That our AMA oppose
23 service obligations linked to VHA GME residency or fellowship positions, particularly for
24 resident physicians rotating through the VA for only a portion of their GME training.

25

26 Your Reference Committee heard mixed testimony on this resolution. Our AMA has long
27 been an advocate for preservation and expansion of GME funding to mitigate projected
28 physician shortages and ensure that positions are available for medical school graduates
29 applying to residency programs. Currently, there are no service obligations for VA
30 residency programs, and our AMA does not have existing policy opposing a GME
31 expansion plan linked to a service obligation. However, it was noted that all funding for
32 residency/fellowship positions, whether from private, Veterans Administration (VA), and/or
33 Centers for Medicare & Medicaid Services (CMS) sources, carries with it the expectation
34 that residents/fellows perform service for patients during their years in the training
35 program. Due to the complicated rules at institutions that sponsor residency programs
36 related to full funding for a resident full-time employee, it was recommended that Resolve
37 3 be referred for further study. Therefore, your Reference Committee recommends that
38 Resolves 1 and 2 of Resolution 954 be adopted and Resolve 3 be referred.

1 (6) RESOLUTION 955 - EQUALITY FOR COMLEX AND
2 USMLE

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 955 be adopted.

8
9 Resolution 955 asks: That our American Medical Association promote equal acceptance
10 of the USMLE and COMLEX at all United States residency programs; That our AMA work
11 with appropriate stakeholders including but not limited to the National Board of Medical
12 Examiners, Association of American Medical Colleges, National Board of Osteopathic
13 Medical Examiners, Accreditation Council for Graduate Medical Education and American
14 Osteopathic Association to educate Residency Program Directors on how to interpret and
15 use COMLEX scores; and That our AMA work with Residency Program Directors to
16 promote higher COMLEX utilization with residency program matches in light of the new
17 single accreditation system.

18
19 Your Reference Committee heard strong testimony in support of this resolution. Testimony
20 acknowledged that the United States Medical Licensing Examination (USMLE) and
21 Comprehensive Osteopathic Medical Licensing Examination (COMLEX) are credentialing
22 examinations that have been increasingly used in recent years as selection criteria for
23 acceptance into a residency program, which is not their intended purpose. Testimony also
24 noted the high costs of these examinations and the large disparity between program
25 directors' usage of the examinations for residency selection criteria, with greater
26 preference for the USMLE over the COMLEX, despite testimony indicating a strong
27 correlation of scores among people who take both exams. This resolution is calling for
28 equal acceptance of the USMLE and COMLEX at all U.S. residency programs. This is
29 consistent with HOD Policy H-275.953, "The Grading Policy for Medical Licensure
30 Examinations," which promotes the principle that selection of residents should be based
31 on a broad variety of evaluative criteria, and proposes that ACGME program requirements
32 state clearly that residency program directors not use NBME or USMLE ranked passing
33 scores as a screening criterion for residency selection. This issue is timely as the single
34 accreditation pathway and National Resident Matching Program will be the primary
35 avenue that all osteopathic medical students will participate in for residency application.
36 In addition, the COMLEX examination is a graduation requirement for all osteopathic
37 medical students, and the examination taken by one in five future physicians is a
38 measurement tool that all program directors should be familiar with and accept. Therefore,
39 your Reference Committee recommends that Resolution 955 be adopted.

1 (7) COUNCIL ON MEDICAL EDUCATION REPORT 1 -
2 COMPETENCY OF SENIOR PHYSICIANS

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Recommendation 1.a and 1.e in Council on Medical
8 Education Report 1 be amended by addition and deletion,
9 to read as follows:

10
11 1. That our American Medical Association (AMA) make
12 available to all interested parties the Assessment of
13 Senior/Late Career Physicians Guiding Principles:

14
15 a) Evidence-based: The development of guidelines
16 for assessing and screening senior/late career
17 physicians is based on evidence of the importance
18 of cognitive changes associated with aging that are
19 relevant to physician performance. ~~Current research
20 suggests that physician competency and practice
21 performance decline with increasing years in
22 practice. Some physicians may suffer from declines
23 in practice performance with advancing age.~~
24 ~~However, r~~Research also suggests that the effect of
25 age on an individual physician's competency can be
26 highly variable, and wide variations are seen in
27 cognitive performance with aging.

28
29 e) Fair and equitable: The goal of screening and
30 assessment is to optimize physician competency
31 and performance through education, remediation,
32 and modifications to physicians' practice
33 environment or scope. Unless public health or
34 patient safety is directly threatened, physicians
35 should retain the right to modify their practice
36 environment to allow them to continue to provide
37 safe and effective care. ~~When public health or
38 patient safety is directly threatened, removal from
39 practice is one potential outcome.~~

40
41 RECOMMENDATION B:

42
43 Madam Speaker, your Reference Committee recommends
44 that the recommendations in Council on Medical Education
45 Report 1 be adopted as amended and the remainder of the
46 report be filed.

1 Council on Medical Education Report 1 asks: 1. That our American Medical Association
2 (AMA) make available to all interested parties the Assessment of Senior/Late Career
3 Physicians Guiding Principles: a) Evidence-based: The development of guidelines for
4 assessing and screening senior/late career physicians is based on evidence of the
5 importance of cognitive changes associated with aging that are relevant to physician
6 performance. Current research suggests that physician competency and practice
7 performance decline with increasing years in practice. However, research also suggests
8 that the effect of age on an individual physician's competency can be highly variable, and
9 wide variations are seen in cognitive performance with aging. b) Ethical: Guidelines should
10 be based on the principles of medical ethics. Self-regulation is an important aspect of
11 medical professionalism. Physicians should be involved in the development of
12 guidelines/standards for monitoring and assessing both their own and their colleagues'
13 competency. c) Relevant: Guidelines, procedures, or methods of assessment should be
14 relevant to physician practices to inform judgments and provide feedback regarding
15 physicians' ability to perform the tasks specifically required in their practice environment.
16 d) Accountable: The ethical obligation of the profession to the health of the public and
17 patient safety should be the primary driver for establishing guidelines and informing
18 decision making about physician screening and assessment results. e) Fair and equitable:
19 The goal of screening and assessment is to optimize physician competency and
20 performance through education, remediation, and modifications to physicians' practice
21 environment or scope. Unless public health or patient safety is directly threatened,
22 physicians should retain the right to modify their practice environment to allow them to
23 continue to provide safe and effective care. When public health or patient safety is directly
24 threatened, removal from practice is one potential outcome. f) Transparent: Guidelines,
25 procedures or methods of screening and assessment should be transparent to all parties,
26 including the public. Physicians should be aware of the specific methods used,
27 performance expectations and standards against which performance will be judged, and
28 the possible outcomes of the screening or assessment. g) Supportive: Education and/or
29 remediation practices that result from screening and /or assessment procedures should
30 be supportive of physician wellness, ongoing, and proactive. h) Cost conscious:
31 Procedures and screening mechanisms that are distinctly different from "for cause"
32 assessments should not result in undue cost or burden to senior physicians providing
33 patient care. Hospitals and health care systems should provide easily accessible
34 screening assessments for their employed senior physicians. Similar procedures and
35 screening mechanisms should be available to senior physicians who are not employed by
36 hospitals and health care systems; 2. That our AMA encourage the Federation of State
37 Medical Boards, Council of Medical Specialty Societies, and other interested organizations
38 to develop educational materials on the effects of age on physician practice for senior/late
39 career physicians; and 3. That Policy D-275.956, "Assuring Safe and Effective Care for
40 Patients by Senior/Late Career Physicians," be rescinded, as having been fulfilled by this
41 report.

42
43 Your Reference Committee heard strong support for Council on Medical Education Report
44 1. This report outlines a set of Guiding Principles developed by the Council on Medical
45 Education, with extensive feedback and assistance from our AMA's Work Group on
46 Assessment of Senior/Late Career Physicians, which included key stakeholders
47 representing physicians, medical specialty societies, accrediting and certifying
48 organizations, hospitals and other health care institutions, and patients' advocates, as well
49 as other content experts who research physician competence and administer assessment

1 programs. The Guiding Principles provide direction and serve as a reference for the
2 development of guidelines for screening and assessing senior/late career physicians.
3 Other testimony alluded to the application of the Guiding Principles, and queried whether
4 our AMA was advocating for a screening process for senior/late career physicians. Further
5 testimony from the Council on Medical Education clarified that this is not the case, and
6 that the Principles are intended to ensure that physicians can self-advocate when
7 discussions regarding their competency are raised by their institutions or practices. In
8 addition, the first recommendation (Guiding Principle 1.a) was amended to reflect
9 testimony that not all physicians suffer from declines in practice performance with
10 advancing age. Your Reference Committee also deleted text in Guiding Principle 1.e that
11 appeared to be redundant. Your Reference Committee therefore recommends that
12 Council on Medical Education Report 1 be adopted as amended.
13

14 (8) COUNCIL ON MEDICAL EDUCATION REPORT 3 -
15 DEVELOPING PHYSICIAN-LED PUBLIC HEALTH/
16 POPULATION HEALTH CAPACITY IN RURAL
17 COMMUNITIES

18 RECOMMENDATION A:

19 Madam Speaker, your Reference Committee recommends
20 that Recommendation 3 in Council on Medical Education
21 Report 3 be amended by addition and deletion, to read as
22 follows:

23 That our AMA encourage the Association of American
24 Medical Colleges (AAMC), American Association of
25 Colleges of Osteopathic Medicine (AACOM), and
26 Accreditation Council for Graduate Medical Education
27 (ACGME) to highlight public/population health leadership
28 learning opportunities to all learners, but especially
29 encourage dissemination to women physician groups and
30 other groups typically and those who are underrepresented
31 in medicine. (Directive to Take Action)

32 RECOMMENDATION B:

33 Madam Speaker, your Reference Committee recommends
34 that the recommendations in Council on Medical Education
35 Report 3 be adopted as amended and the remainder of the
36 report be filed.

37 Council on Medical Education Report 3 asks:

- 44 1. That Policy D-295.311, "Developing Physician Led Public Health / Population Health
45 Capacity in Rural Communities," be rescinded, as having been fulfilled by this report;
- 46 2. That our American Medical Association (AMA) reaffirm the following policies:
 - 47 • D-295.327, "Integrating Content Related to Public Health and Preventive Medicine
48 Across the Medical Education Continuum"

1 • D-305.964, "Support for the Epidemic Intelligence Service (EIS) Program and
2 Preventive Medicine Residency Expansion"
3 • D-305.974, "Funding for Preventive Medicine Residencies"
4 • H-425.982, "Training in the Principles of Population-Based Medicine"
5 • D-440.951, "One-Year Public Health Training Options for all Specialties"
6 • H-440.954, "Revitalization of Local Public Health Units for the Nation"
7 • H-440.888, "Public Health Leadership"
8 • H-440.969, "Meeting Public Health Care Needs Through Health Professions
9 Education"

10 3. That our AMA encourage the Association of American Medical Colleges (AAMC),
11 American Association of Colleges of Osteopathic Medicine (AACOM), and Accreditation
12 Council for Graduate Medical Education (ACGME) to highlight public/population health
13 leadership learning opportunities to all learners, but especially to women and those who
14 are underrepresented in medicine; and 4. That our AMA encourage public health
15 leadership programs to evaluate the effectiveness of various leadership interventions.

16
17 Online testimony regarding this report was unanimously supportive. Testimony specifically
18 applauded the report's thorough listing of currently available training opportunities across
19 the continuum, as well as the call for relevant organizations to highlight learning
20 opportunities in rural and public health. Your Reference Committee also heard
21 overwhelmingly positive in-person testimony, which noted that the report effectively
22 addresses the HOD mandate to study innovative approaches that support interested
23 physicians as they seek qualifications and credentials in preventive medicine/public health
24 to strengthen public health leadership. Testimony also, however, identified important
25 related policy gaps, and your Reference Committee agrees that our AMA should consider
26 future policy that addresses these gaps, such as emphasizing concrete steps physicians
27 currently practicing in rural areas can take to enhance their own public/population health
28 skills. A minor editorial change was proposed to one of the report's recommendations,
29 which your Reference Committee agrees will strengthen the report's policy impact.
30 Therefore, your Reference Committee recommends that Council on Medical Education
31 Report 3 be adopted as amended.

32
33 (9) COUNCIL ON MEDICAL EDUCATION REPORT 4 -
34 RECONCILIATION OF AMA POLICY ON PRIMARY
35 CARE WORKFORCE

36
37 RECOMMENDATION A:

38
39 Madam Speaker, your Reference Committee recommends
40 that Recommendation 1 in Council on Medical Education 4
41 be amended by addition and deletion, to read as follows:

42
43 That our American Medical Association (AMA) adopt as
44 policy "Principles of and Actions to Address Primary Care
45 Workforce" the language shown in column 1 in Appendix A
46 to this report, with the following deletion to item 8. (New
47 HOD Policy)

1 8. Curriculum: Voluntary efforts to develop and expand both
2 undergraduate and graduate medical education programs
3 to educate primary care physicians in increasing numbers
4 should be continued, ~~including such innovations as a three~~
5 ~~year medical school curriculum that leads directly to primary~~
6 ~~care residency programs. The establishment of appropriate~~
7 ~~administrative units for family medicine should be~~
8 ~~encouraged.~~

9
10 RECOMMENDATION B:

11
12 Madam Speaker, your Reference Committee recommends
13 that the recommendations in Council on Medical Education
14 Report 4 be adopted as amended and the remainder of the
15 report be filed.

16
17 Council on Medical Education Report 4 asks:

18 1. That our American Medical Association (AMA) adopt as policy "Principles of and Actions
19 to Address Primary Care Workforce" the language shown in column 1 in Appendix A to
20 this report;

21 2. That our AMA rescind the following policies, as shown in Appendix C:

- 22 • D-200.979, "Barriers to Primary Care as a Medical School Choice"
- 23 • D-200.994, "Appropriations for Increasing Number of Primary Care Physicians"
- 24 • H-200.956, "Appropriations for Increasing Number of Primary Care Physicians"
- 25 • H-200.966, "Federal Financial Incentives and Medical Student Career Choice"
- 26 • H-200.973, "Increasing the Availability of Primary Care Physicians"
- 27 • H-200.975, "Availability, Distribution and Need for Family Physicians"
- 28 • H-200.977, "Establishing a National Priority and Appropriate Funding for Increased
29 Training of Primary Care Physicians"
- 30 • H-200.978, "Loan Repayment Programs for Primary Care Careers"
- 31 • H-200.982, "Significant Problem of Access to Health Care in Rural and Urban
32 Underserved Areas"
- 33 • H-200.997, "Primary Care"
- 34 • H-295.956, "Educational Grants for Innovative Programs in Undergraduate and
35 Residency Training for Primary Care Careers"
- 36 • H-300.957, "Promoting Primary Care Services Through Continuing Medical
37 Education"
- 38 • H-310.973, "Primary Care Residencies in Community Hospitals"

39 3. That H-200.972, "Primary Care Physicians in the Inner City," be amended by addition
40 and deletion, and a title change, to read as follows:

41 "Primary Care Physicians in Underserved Areas"

42 Our AMA should pursue the following plan to improve the recruitment and retention of
43 physicians in ~~the inner city underserved areas~~: (1) Encourage the creation and pilot-testing
44 of school-based, ~~church~~ ~~faith~~-based, and community-based urban/rural "family ~~h~~health
45 clinics, with an emphasis on health education, prevention, primary care, and prenatal care.
46 (2) Encourage the affiliation of these family health clinics with ~~urban~~ local medical schools
47 and teaching hospitals. (3) Promote medical student rotations through the various inner-
48 city neighborhood family health clinics, with financial assistance to the clinics to
49 compensate their teaching efforts. (4) Encourage medical schools and teaching hospitals

1 to integrate third- and fourth-year ~~undergraduate medical education and residency training~~
2 into ~~these teams.~~ (53) Advocate for the implementation of AMA policy that supports
3 extension of the rural health clinic concept to urban areas with appropriate federal
4 agencies. (6) Study the concept of having medical schools with active outreach programs
5 in the inner city offer additional training to physicians from nonprimary care specialties
6 who are interested in achieving specific primary care competencies. (7) Consider
7 expanding opportunities for practicing physicians in other specialties to gain specific
8 primary care competencies through short-term preceptorships or postgraduate fellowships
9 offered by departments of family practice, internal medicine, pediatrics, etc. These may
10 be developed so that they are part time, thereby allowing physicians enrolling in these
11 programs to practice concurrently. (84) Encourage the AMA Senior Physicians Services
12 Group Section to consider the use involvement of retired physicians in underserved urban
13 settings of ~~retired physicians~~, with appropriate mechanisms to ensure their competence.
14 (95) Urge ~~urban~~ hospitals and medical societies to develop opportunities for physicians to
15 work part-time to staff ~~urban~~ health clinics that help meet the needs of underserved patient
16 populations. (106) Encourage the AMA and state medical associations to incorporate into
17 state and federal health system reform legislative relief or immunity from professional
18 liability for senior, part-time, or other physicians who ~~serve the inner-city poor~~ help meet
19 the needs of underserved patient populations. (11) Urge medical schools to seek out those
20 students whose profiles indicate a likelihood of practicing in underserved urban areas,
21 while establishing strict guidelines to preclude discrimination. (12) Encourage medical
22 school outreach activities into secondary schools, colleges, and universities to stimulate
23 students with these profiles to apply to medical school. (13) Encourage medical schools
24 to continue to change their curriculum to put more emphasis on primary care. (14) Urge
25 state medical associations to support the development of methods to improve physician
26 compensation for serving this population, such as Medicaid case management programs
27 in their respective states. (157) Urge ~~urban~~ hospitals and medical centers to seek out the
28 use of available military health care resources and personnel, which can be used to fill
29 gaps in ~~urban~~ care help meet the needs of underserved patient populations. (16) Urge
30 CMS to explore the use of video and computer capabilities to improve access to and
31 support for ~~urban~~ primary care practices in underserved settings. (17) Urge ~~urban~~
32 hospitals, medical centers, state medical associations, and specialty societies to consider
33 the expanded use of mobile health care capabilities. (18) Continue to urge measures to
34 enhance payment for primary care in the inner city.

35
36 Your Reference Committee heard testimony overwhelmingly in support of the work of the
37 Council on Medical Education on reconciling multiple AMA policies on this important topic.
38 One friendly amendment was proffered to the Council on Medical Education prior to the
39 Reference Committee hearing by the Young Physicians Section, which noted that a
40 phrase in item 8 of the proposed new policy was not currently reflected in existing policy,
41 and therefore would be outside the permissible parameters of a reconciliation report. (See
42 AMA Policy G-600.111, "Consolidation and Reconciliation of AMA Policy," which states:
43 "[4.] The consolidation process permits editorial amendments for the sake of clarity, so
44 long as the proposed changes are transparent to the House and do not change the
45 meaning.") This deletion was supported by other delegations that testified. Therefore, your
46 Reference Committee recommends that Council on Medical Education Report 4 be
47 adopted as amended.

1 (10) RESOLUTION 956 - INCREASING RURAL ROTATIONS
2 DURING RESIDENCY

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolve 1 of Resolution 956 be amended by addition
8 and deletion, to read as follows:

9
10 RESOLVED, That our American Medical Association work
11 with state and specialty societies, medical schools, teaching
12 hospitals, the Accreditation Council for Graduate Medical
13 Education (ACGME), the Centers for Medicare and
14 Medicaid Services (CMS) and other interested stakeholders
15 to identify, encourage and incentivize qualified rural
16 physicians to serve as preceptors, and volunteer faculty,
17 etc. for rural rotations in residency (Directive to Take
18 Action); and be it further

19
20 RECOMMENDATION B:

21
22 Madam Speaker, your Reference Committee recommends
23 that Resolve 2 of Resolution 956 be amended by deletion,
24 to read as follows:

25
26 RESOLVED, That our AMA work with the ACGME, the
27 American Board of Medical Specialties, the Federation of
28 State Medical Boards, CMS and other interested
29 stakeholders to lessen or remove regulations or
30 requirements on residency training and physician practice
31 that preclude formal educational experiences and rotations
32 for residents in rural areas (Directive to Take Action); and
33 be it further

34
35 RECOMMENDATION C:

36
37 Madam Speaker, your Reference Committee recommends
38 that Resolve 3 of Resolution 956 be amended by addition
39 and deletion, to read as follows:

40
41 RESOLVED, That our AMA work with interested
42 stakeholders to identify strategies to increase residency
43 training opportunities in rural areas with a report back to the
44 House of Delegates and that our AMA work with interested
45 stakeholders to formulate an actionable plan of advocacy
46 with the goal of increasing residency training in rural areas.
47 (Directive to Take Action); and be it further

1 RECOMMENDATION D:

2
3 Madam Speaker, your Reference Committee recommends
4 that Resolve 4 of Resolution 956 be amended by deletion,
5 to read as follows:

6
7 ~~RESOLVED, That our AMA work with state and specialty~~
8 ~~societies and other interested stakeholders to identify~~
9 ~~appropriately qualified rural physicians who would be willing~~
10 ~~to serve as preceptors for rural rotations in residency~~
11 ~~(Directive to Take Action); and be it further~~

12 RECOMMENDATION E:

13
14 Madam Speaker, your Reference Committee recommends
15 that Resolve 5 of Resolution 956 be amended by deletion,
16 to read as follows:

17
18 ~~RESOLVED, That our AMA work with the ACCME and other~~
19 ~~interested stakeholders to lessen the documentation~~
20 ~~requirements for off-site rural rotations during residency so~~
21 ~~that affiliated rural supervising faculty can focus on~~
22 ~~educating rotating residents (Directive to Take Action); and~~
23 ~~be it further~~

24 RECOMMENDATION F:

25
26 Madam Speaker, your Reference Committee recommends
27 that Resolve 6 of Resolution 956 be amended by deletion,
28 to read as follows:

29
30 ~~RESOLVED, That our AMA work with interested~~
31 ~~stakeholders to study other ways to increase training in rural~~
32 ~~areas (Directive to Take Action); and be it further~~

33 RECOMMENDATION G:

34
35 Madam Speaker, your Reference Committee recommends
36 that Resolve 7 of Resolution 956 be amended by deletion,
37 to read as follows:

38
39 ~~RESOLVED, That our AMA formulate an actionable plan of~~
40 ~~advocacy based on the results of the above study with the~~
41 ~~goal of increasing residency training in rural areas.~~
42 ~~(Directive to Take Action)~~

1 RECOMMENDATION H:

2
3 Madam Speaker, your Reference Committee recommends
4 that Resolution 956 be adopted as amended.

5
6 Resolution 956 asks: That our American Medical Association work with state and specialty
7 societies, medical schools, teaching hospitals, the Accreditation Council for Graduate
8 Medical Education (ACGME), the Centers for Medicare and Medicaid Services (CMS) and
9 other interested stakeholders to encourage and incentivize qualified rural physicians to
10 serve as preceptors, volunteer faculty, etc. for rural rotations in residency; That our AMA
11 work with the ACGME, the American Board of Medical Specialties, the Federation of State
12 Medical Boards, CMS and other interested stakeholders to lessen or remove regulations
13 or requirements on residency training and physician practice that preclude formal
14 educational experiences and rotations for residents in rural areas; That our AMA work with
15 interested stakeholders to identify strategies to increase residency training opportunities
16 in rural areas with a report back to the House of Delegates; That our AMA work with state
17 and specialty societies and other interested stakeholders to identify appropriately qualified
18 rural physicians who would be willing to serve as preceptors for rural rotations in residency;
19 That our AMA work with the ACGME and other interested stakeholders to lessen the
20 documentation requirements for off-site rural rotations during residency so that affiliated
21 rural supervising faculty can focus on educating rotating residents; That our AMA work
22 with interested stakeholders to study other ways to increase training in rural areas; and
23 That our AMA formulate an actionable plan of advocacy based on the results of the above
24 study with the goal of increasing residency training in rural areas.

25
26 Online testimony was mostly supportive of the resolution's intent, although Resolves 2
27 and 5 were recommended against adoption by the Council on Medical Education because
28 our AMA lacks authority to define residency regulations or requirements. In-person
29 testimony also strongly supported this resolution, with multiple delegates highlighting the
30 problems associated with physician maldistribution, the importance of exposure to rural
31 practice for all trainees, and the barriers programs face when attempting to provide this
32 exposure. Significant amendments were offered during the hearing, which help to clarify
33 and focus the impact of this item. Your Reference Committee therefore recommends that
34 Resolution 956 be adopted as amended.

1 (11) RESOLUTION 957 - BOARD CERTIFYING BODIES
2

3 RECOMMENDATION A:
4

5 Madam Speaker, your Reference Committee recommends
6 that Resolve 1 of Resolution 957 be amended by addition
7 and deletion, to read as follows:
8

9 RESOLVED, That our American Medical Association
10 ~~conduct a~~ continue studying of the certifying bodies that
11 compete with the American Board of Medical Specialties
12 and ~~issue~~ provide an update in the Council on Medical
13 Education's annual report on maintenance of certification at
14 A-19 opining on the qualifications of each such certifying
15 body and whether each such certifying body should be
16 added to the list of approved certifying entities in states
17 where they are not currently approved.
18

19 RECOMMENDATION B:
20

21 Madam Speaker, your Reference Committee recommends
22 that Resolve 2 of Resolution 957 be amended by deletion,
23 to read as follows:
24

25 ~~RESOLVED, That our AMA develop model state legislation~~
26 ~~that would encourage competition among qualified certifying~~
27 ~~bodies and would modify board certification requirements~~
28 ~~such that maintenance of certification participation would~~
29 ~~not be a requirement for board recertification.~~
30

31 RECOMMENDATION C:
32

33 Madam Speaker, your Reference Committee recommends
34 that Resolution 957 be adopted as amended.
35

36 Resolution 957 asks: That our American Medical Association conduct a study of the
37 certifying bodies that compete with the American Board of Medical Specialties and issue
38 a report opining on the qualifications of each such certifying body and whether each such
39 certifying body should be added to the list of approved certifying entities in states where
40 they are not currently approved; and That our AMA develop model state legislation that
41 would encourage competition among qualified certifying bodies and would modify board
42 certification requirements such that maintenance of certification participation would not be
43 a requirement for board recertification.
44

45 Your Reference Committee heard mixed online and in-person testimony on this item.
46 Testimony noted that the Council on Medical Education studied the available certification
47 processes for physicians and reported to the HOD in Council on Medical Education
48 Reports 2-A-16 and 2-A-17, both of which were adopted. It was also noted that the
49 resolution's reference to the list of certifying entities may be potentially inaccurate since

1 only those state medical boards that regulate physician use of the term "board certified"
2 maintain a list of "approved certifying entities." Our AMA maintains robust policy on
3 maintenance of certification (MOC), including policy related to state legislative efforts. Our
4 AMA has also developed two model bills, including the Right to Treat Act, which prohibits
5 licensing boards, hospitals, and insurers from requiring a physician to maintain certification
6 for licensure, licensure renewal, hospital staff or admitting privileges, or reimbursement.
7 In addition, our AMA's Truth in Advertising Act contains a drafting note that allows for
8 physicians certified by the American Board of Medical Specialties (ABMS) and American
9 Osteopathic Association (AOA) and certain alternative specialty certification boards to
10 advertise themselves as being board certified. This model legislation specifically allows a
11 pathway by which non-ABMS/AOA specialty boards may demonstrate their validity. The
12 ABMS and AOA are both private entities whose standards are not subject to regulation by
13 the AMA, and thus, model legislation to that effect would not be effective. Furthermore,
14 action by our AMA to develop model legislation that separates continuing board
15 certification/MOC from board certification could eventually invite government intervention
16 and oversight, resulting in more tedious physician bureaucracy and regulation. That said,
17 there was still concern expressed via testimony about lowering the costs for physicians to
18 be certified and improving the quality of certification services. The Council continues to be
19 actively engaged in following the work of the Vision for the Future Commission, which is
20 scheduled to release recommendations to the ABMS regarding the future of continuing
21 certification in February 2019. The Council will address the Vision Commission's
22 recommendations fully in its A-19 report on this topic. Accordingly, for all of the above
23 reasons, your Reference Committee recommends that Resolution 957 be adopted as
24 amended.

25
26 (12) RESOLUTION 961 - PROTECT PHYSICIAN-LED
27 MEDICAL EDUCATION

28
29 RECOMMENDATION A:

30
31 Madam Speaker, your Reference Committee recommends
32 that Policy H-310.912 and H-295.955 be reaffirmed in lieu
33 of Resolve 1 of Resolution 961.

34
35 RECOMMENDATION B:

36
37 Madam Speaker, your Reference Committee recommends
38 that Resolve 2 of Resolution 961 be amended by addition
39 and deletion, to read as follows:

40
41 RESOLVED, That our AMA provide publicize to medical
42 students, residents, and fellows ~~a clear online resource~~
43 outlining their rights, as per Liaison Committee on Medical
44 Education and Accreditation Council for Graduate Medical
45 Education guidelines, to physician-led education and a
46 means to report violations without fear of retaliation.
47 (Directive to Take Action)

1 RECOMMENDATION C:

2
3 Madam Speaker, your Reference Committee recommends
4 that Resolution 961 be adopted as amended.

5
6 Resolution 961 asks: That our American Medical Association, in their role as a member
7 organization of the Liaison Committee on Medical Education and Accreditation Council for
8 Graduate Medical Education, strongly advocate for the rights of medical students,
9 residents, and fellows to be trained, supervised, and evaluated by licensed physicians;
10 and That our AMA provide medical students, residents, and fellows a clear online resource
11 outlining their rights, as per Liaison Committee on Medical Education and Accreditation
12 Council for Graduate Medical Education guidelines, to physician-led education and a
13 means to report violations without fear of retaliation.

14
15 Your Reference Committee heard mixed testimony on this item, with support for adoption,
16 referral, and reaffirmation of current policy, highlighting both the complexity and
17 importance of this issue. Many of those who testified on all sides of the issue prefaced
18 their statements with accolades for the role of non-physician educators in their own
19 education and training—analogous to our AMA's model of a physician-led team-based
20 care paradigm that encourages non-physician involvement in a patient's care, under the
21 overall guidance of a physician. That said, it is difficult to question the effectiveness of the
22 physician educator/mentor in this role; physicians should provide education to the next
23 generation of experts. In addition, students and trainees should be able to express
24 concerns about the quality of their education, and their instructors, without fear of
25 retribution from their respective institutions. Your Reference Committee believes that
26 Resolve 1 is already reflected in two existing AMA policies, and recommends their
27 reaffirmation in lieu of Resolve 1. These existing policies support the primacy of physician
28 educators in the clinical setting, yet clearly value the contribution of non-physician
29 educators. Your Reference Committee suggests additions and deletions to Resolve 2 to
30 clarify the intended action and adoption of the Resolve as amended.

31
32 Policy recommended for reaffirmation:

33
34 H-310.912, "Residents and Fellows' Bill of Rights"

35
36 1. Our AMA continues to advocate for improvements in the ACGME Institutional and
37 Common Program Requirements that support AMA policies as follows: a) adequate
38 financial support for and guaranteed leave to attend professional meetings; b)
39 submission of training verification information to requesting agencies within 30 days of
40 the request; c) adequate compensation with consideration to local cost-of-living factors
41 and years of training, and to include the orientation period; d) health insurance benefits
42 to include dental and vision services; e) paid leave for all purposes (family,
43 educational, vacation, sick) to be no less than six weeks per year; and f) stronger due
44 process guidelines.

45
46 2. Our AMA encourages the ACGME to ensure access to educational programs and
47 curricula as necessary to facilitate a deeper understanding by resident physicians of
48 the US health care system and to increase their communication skills.

1 3. Our AMA regularly communicates to residency and fellowship programs and other
2 GME stakeholders through various publication methods (e.g., the AMA GME e-letter)
3 this Residents and Fellows' Bill of Rights.

4
5 4. Our AMA: a) will promote residency and fellowship training programs to evaluate
6 their own institution's process for repayment and develop a leaner approach. This
7 includes disbursement of funds by direct deposit as opposed to a paper check and an
8 online system of applying for funds; b) encourages a system of expedited repayment
9 for purchases of \$200 or less (or an equivalent institutional threshold), for example
10 through payment directly from their residency and fellowship programs (in contrast to
11 following traditional workflow for reimbursement); and c) encourages training
12 programs to develop a budget and strategy for planned expenses versus unplanned
13 expenses, where planned expenses should be estimated using historical data, and
14 should include trainee reimbursements for items such as educational materials,
15 attendance at conferences, and entertaining applicants. Payment in advance or within
16 one month of document submission is strongly recommended.

17
18 5. Our AMA encourages teaching institutions to explore benefits to residents and
19 fellows that will reduce personal cost of living expenditures, such as allowances for
20 housing, childcare, and transportation.

21
22 6. Our AMA adopts the following 'Residents and Fellows' Bill of Rights' as applicable
23 to all resident and fellow physicians in ACGME-accredited training programs:

24
25 **RESIDENTS AND FELLOWS' BILL OF RIGHTS**

26
27 Residents and fellows have a right to:

28
29 A. An education that fosters professional development, takes priority over service, and
30 leads to independent practice.

31
32 With regard to education, residents and fellows should expect: (1) A graduate medical
33 education experience that facilitates their professional and ethical development, to
34 include regularly scheduled didactics for which they are released from clinical duties.
35 Service obligations should not interfere with educational opportunities and clinical
36 education should be given priority over service obligations; (2) Faculty who devote
37 sufficient time to the educational program to fulfill their teaching and supervisory
38 responsibilities; (3) Adequate clerical and clinical support services that minimize the
39 extraneous, time-consuming work that draws attention from patient care issues and
40 offers no educational value; (4) 24-hour per day access to information resources to
41 educate themselves further about appropriate patient care; and (5) Resources that will
42 allow them to pursue scholarly activities to include financial support and education
43 leave to attend professional meetings.

44
45 B. Appropriate supervision by qualified faculty with progressive resident responsibility
46 toward independent practice.

47
48 With regard to supervision, residents and fellows should expect supervision by
49 physicians and non-physicians who are adequately qualified and which allows them to

1 assume progressive responsibility appropriate to their level of education, competence,
2 and experience.

3
4 C. Regular and timely feedback and evaluation based on valid assessments of
5 resident performance.

6
7 With regard to evaluation and assessment processes, residents and fellows should
8 expect: (1) Timely and substantive evaluations during each rotation in which their
9 competence is objectively assessed by faculty who have directly supervised their
10 work; (2) To evaluate the faculty and the program confidentially and in writing at least
11 once annually and expect that the training program will address deficiencies revealed
12 by these evaluations in a timely fashion; (3) Access to their training file and to be made
13 aware of the contents of their file on an annual basis; and (4) Training programs to
14 complete primary verification/credentialing forms and recredentialing forms, apply all
15 required signatures to the forms, and then have the forms permanently secured in their
16 educational files at the completion of training or a period of training and, when
17 requested by any organization involved in credentialing process, ensure the
18 submission of those documents to the requesting organization within thirty days of the
19 request.

20
21 D. A safe and supportive workplace with appropriate facilities.

22
23 With regard to the workplace, residents and fellows should have access to: (1) A safe
24 workplace that enables them to fulfill their clinical duties and educational obligations;
25 (2) Secure, clean, and comfortable on-call rooms and parking facilities which are
26 secure and well-lit; (3) Opportunities to participate on committees whose actions may
27 affect their education, patient care, workplace, or contract.

28
29 E. Adequate compensation and benefits that provide for resident well-being and
30 health.

31
32 (1) With regard to contracts, residents and fellows should receive: a. Information about
33 the interviewing residency or fellowship program including a copy of the currently used
34 contract clearly outlining the conditions for (re)appointment, details of remuneration,
35 specific responsibilities including call obligations, and a detailed protocol for handling
36 any grievance; and b. At least four months advance notice of contract non-renewal
37 and the reason for non-renewal.

38
39 (2) With regard to compensation, residents and fellows should receive: a. Compensation for time at orientation; and b. Salaries commensurate with their level of
40 training and experience, and that reflect cost of living differences based on
41 geographical differences.

42
43 (3) With Regard to Benefits, Residents and Fellows Should Receive: a. Quality and
44 affordable comprehensive medical, mental health, dental, and vision care; b. Education on the signs of excessive fatigue, clinical depression, and substance abuse
45 and dependence; c. Confidential access to mental health and substance abuse
46 services; d. A guaranteed, predetermined amount of paid vacation leave, sick leave,
47 maternity and paternity leave and educational leave during each year in their training
48
49

1 program the total amount of which should not be less than six weeks; and e. Leave in
2 compliance with the Family and Medical Leave Act.

3
4 F. Duty hours that protect patient safety and facilitate resident well-being and
5 education.

6
7 With regard to duty hours, residents and fellows should experience: (1) A reasonable
8 work schedule that is in compliance with duty-hour requirements set forth by the
9 ACGME or other relevant accrediting body; and (2) At-home call that is not so frequent
10 or demanding such that rest periods are significantly diminished or that duty-hour
11 requirements are effectively circumvented.

12
13 G. Due process in cases of allegations of misconduct or poor performance.

14
15 With regard to the complaints and appeals process, residents and fellows should have
16 the opportunity to defend themselves against any allegations presented against them
17 by a patient, health professional, or training program in accordance with the due
18 process guidelines established by the AMA.

19
20 H. Access to and protection by institutional and accreditation authorities when
21 reporting violations.

22
23 With regard to reporting violations to the ACGME, residents and fellows should: (1) Be
24 informed by their program at the beginning of their training and again at each semi-
25 annual review of the resources and processes available within the residency program
26 for addressing resident concerns or complaints, including the program director,
27 Residency Training Committee, and the designated institutional official; (2) Be able to
28 file a formal complaint with the ACGME to address program violations of residency
29 training requirements without fear of recrimination and with the guarantee of due
30 process; and (3) Have the opportunity to address their concerns about the training
31 program through confidential channels, including the ACGME concern process and/or
32 the annual ACGME Resident Survey.

33
34 H-295.955, "Teacher-Learner Relationship In Medical Education"

35
36 The AMA recommends that each medical education institution have a widely
37 disseminated policy that: (1) sets forth the expected standards of behavior of the
38 teacher and the learner; (2) delineates procedures for dealing with breaches of that
39 standard, including: (a) avenues for complaints, (b) procedures for investigation, (c)
40 protection and confidentiality, (d) sanctions; and (3) outlines a mechanism for
41 prevention and education. The AMA urges all medical education programs to regard
42 the following Code of Behavior as a guide in developing standards of behavior for both
43 teachers and learners in their own institutions, with appropriate provisions for
44 grievance procedures, investigative methods, and maintenance of confidentiality.

45
46 CODE OF BEHAVIOR

47 The teacher-learner relationship should be based on mutual trust, respect, and
48 responsibility. This relationship should be carried out in a professional manner, in a

1 learning environment that places strong focus on education, high quality patient care,
2 and ethical conduct.

3
4 A number of factors place demand on medical school faculty to devote a greater
5 proportion of their time to revenue-generating activity. Greater severity of illness
6 among inpatients also places heavy demands on residents and fellows. In the face of
7 sometimes conflicting demands on their time, educators must work to preserve the
8 priority of education and place appropriate emphasis on the critical role of teacher.

9
10 In the teacher-learner relationship, each party has certain legitimate expectations of
11 the other. For example, the learner can expect that the teacher will provide instruction,
12 guidance, inspiration, and leadership in learning. The teacher expects the learner to
13 make an appropriate professional investment of energy and intellect to acquire the
14 knowledge and skills necessary to become an effective physician. Both parties can
15 expect the other to prepare appropriately for the educational interaction and to
16 discharge their responsibilities in the educational relationship with unfailing honesty.

17
18 Certain behaviors are inherently destructive to the teacher-learner relationship.
19 Behaviors such as violence, sexual harassment, inappropriate discrimination based
20 on personal characteristics must never be tolerated. Other behavior can also be
21 inappropriate if the effect interferes with professional development. Behavior patterns
22 such as making habitual demeaning or derogatory remarks, belittling comments or
23 destructive criticism fall into this category. On the behavioral level, abuse may be
24 operationally defined as behavior by medical school faculty, residents, or students
25 which is consensually disapproved by society and by the academic community as
26 either exploitive or punishing. Examples of inappropriate behavior are: physical
27 punishment or physical threats; sexual harassment; discrimination based on race,
28 religion, ethnicity, sex, age, sexual orientation, gender identity, and physical
29 disabilities; repeated episodes of psychological punishment of a student by a particular
30 superior (e.g., public humiliation, threats and intimidation, removal of privileges);
31 grading used to punish a student rather than to evaluate objective performance;
32 assigning tasks for punishment rather than educational purposes; requiring the
33 performance of personal services; taking credit for another individual's work;
34 intentional neglect or intentional lack of communication.

35
36 On the institutional level, abuse may be defined as policies, regulations, or procedures
37 that are socially disapproved as a violation of individuals' rights. Examples of
38 institutional abuse are: policies, regulations, or procedures that are discriminatory
39 based on race, religion, ethnicity, sex, age, sexual orientation, gender identity, and
40 physical disabilities; and requiring individuals to perform unpleasant tasks that are
41 entirely irrelevant to their education as physicians.

42
43 While criticism is part of the learning process, in order to be effective and constructive,
44 it should be handled in a way to promote learning. Negative feedback is generally more
45 useful when delivered in a private setting that fosters discussion and behavior
46 modification. Feedback should focus on behavior rather than personal characteristics
47 and should avoid pejorative labeling.

1 Because people's opinions will differ on whether specific behavior is acceptable,
2 teaching programs should encourage discussion and exchange among teacher and
3 learner to promote effective educational strategies. People in the teaching role
4 (including faculty, residents, and students) need guidance to carry out their
5 educational responsibilities effectively.

6
7 Medical schools are urged to develop innovative ways of preparing students for their
8 roles as educators of other students as well as patients.

9
10 (13) RESOLUTION 959 - PHYSICIAN AND MEDICAL
11 STUDENT MENTAL HEALTH AND SUICIDE

12
13 RECOMMENDATION:

14
15 Madam Speaker, your Reference Committee recommends
16 that Resolution 959 be referred.

17 Resolution 959 asks: That our American Medical Association create a new Physician and
18 Medical Student Suicide Prevention Committee with the goal of addressing suicides and
19 mental health disease in physicians and medical students. This committee will be charged
20 with: 1) Developing novel policies to decrease physician and medical trainee stress and
21 improve professional satisfaction. 2) Vociferous, repeated and widespread messaging to
22 physicians and medical students encouraging those with mood disorders to seek help. 3)
23 Working with state medical licensing boards and hospitals to help remove any stigma of
24 mental health disease and to alleviate physician and medical student fears about the
25 consequences of mental illness and their medical license and hospital privileges. 4)
26 Establishing a 24-hour mental health hotline staffed by mental health professionals
27 whereby a troubled physician or medical student can seek anonymous advice.
28 Communication via the 24-hour help line should remain anonymous. This service can be
29 directly provided by the AMA or could be arranged through a third party, although
30 volunteer physician counselors may be an option for this 24-hour phone service.

31
32 Online testimony regarding this item was supportive of the resolution's intent, but
33 testimony also noted that the Council on Medical Education is currently writing a report
34 related to this topic, and therefore recommended referral of this topic for inclusion in that
35 report when it is presented to the HOD at the 2019 Annual Meeting. Your Reference
36 Committee heard in-person testimony in support of much of the resolution, but testimony
37 was mixed regarding calls for the establishment and staffing of a 24-hour mental health
38 hotline. Many called for referral, noting that the Council on Medical Education could
39 consider appropriate deliverables to further establish our AMA's leadership role in this
40 space, and to make a recommendation regarding the establishment of and role for an
41 AMA committee or task force related to this topic. The Council on Medical Education
42 testified that it will incorporate this content into its planned report to the HOD for the 2019
43 Annual Meeting. Therefore, your Reference Committee recommends that Resolution 959
44 be referred.

1 (14) RESOLUTION 960 - INADEQUATE RESIDENCY SLOTS
2

3 RECOMMENDATION:
4

5 Madam Speaker, your Reference Committee recommends
6 that Policy D-305.967(32) be reaffirmed in lieu of Resolution
7 960.
8

9 Resolution 960 asks: That our American Medical Association adopt policy to establish
10 parity between the number of medical school graduates and the number of match
11 positions and withhold support for any further increase in medical school enrollment,
12 unless there is a corresponding increase in residency positions; and That our AMA lobby
13 the federal government for increased funding for residency spots, to investigate other
14 sustainable models for residency position funding and to advocate for loan repayment
15 waivers for individuals who fail to match.
16

17 Your Reference Committee heard mixed testimony on this item, with the majority,
18 however, in favor of reaffirmation of current policy. In June 2018, the House of Delegates
19 approved the recommendations of Council on Medical Education Report 3-A-18, which
20 was in turn incorporated into Policy D-305.967(32), further clarifying our AMA's policy on
21 funding of residency slots. Some testimony noted a shortage of residency program slots
22 for medical students seeking entry into graduate medical education, but this is not
23 numerically factual unless international medical graduates are included in the total count
24 of available residency slots. It was expressed that any sort of cap on medical student
25 enrollment could send the wrong message, given current and projected shortages in many
26 specialties and geographic areas, and could lead to potential unintended consequences
27 and exacerbation of physician maldistribution in medically underserved areas, and
28 possible restraint of trade concerns. The bulk of testimony was also opposed to any sort
29 of loan repayment waiver for those who fail to match, which could lead to perverse
30 incentives. Reports by our AMA Council on Medical Education are a better and more finely
31 tuned mechanism for the continued evolution of AMA policy on this critical topic for
32 physicians and our patients. In summary, your Reference Committee believes that existing
33 policy covers the intent of this item, and recommends reaffirmation of this policy in lieu of
34 Resolution 960.
35

36 Policy recommended for reaffirmation:
37

38 Policy D-305.967(32), "The Preservation, Stability and Expansion of Full Funding for
39 Graduate Medical Education"

40 Our AMA will: (a) encourage all existing and planned allopathic and osteopathic
41 medical schools to thoroughly research match statistics and other career placement
42 metrics when developing career guidance plans; (b) strongly advocate for and work
43 with legislators, private sector partnerships, and existing and planned osteopathic and
44 allopathic medical schools to create and fund graduate medical education (GME)
45 programs that can accommodate the equivalent number of additional medical school
46 graduates consistent with the workforce needs of our nation; and (c) encourage the
47 Liaison Committee on Medical Education (LCME), the Commission on Osteopathic
48 College Accreditation (COCA), and other accrediting bodies, as part of accreditation
49 of allopathic and osteopathic medical schools, to prospectively and retrospectively
monitor medical school rates of placement into GME as well as GME completion.

1 Madam Speaker, this concludes the report of Reference Committee C. I would like to
2 thank Jerry P. Abraham, MD, MPH; John C. Moorhead, MD; Lucy Nam; Brigitta J.
3 Robinson, MD, FACS; Martin D. Trichtinger, MD, FACP; and Roxanne Tyroch, MD, FACP;
4 and all those who testified before the committee, as well as our AMA staff, including
5 Catherine Welcher; Carrie Radabaugh; Fred Lenhoff; and Susan Skochelak, MD, MPH.

Jerry P. Abraham, MD, MPH
American Academy of Family
Physicians

John C. Moorhead, MD
American College of Emergency
Physicians

Lucy Nam
Medical Student Section
(Alternate) Maryland

Brigitta J. Robinson, MD, FACS
(Alternate) Colorado

Martin D. Trichtinger, MD, FACP
Pennsylvania

Roxanne Tyroch, MD, FACP
(Alternate) Texas

Peter C. Amadio, MD
American Association for Hand Surgery
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (I-18)

Report of Reference Committee F

Greg Tarasidis, MD, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:

2 **RECOMMENDED FOR ADOPTION**

3

4 1. Report of the House of Delegates Committee on Compensation of the Officers

5 2. Council on Long Range Planning and Development Report 1 – Women

6 Physicians Section Five-Year Review

7

8 **RECOMMENDED FOR ADOPTION AS AMENDED OR SUBSTITUTED**

9

10 3. Board of Trustees Report 1 – Data Used to Apportion Delegates

11 4. Board of Trustees Report 10 – Training Physicians in the Art of Public Forum

12 5. Resolution 603 – Support of AAIP’s “Desired Qualifications for Indian Health

13 Service Director”

14

15 **RECOMMENDED FOR REFERRAL**

16 6. Resolution 604 – Physician Health Policy Opportunity

17

18 The following resolutions were Recommended Against Consideration:

19

- 20 • Resolution 601 – Creation of an AMA Election Reform Committee
- 21 • Resolution 602 – AMA Policy Statement with Editorials

1 (1) REPORT OF THE HOUSE OF DELEGATES COMMITTEE
2 ON COMPENSATION OF THE OFFICERS

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that the recommendations in the Report of the House of
8 Delegates Committee on the Compensation of the Officers
9 be adopted and the remainder of the Report be filed.

10
11 The Report of the House of Delegates Committee on Compensation of the Officers
12 recommends the following recommendations be adopted and the remainder of the report
13 be filed:

14
15 1. That there be no change to the current Definitions effective July 1, 2018 as they
16 appear in the Travel and Expenses Standing Rules for AMA Officers for the
17 Governance Honorarium, Per Diem for External Representation and Telephonic
18 Per Diem for External Representation.

19
20 2. Annual Health Insurance Stipend (Stipend) – The purpose of this payment is to
21 provide a Health Insurance Stipend (Stipend) to compensate the President,
22 President-Elect and Immediate Past President under age 65, when the
23 President(s) loses his/her employer-provided medical insurance coverage during
24 his/her term. President(s) who lose his/her employer insurance will substantiate
25 his/her eligibility for the Stipend by written notice to the Board Chair detailing the
26 effective date of the loss of coverage and listing covered family members. The
27 President receiving the Stipend will have the sole discretion to determine the
28 appropriate health insurance coverage for the himself/herself and the family, and
29 provide proof of purchasing such coverage to the Board Chair.

30
31 The amount of the Stipend will be 70% of the then current Gold Plan premium in
32 the President(s) state/county of residence for each covered family member. If there
33 are multiple Gold Plans in the state/county, the Stipend will be based on the
34 average of the then current Gold Plan premiums. The amount of the Stipend will
35 be updated January 1 of each Plan year based on then Gold Plan premiums and
36 covered family members. Should a President reach age 65 during his/her term(s),
37 the Stipend will end the month Medicare coverage begins. In all cases the Stipend
38 will end the sooner the President(s) obtains other health insurance coverage,
39 reaches age 65 or the month following the end of his/her term as Immediate Past
40 President. The Stipend will be paid monthly. The amount of the Stipend will be
41 reported as taxable income for the President each calendar year and will be
42 included in this Committee's annual report to the House which documents
43 compensation paid to Officers and the IRS reported taxable value of benefits,
44 perquisites, services and in-kind payments.

45
46 3. Except as noted above, there will be no other changes to the Officers'
47 compensation for the period beginning January 1, 2019. (Directive to Take Action)

48
49 Your Reference Committee noted that the report reflected the level of commitment needed
50 in supporting our AMA may necessitate the President, President-Elect, and Immediate

1 Past President reduce his/her work schedule with his/her employer to a part-time status,
2 which may result in the President, President-Elect, and Immediate Past President losing
3 his/her eligibility for employer's health insurance coverage. For this reason, the
4 Compensation Committee is recommending that the President, President-Elect, and
5 Immediate Past President, who are not Medicare-eligible, receive a stipend based on 70%
6 of the then current Gold Plan premium in the Presidents' state/county of residence for
7 each covered family member. The amount of the stipend will be reported as taxable
8 income for the President, President-Elect, and Immediate Past President each calendar
9 year and will be included in the Compensation Committee's annual report to the House of
10 Delegates.

11
12 Your Reference Committee received limited testimony in response to the introduction of
13 the revised Report of the House of Delegates Committee on Compensation of the Officers.
14 However, the testimony did raise a specific concern regarding insurance coverage for our
15 Presidents if the President turns 65 years of age during his/her term and the family is
16 ineligible for Medicare. In turn, a representative of the Compensation Committee
17 responded that the issue was noted and will be addressed in a subsequent report at the
18 2019 Annual Meeting.

19
20 Your Reference Committee extends its appreciation to the Compensation Committee for
21 its thorough work on behalf of our House of Delegates.

22
23
24 (2) COUNCIL ON LONG RANGE PLANNING AND
25 DEVELOPMENT REPORT 1 - WOMEN PHYSICIANS
26 SECTION FIVE-YEAR REVIEW

27
28 RECOMMENDATION:

29
30 Madam Speaker, your Reference Committee recommends
31 that the recommendation in Council on Long Range
32 Planning and Development Report 1 be adopted and the
33 remainder of the Report be filed.

34
35 Council on Long Range Planning and Development Report 1 recommends that our
36 American Medical Association renew delineated section status for the Women Physicians
37 Section through 2023 with the next review no later than the 2023 Interim Meeting and that
38 the remainder of the report be filed. (Directive to Take Action)

39
40 Having received no testimony in opposition to the Council on Long Range Planning and
41 Development Report 1, your Reference Committee wishes to extend its appreciation to
42 the Council and the Women Physicians Section for their cooperative and collaborative
43 efforts to present a thorough review of the Section.

1 (3) BOARD OF TRUSTEES REPORT 1 - DATA USED TO
2 APPORTION DELEGATES

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that the recommendation in Board of Trustees Report 1 be
8 amended by addition and deletion to read as follows:

9
10 1. Our AMA shall issue an annual, midyear report on or
11 around June 30 to inform each national medical
12 specialty and state medical society of its current AMA
13 membership count status report. (Directive to Take
14 Action)

15
16 2. ~~For these reasons, the~~ The Board of Trustees
17 recommends that Resolution 604-A-18 not be adopted
18 and the remainder of this report be filed.

19
20 RECOMMENDATION B:

21
22 Madam Speaker, your Reference Committee recommends
23 that the recommendations in Board of Trustees Report 1 be
24 adopted as amended and the remainder of the Report be
25 filed.

26
27 Board of Trustees Report 1 is presented in response to Resolution 604-A-18, "AMA
28 Delegation Entitlements," which called upon our American Medical Association to continue
29 to provide a count of AMA members for AMA delegation entitlements to the House of
30 Delegates as of December 31 and also provide a second count of AMA members within
31 the first two weeks of the new year and that the higher of the two counts be used for state
32 and national specialty society delegation entitlements during the current year. (Directive
33 to Take Action)

34
35 Additionally, Resolution 604 called upon the Council on Constitution and Bylaws to
36 prepare appropriate language to add a second period of time to determine AMA delegation
37 entitlements to be considered by the AMA House of Delegates at its earliest opportunity.
38 (Modify AMA Bylaws)

39
40 In their report, the Board of Trustees recommends that Resolution 604-A-18 not be
41 adopted and the remainder of the report be filed.

42
43 Your Reference Committee heard testimony supporting original Resolution 604-A-18.
44 Your Reference Committee also sought further clarification as to how the current
45 apportionment process functions. Each state and specialty society receives delegate
46 apportionment for the HOD based on the prior year's membership count as of December
47 31. As an example, a non-member who chooses to pay next year's dues during the current
48 calendar year is not an actual member of the AMA until January 1 of the ensuing year,
49 although said non-member does receive AMA benefits immediately. If a society wishes to
50 have a new member "count" toward apportionment of delegate seats applied to the

1 immediate following year, it would need the member to pay appropriate current year dues
2 and, thus, be an actual AMA member during the current calendar year. This process is the
3 same for all state and specialty societies.

4
5 Your Reference Committee recognizes there may be delegations in our AMA House of
6 Delegates whose AMA membership count places them on the threshold of acquiring an
7 additional Delegate; therefore, your Reference Committee supports the proffered,
8 amendment to the Board of Trustees report, which serves to provide every delegation in
9 our AMA House of Delegates with a mid-year membership status report with which to
10 adjust recruitment efforts during the latter half of the year to achieve the desired year-end
11 goal.

12
13
14 (4) BOARD OF TRUSTEES REPORT 10 - TRAINING
15 PHYSICIANS IN THE ART OF PUBLIC FORUM

16
17 RECOMMENDATION A:

18
19 Madam Speaker, your Reference Committee recommends
20 that the recommendation in Board of Trustees Report 10 be
21 amended by addition and deletion to read as follows:

22
23 1. Physicians who want to learn more about public
24 speaking can leverage existing resources both within
25 and outside the AMA. AMA can make public speaking
26 tips available through online tools and resources that
27 would be publicized on our website. Physicians and
28 physicians-in-training who want to publicly communicate
29 about the AMA's ongoing work are invited to learn more
30 through the AMA Ambassador program.

31
32 Meanwhile, STEPS Forward provides helpful tips to
33 physicians and physicians-in-training wanting to
34 improve communication within their practice and
35 AMPAC is available for physicians and physicians-in-
36 training who want to advocate and communicate about
37 the needs of patients, and physicians, and physicians-
38 in-training in the pursuit of public office. There are also
39 resources provided to physicians and physicians-in-
40 training at various Federation organizations and through
41 the American Association of Physician Leadership
42 (AAPL) to support those who are interested in training of
43 this nature.

44
45 Because public speaking is a skill that is best learned
46 through practice and coaching in a small group or one-
47 on-one setting, we also encourage individuals to pursue
48 training through their state or specialty medical society
49 or through a local chapter of Toastmasters International.

1 The Board of Trustees recommends that the AMA's
2 Enterprise Communications and Marketing department
3 work to develop online tools and resources that would
4 be published on the AMA website to help physicians and
5 physicians-in-training learn more about public speaking
6 in-lieu of Resolution 606-A-18 and the remainder of the
7 report to be filed.

8

9 2. That our AMA offer live education sessions at least
10 annually for AMA members to develop their public
11 speaking skills. (Directive to Take Action)

12 RECOMMENDATION B:

13 Madam Speaker, your Reference Committee recommends
14 that the recommendations in Board of Trustees Report 10
15 be adopted as amended in lieu of Resolution 606-A-18 and
16 the remainder of the Report be filed.

17 RECOMMENDATION C:

18 Madam Speaker, your Reference Committee recommends
19 that the title of Board of Trustees Report 10 be changed to
20 read as follows:

21 TRAINING PHYSICIANS AND PHYSICIANS-IN-TRAINING
22 IN THE ART OF PUBLIC SPEAKING

23 Board of Trustees Report 10 is presented in response to Resolution 606-A-18, which
24 called upon our American Medical Association to establish a program for training
25 physicians in the art and science of conducting public forums in order to ensure that the
26 public is well informed on the health care system of our country. (Directive to Take Action)

27 In their report, the Board of Trustees recommends that the AMA's Enterprise
28 Communications and Marketing department work to develop online tools and resources
29 that would be published on the AMA website to help physicians learn more about public
30 speaking in lieu of Resolution 606-A-18 and that the remainder of the report to be filed.
31 (Directive to Take Action)

32 While your Reference Committee received testimony favoring adoption of Board of
33 Trustees Report 10, there was considerable testimony in support of providing in-person
34 training to enhance public speaking skills. Therefore, your Reference Committee
35 recommends that Board of Trustees Report 10 be amended to include live education
36 sessions in conjunction with meetings that are hosted regularly by our AMA.

1 (5) RESOLUTION 603 - SUPPORT OF AAIP'S "DESIRED
2 QUALIFICATIONS FOR INDIAN HEALTH SERVICE
3 DIRECTOR"

4
5 RECOMMENDATION A:

6
7 Madam Speaker, your Reference Committee recommends
8 that Resolution 603 be amended by addition and deletion to
9 read as follows:

10
11 RESOLVED, That our American Medical Association
12 support the "Desired Qualifications for the following
13 qualifications for the Director of the Indian Health Service"
14 set forth by the Association of American Indian Physicians.:

- 15 1. Health profession, preferably an MD or DO, degree and
at least five years of clinical experience at an Indian
Health Service medical site or facility.
- 16 2. Demonstrated long-term interest, commitment, and
activity within the field of Indian Health.
- 17 3. Lived on tribal lands or rural American Indian or Alaska
Native community or has interacted closely with an
urban Indian community.
- 18 4. Leadership position in American Indian/Alaska Native
health care or a leadership position in an academic
setting with activity in American Indian/ Alaska Native
health care.
- 19 5. Experience in the Indian Health Service or has worked
extensively with Indian Health Service, Tribal, or Urban
Indian health programs.
- 20 6. Knowledge and understanding of social and cultural
issues affecting the health of American Indian and
Alaska Native people.
- 21 7. Knowledge of health disparities among Native
Americans / Alaska Natives, including the pathophysiological
basis of the disease process and the social
determinants of health that affect disparities.
- 22 8. Experience working with Indian Tribes and Nations and
an understanding of the Trust Responsibility of the
Federal Government for American Indian and Alaska
Natives as well as an understanding of the sovereignty
of American Indian and Alaska Native Nations.
- 23 9. Experience with management, budget, and federal
programs.

44 (New HOD Policy)

1 RECOMMENDATION B:

2
3 Madam Speaker, your Reference Committee recommends
4 that Resolution 603 be adopted as amended.

5 RECOMMENDATION C:

6
7 Madam Speaker, your Reference Committee recommends
8 that the title of Resolution 603 be changed to read as
9 follows:

10
11 DESIRED QUALIFICATIONS FOR INDIAN HEALTH
12 SERVICE DIRECTOR

13
14 Resolution 603 calls upon our AMA to support the "Desired Qualifications for the Director
15 of the Indian Health Service" set forth by the Association of American Indian Physicians.
16 (New HOD Policy)

17
18 Having received limited but supportive testimony, your Reference Committee favors our
19 AMA's support of the Association of American Indian Physicians desired qualifications for
20 the Director of the Indian Health Service. Testimony also indicated the importance of
21 having a Director of the Indian Health Service that possess a comprehensive
22 understanding of the needs of this population and qualifications for this position should be
23 outlined in AMA policy.

24
25
26 (6) RESOLUTION 604 - PHYSICIAN HEALTH POLICY
27 OPPORTUNITY

28
29 RECOMMENDATION:

30
31 Madam Speaker, your Reference Committee recommends
32 that Resolution 604 be referred.

33
34 Resolution 604 calls upon our AMA, in collaboration with the state and specialty societies,
35 to make it a priority to give physicians the opportunity to serve in federal and state health
36 care agency positions by providing the training and transitional opportunities to move from
37 clinical practice to health policy. (New HOD Policy)

38
39 Additionally, Resolution 604 calls upon our AMA to study and report back to the House of
40 Delegates at the 2019 Interim Meeting with findings and recommendations for action on
41 how best to increase opportunities to train physicians in transitioning from clinical practice
42 to health policy. (Directive to Take Action)

43
44 Resolution 604 further calls upon our AMA to explore the creation of an AMA health policy
45 fellowship, or work with the Robert Wood Johnson Foundation to ensure that there are
46 designated physician fellowship positions within their Health Policy Fellowship program to
47 train physicians in transitioning from clinical practice to health policy. (Directive to Take
48 Action)

1 Your Reference Committee heard testimony that it is critical to have physicians with
2 clinical experience serve in government regulatory agencies to help shape health policy.
3 However, testimony regarding identifying a partnership with the Robert Wood Johnson
4 Foundation was mixed. Testimony indicated that there has been a steady decline in the
5 number of spots for physicians in the Robert Wood Johnson health policy fellowship
6 program and recommended that our AMA consider broadening any potential
7 partnerships. Further, it was noted that developing a health policy fellowship program
8 can be an intricate process that should be carefully evaluated.
9

10 Your Reference Committee received testimony favoring our AMA conducting a study to
11 determine how best to increase opportunities to train physicians in transitioning from
12 clinical practice to health policy. For these reasons, your Reference Committee
13 recommends that Resolution 604 be referred to allow our AMA to conduct a study with a
14 report at the 2019 Interim Meeting that details the impact our AMA can have on this
15 issue and to consider potential partnerships.
16

17 Madam Speaker, this concludes the report of Reference Committee F. I would like to thank
18 Michael D. Chafty, MD, JD, Melissa J. Garretson, MD, Jerry L. Halverson, MD, Candace
19 E. Keller, MD, MPH, A. Lee Morgan, MD, Ann R. Stroink, MD, and all those who testified
20 before the Committee.

Michael D. Chafty, MD, JD
Michigan

Candace E. Keller, MD, MPH
American Society of Anesthesiologists

Melissa J. Garretson, MD
American Academy of Pediatrics

A. Lee Morgan, MD
Colorado

Jerry L. Halverson, MD
American Psychiatric Association

Ann R. Stroink, MD
Congress of Neurological Surgeons

Greg Tarasidis, MD
South Carolina
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (I-18)

Report of Reference Committee J

Steven Chen, MD, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:

3 RECOMMENDED FOR ADOPTION

- 5 1. Council on Medical Service Report 2 - Air Ambulance Regulations and Payments
- 6 2. Council on Medical Service Report 3 - Sustain Patient-Centered Medical Home
- 7 Practices
- 8 3. Joint Report of the Council on Medical Service and the Council on Science and
- 9 Public Health - Aligning Clinical and Financial Incentives for High-Value Care
- 10 4. Resolution 801 - Encourage Final Evaluation Reports of Section 1115
- 11 Demonstrations at the End of the Demonstration Cycle
- 12 5. Resolution 804 - Arbitrary Documentation Requirements for Outpatient Services
- 13 6. Resolution 810 - Medicare Advantage Step Therapy

15 RECOMMENDED FOR ADOPTION AS AMENDED OR SUBSTITUTED

- 17 7. Board of Trustees Report 9 - Hospital Closures and Physician Credentialing
- 18 8. Council on Medical Service Report 1 - Prescription Drug Importation for Personal
- 19 Use
- 20 9. Council on Medical Service Report 4 - The Site-of-Service Differential
- 21 10. Resolution 802 - Due Diligence for Physicians and Practices Joining an ACO with
- 22 Risk Based Models (Up Side and Down Side Risk)
- 23 11. Resolution 803 - Insurance Coverage for Additional Screening Recommended in
- 24 States with Laws Requiring Notification of "Dense Breasts" on Mammogram
- 25 12. Resolution 805 - Prompt Pay
- 26 13. Resolution 806 - Telemedicine Models and Access to Care in Post-Acute and
- 27 Long-Term Care
- 28 14. Resolution 808 - The Improper Use of Beers or Similar Criteria and Third-Party
- 29 Payer Compliance Activities (H-185.940)
- 30 15. Resolution 812 - ICD Code for Patients Harm From Payer Interference
- 31 16. Resolution 814 - Prior Authorization Relief in Medicare Advantage Plans
- 32 17. Resolution 820 - Ensuring Quality Health Care for Our Veterans

34 RECOMMENDED FOR REFERRAL

- 36 18. Resolution 826 - Developing Sustainable Solutions to Discharge of Chronically-
- 37 Homeless Patients

39 RECOMMENDED FOR NOT ADOPTION

- 41 19. Resolution 822 - Bone Density Reimbursement

1 **RECOMMENDED FOR REAFFIRMATION IN LIEU OF**

2

3 20. Resolution 807 - Emergency Department Copayments for Medicaid Beneficiaries

4 21. Resolution 818 - Drug Pricing Transparency

5 22. Resolution 823 - Medicare Cuts to Radiology Imaging

Existing policy was reaffirmed in lieu of the following resolutions via the Reaffirmation Consent Calendar:

- Resolution 809 - Medicaid Clinical Trials Coverage
- Resolution 813 - Direct Primary Care Health Savings Account Clarification
- Resolution 815 - Uncompensated Physician Labor
- Resolution 816 - Medicare Advantage Plan Inadequacies
- Resolution 817 - Increase Reimbursement for Psychiatric Services
- Resolution 819 - Medicare Reimbursement Formula for Oncologists Administering Drugs
- Resolution 821 - Direct Primary Care and Concierge Medicine Based Practices

The following resolution was withdrawn by the sponsor:

- Resolution 811 - Infertility Benefits for Active-Duty Military Personnel

The following resolutions were recommended against consideration:

- Resolution 824 – Impact on the Medical Staff of the Success or Failure in Generating Savings of Hospital Integrated System ACOs
- Resolution 825 – Preservation of the Patient-Physician Relationship

1 (1) COUNCIL ON MEDICAL SERVICE REPORT 2 - AIR
2 AMBULANCE REGULATIONS AND PAYMENTS

3
4 RECOMMENDATION:

5 Madam Speaker, your Reference Committee recommends
6 that the recommendations in Council on Medical Service
7 Report 2 be adopted and the remainder of the report be
8 filed.

9
10 Council on Medical Service Report 2 recommends that our AMA amend Policy, H-
11 130.954 by addition to support the education of first responders about the costs
12 associated with inappropriate use of emergency patient transportation systems; support
13 increased data collection and data transparency of air ambulance providers and services
14 to the appropriate state and federal agencies, particularly increased price transparency;
15 work with relevant stakeholders to evaluate the Airline Deregulation Act as it applies to
16 air ambulances; support stakeholders sharing air ambulance best practices across
17 regions; and rescind Policy D-130.964.

18
19 Testimony on Council on Medical Service Report 2 was unanimously supportive. A
20 member of the Council on Medical Service introduced the report noting that there is little
21 reliable data on the costs and charges of air ambulance services. Additionally, the
22 Council explained that it declined to call for increased consumer education on the costs
23 of air ambulance services out of concern that it would result in patients declining
24 potentially life-saving transportation and care. The Council further stated that the
25 profound lack of data on air ambulances precludes it from proposing amendment to the
26 Airline Deregulation Act. Importantly, the Council highlighted that the recent Federal
27 Aviation Administration Reauthorization called for the establishment of a consumer
28 hotline for consumer complaints, and an advisory committee to look into surprise billing
29 and create industry best practices.

30
31 Numerous speakers highlighted that air ambulances often fly across state lines and
32 stated that this ability must be preserved, as conserved in the Council report. An
33 amendment was offered by an individual representing the air ambulance industry calling
34 for increased payment of air ambulance services from Medicare and Medicaid. However,
35 your Reference Committee declines to accept this amendment and believes that
36 increased data transparency and availability is critical before calling for such a request.
37 Another speaker noted that individuals often can pay a monthly fee to air ambulance
38 companies that protect them from high bills for utilizing the company's services.
39 However, additional testimony stated that this suggestion amounts to additional patient
40 burden and expense, and your Reference Committee believes that this practice may be
41 problematic in areas where there are multiple air ambulance providers or if an accident
42 necessitating air ambulance care occurs outside of that provider's service area.
43 Accordingly, your Reference Committee recommends that the recommendations in
44 Council on Medical Service Report 2 be adopted and the remainder of the report be
45 filed.

1 (2) COUNCIL ON MEDICAL SERVICE REPORT 3 - SUSTAIN
2 PATIENT-CENTERED MEDICAL HOME PRACTICES

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that the recommendations in Council on Medical Service
8 Report 3 be adopted and the remainder of the report be
9 filed.

10
11 Council on Medical Service Report 3 recommends that our AMA reaffirm Policies H-
12 160.919 and H-385.908; amend Policy H-160.918 to also urge CMS to assist physician
13 practices seeking to sustain medical home status with financial and other resources, and
14 delete [d] which states that our AMA "will advocate that all health plans and CMS use a
15 single standard to determine whether a physician practice qualifies to be a patient-
16 centered medical home;" advocate that all payers support and assist PCMH
17 transformation and maintenance efforts at levels that provide a stable platform for
18 optimized patient-centered care recognizing that payer support is crucial to the long-term
19 sustainability of delivery reform; and encourage health agencies, health systems, and
20 other stakeholders to support and assist patient-centered medical home transformation
21 and maintenance efforts at levels that provide a stable platform for optimized patient-
22 centered care.

23
24 Testimony on Council on Medical Service Report 3 was unanimously supportive.
25 Testimony thanked the Council for its thoughtful report. A member of the Council on
26 Medical Service introduced the report noting that the Council believes that primary care
27 and the PCMH are bedrocks of high-quality, patient-centered care. However, in order to
28 make the transition to and sustain a PCMH, practices of all sizes and settings must have
29 the support to confront the challenges of practice transformation from the Centers for
30 Medicare and Medicaid Services, third-party insurers, and other stakeholders.
31 Accordingly, your Reference Committee recommends that the recommendations in
32 Council on Medical Service Report 3 be adopted and the remainder of the report be
33 filed.

34
35 (3) JOINT REPORT OF THE COUNCIL ON MEDICAL
36 SERVICE AND THE COUNCIL ON SCIENCE AND
37 PUBLIC HEALTH - ALIGNING CLINICAL AND FINANCIAL
38 INCENTIVES FOR HIGH-VALUE CARE

39
40 RECOMMENDATION:

41
42 Madam Speaker, your Reference Committee recommends
43 that the recommendations in the Joint Report of the
44 Council on Medical Service and the Council on Science
45 and Public Health be adopted and the remainder of the
46 report be filed.

47
48 The Joint Report of the Council on Medical Service and the Council on Science and
49 Public Health recommends that our AMA reaffirm Policies H-155.960, H-185.939 and H-
50 165.856; support VBID plans designed in accordance with the tenets of "clinical nuance,"

1 recognizing that (1) medical services may differ in the amount of health produced, and
2 (2) the clinical benefit derived from a specific service depends on the person receiving it,
3 as well as when, where, and by whom the service is provided; support initiatives that
4 align provider-facing financial incentives created through payment reform and patient-
5 facing financial incentives created through benefit design reform, to ensure that patient,
6 provider, and payer incentives all promote the same quality care. Such initiatives may
7 include reducing patient cost-sharing for the items and services that are tied to provider
8 quality metrics; develop coding guidance tools to help providers appropriately bill for
9 zero-dollar preventive interventions and promote common understanding among health
10 care providers, payers, patients, and health care information technology vendors
11 regarding what will be covered at given cost-sharing levels; develop physician
12 educational tools that prepare physicians for conversations with their patients about the
13 scope of preventive services provided without cost-sharing and instances where and
14 when preventive services may result in financial obligations for the patient; continue to
15 support requiring private health plans to provide coverage for evidence-based preventive
16 services without imposing cost-sharing (such as co-payments, deductibles, or
17 coinsurance) on patients; continue to support implementing innovative VBID programs in
18 Medicare Advantage plans; support legislative and regulatory flexibility to accommodate
19 VBID that (a) preserves health plan coverage without patient cost-sharing for evidence-
20 based preventive services; and (b) allows innovations that expand access to affordable
21 care, including changes needed to allow High Deductible Health Plans paired with
22 Health Savings Accounts to provide pre-deductible coverage for preventive and chronic
23 care management services; and encourage national medical specialty societies to
24 identify services that they consider to be high-value and collaborate with payers to
25 experiment with benefit plan designs that align patient financial incentives with utilization
26 of high-value services.

27
28 Testimony on the Joint Report of the Council on Medical Service and the Council on
29 Science and Public Health was generally supportive. A member of the Council on
30 Medical Service introduced the report and underscored that the recommendations of the
31 report expand the AMA's leadership on coverage for high-value care and build on AMA
32 policy regarding value-based insurance design (VBID). A member of the Council on
33 Science and Public Health testified that the recommendations of the report recognize
34 that health insurance must provide ongoing access to care for patients with chronic
35 disease. Your Reference Committee believes that the Joint Report of the Council on
36 Medical Service and the Council on Science and Public Health addresses challenges
37 associated with the preventive services benefit of the Affordable Care Act and
38 opportunities to better align incentives around high-value care, including through
39 application of VBID. Accordingly, your Reference Committee recommends that the
40 recommendations of the Joint Report of the Council on Medical Service and the Council
41 on Science and Public Health be adopted and the remainder of the report be filed.

1 (4) RESOLUTION 801 - ENCOURAGE FINAL EVALUATION
2 REPORTS OF SECTION 1115 DEMONSTRATIONS AT
3 THE END OF THE DEMONSTRATION CYCLE

4
5 RECOMMENDATION:

6
7 Madam Speaker, your Reference Committee recommends
8 that Resolution 801 be adopted.

9
10 Resolution 801 asks that our AMA encourage the Centers for Medicare & Medicaid
11 Services to establish written procedures that require final evaluation reports of Section
12 1115 Demonstrations at the end of each demonstration cycle, regardless of renewal
13 status.

14
15 Your Reference Committee heard supportive testimony on Resolution 801. Your
16 Reference Committee believes Resolution 801 is consistent with existing AMA policy
17 regarding the evaluation of demonstration programs, and recommends its adoption.

18
19 (5) RESOLUTION 804 - ARBITRARY DOCUMENTATION
20 REQUIREMENTS FOR OUTPATIENT SERVICES

21
22 RECOMMENDATION:

23
24 Madam Speaker, your Reference Committee recommends
25 that Resolution 804 be adopted.

26
27 The revised Resolution 804 asks that our AMA agree that documentation for outpatient
28 physician services should be completed in a timely manner; and work with government
29 health plans and private insurers to help them better understand the unintended
30 consequences of imposing documentation rules with unrealistically short timeframes,
31 and that our AMA oppose the use of such rules or regulations in determining whether
32 submitted claims are valid and payable.

33
34 Testimony on Resolution 804 was unanimously supportive. Testimony stated that our
35 AMA should help prevent public and private payers from implementing onerous
36 documentation requirements on physicians, and your Reference Committee agrees.
37 Accordingly, your Reference Committee recommends that Resolution 804 be adopted.

38
39 (6) RESOLUTION 810 - MEDICARE ADVANTAGE STEP
40 THERAPY

41
42 RECOMMENDATION:

43
44 Madam Speaker, your Reference Committee recommends
45 that Resolution 810 be adopted.

46
47 Resolution 810 asks that our AMA continue strong advocacy for the rejection of step
48 therapy in Medicare Advantage plans and impede the implementation of the practice
49 before it takes effect on January 1, 2019.

1 Your Reference Committee heard highly supportive testimony on Resolution 810. Your
2 Reference Committee notes that our AMA and 93 state medical associations and
3 national medical specialty societies raised extensive concerns with CMS in a sign-on
4 letter regarding its new policy allowing Medicare Advantage plans, starting in 2019, to
5 utilize step-therapy protocols for physician-administered drugs covered under Medicare
6 Part B. Your Reference Committee believes that Resolution 810 is highly consistent not
7 only with AMA advocacy efforts to date, but also with existing policy that opposes
8 regulations and demonstration programs that are likely to undermine access to the best
9 course of treatment for individual patients. As such, your Reference Committee
10 recommends that Resolution 810 be adopted.

11

12 (7) BOARD OF TRUSTEES REPORT 9 - HOSPITAL
13 CLOSURES AND PHYSICIAN CREDENTIALING

14

15 RECOMMENDATION A:

16

17 Madam Speaker, your Reference Committee recommends
18 that Recommendation 3 in Board of Trustees Report 9 be
19 amended by addition and deletion as follows:

20

21 3. That our AMA: (a) continue to monitor the development
22 and implementation of physician credentialing repository
23 databases that track hospital affiliations, including tracking
hospital closures, as well as how and where these closed
hospitals are storing physician credentialing information;
24 and (b) explore the feasibility of developing a universal
25 clearinghouse that centralizes the verification of
26 credentialing information ~~as it relates to physician practice~~
~~and affiliation history~~, and report back to the House of
27 Delegates at the 2019 Interim Meeting. (Directive to Take
28 Action)

29

30 RECOMMENDATION B:

31

32

33 Madam Speaker, your Reference Committee recommends
34 that the recommendations in Board of Trustees Report 9
35 be adopted as amended and the remainder of the report
36 be filed.

37

38

39

40 Board of Trustees Report 9 recommends that our AMA reaffirm Policy H-230.956;
41 develop model state legislation and regulations that would require hospitals to: (a)
42 implement a procedure for preserving medical staff credentialing files in the event of the
43 closure of the hospital; and (b) provide written notification to its state health agency and
44 medical staff before permanently closing its facility indicating whether arrangements
45 have been made for the timely transfer of credentialing files and the exact location of
46 those files; continue to monitor the development and implementation of physician
47 credentialing repository databases that track hospital affiliations; and explore the
48 feasibility of developing a universal clearinghouse that centralizes the verification of
49 credentialing information as it relates to physician practice and affiliation history, and
50 report back to the House of Delegates at the 2019 Interim Meeting.

1 Testimony was supportive of Board of Trustees Report 9. A member of the Board of
2 Trustees introduced the report highlighting that the AMA should encourage emulation of
3 appropriate existing laws and regulations by developing model state legislation that
4 supports timely access to credentialing files following the closure of a hospital. An
5 amendment was offered to include tracking hospital closures, and your Reference
6 Committee accepts this amendment. An additional amendment was offered to limit the
7 credentialing information available on the clearinghouse to undergraduate and graduate
8 medical education training. However, your Reference Committee believes that it is likely
9 that the Board of Trustees intended to have additional information available in the
10 clearinghouse besides education, and your Reference Committee proposes an
11 amendment to allow for leeway in what information can and should be made available in
12 the forthcoming clearinghouse. Accordingly, your Reference Committee recommends
13 that the recommendations in Board of Trustees Report 9 be adopted as amended and
14 the remainder of the report be filed.

15
16 (8) COUNCIL ON MEDICAL SERVICE REPORT 1 -
17 PRESCRIPTION DRUG IMPORTATION FOR PERSONAL
18 USE

19 RECOMMENDATION A:

20 Madam Speaker, your Reference Committee recommends
21 that Recommendation 5 in Council on Medical Service
22 Report 4 be amended by addition to read as follows:

23 1. That our American Medical Association (AMA) support
24 the in-person purchase and importation of Health Canada-
25 approved prescription drugs obtained directly from a
26 licensed Canadian pharmacy when product integrity can
27 be assured, provided such drugs are for personal use and
28 of a limited quantity. (New HOD Policy)

29 RECOMMENDATION B:

30 Madam Speaker, your Reference Committee recommends
31 that the recommendations in Council on Medical Service
32 Report 1 be adopted as amended and the remainder of the
33 report be filed.

34 RECOMMENDATION C:

35 Madam Speaker, your Reference Committee recommends
36 that the title of Council on Medical Service Report 1 be
37 changed to read as follows:

38 CANADIAN PRESCRIPTION DRUG IMPORTATION FOR
39 PERSONAL USE

40 Council on Medical Service Report 1 recommends that our AMA support the in-person
41 purchase and importation of prescription drugs obtained directly from a licensed

1 Canadian pharmacy when product integrity can be assured, provided such drugs are for
2 personal use and of a limited quantity; advocate for an increase in funding for the US
3 Food and Drug Administration to administer and enforce a program that allows the in-
4 person purchase and importation of prescription drugs from Canada, if the integrity of
5 prescription drug products imported for personal use can be assured; and reaffirm
6 Policies D-100.983 and D-100.985.

7
8 Your Reference Committee heard predominantly supportive testimony on Council on
9 Medical Service Report 1, with testimony also in support of broadening the focus of its
10 recommendations. In introducing the report, a member of the Council on Medical Service
11 underscored that the recommendations of the report aim to provide patients with an
12 option to lower their out-of-pocket costs for prescription drugs while ensuring that the
13 prescription drugs that are imported in-person from a licensed, "brick-and-mortar"
14 Canadian pharmacy are of the same quality and chemical makeup as those currently
15 distributed in the US. The Council member also noted that the FDA has voiced its
16 confidence in Health Canada in providing effective oversight of drugs approved for use
17 by Canadian patients. A member of the Council on Legislation testified in support of the
18 report, noting that the recommendations of the report are consistent with our AMA's
19 existing policy on prescription drug importation, which the Council on Legislation has
20 used to guide its assessment of legislation introduced to date.

21
22 Some speakers were in support of our AMA also advocating for personal importation of
23 prescription drugs using mail-order and online pharmacies. Your Reference Committee
24 notes that existing Policy D-100.983 listed on the first page of the report, and
25 recommended for reaffirmation, already guides AMA policy with respect to personal
26 importation of prescription drugs via the Internet and mail-order. Namely, the policy
27 predicates AMA support for such importation on ensuring the authenticity and integrity of
28 prescription drugs that are imported. Members of the Council on Medical Service and the
29 Council on Legislation noted that the mechanism outlined in the policy of our AMA to
30 ensure product integrity is the implementation and utilization of "track-and-trace"
31 technology. Testimony underscored that track-and-trace remains an important
32 mechanism to ensure medication efficacy, and that the priority of our AMA with respect
33 to personal importation of prescription drugs needs to be on our patients – that they are
34 able to import prescription drugs for personal use that are of the same potency and
35 purity as they otherwise would have access to in the US.

36
37 Your Reference Committee recognizes the potential for an increased risk to patients of
38 receiving counterfeit or substandard drugs when such drugs are not purchased and
39 imported in-person. In fact, a study by the Food and Drug Administration (FDA) revealed
40 that although nearly half of imported drugs in the study were reported to be Canadian or
41 from Canadian pharmacies, 85 percent of those drugs originated elsewhere and were
42 fraudulently misrepresented as Canadian. Domestically, steps are being taken to
43 implement track-and-trace technology. Namely, the FDA is working towards fully
44 implementing the Drug Supply Chain Security Act by 2023, which outlines steps to build
45 an electronic, interoperable system to identify and trace certain prescription drugs as
46 they are distributed in the US.

47
48 There was also an amendment offered to study and report back regarding the in-person
49 importation of prescription drugs obtained directly from a properly licensed non-US
50 pharmacy beyond Canada, including in Mexico. Your Reference Committee notes that

1 referred Resolution 226-I-17 to which this report responded solely addressed the in-
2 person purchase and importation of prescription drugs from Canada, not other countries.
3 A member of the Council on Medical Service raised concerns with the regulatory and
4 safety standards of Mexico pertaining to prescription drugs and pharmacies. In addition,
5 the member noted that the FDA's enforcement discretion pertaining to prescription drugs
6 imported in-person from other countries would remain, and as such questioned whether
7 such a study would be warranted and be a prudent use of AMA resources.
8

9 Your Reference Committee is offering an amendment to the first recommendation of the
10 report to include a requirement that prescription drugs purchased and imported in-
11 person must be approved by Health Canada. The inclusion of Health Canada in the first
12 recommendation continues our AMA's prioritization of patient safety in prescription drug
13 importation as the agency is the equivalent to the FDA in Canada. As such, your
14 Reference Committee recommends that the recommendations of Council on Medical
15 Service Report 1 be adopted as amended and the remainder of the report be filed.
16

17 (9) COUNCIL ON MEDICAL SERVICE REPORT 4 - THE
18 SITE-OF-SERVICE DIFFERENTIAL
19

20 RECOMMENDATION A:
21

22 Madam Speaker, your Reference Committee recommends
23 that Recommendation 5 in Council on Medical Service
24 Report 4 be amended by addition to read as follows:
25

26 5. That our AMA support Medicare payment policies for
27 outpatient services that are site-neutral without lowering
28 total Medicare payments. Site-neutral payments should be
based on the actual costs of providing those services and
not defined as equal payments or reducing all payments to
the lowest amount paid in any setting. (New HOD Policy)
32

33 RECOMMENDATION B:
34

35 Madam Speaker, your Reference Committee recommends
36 that Recommendation 6 in Council on Medical Service
37 Report 4 be amended by addition and deletion to read as
38 follows:
39

40 6. That our AMA support Medicare payments for the same
41 service routinely and safely provided in multiple outpatient
42 settings (eg, physician offices, HOPDs, and ASCs) that are
43 based on sufficient and accurate data regarding the real
actual costs of providing the service in each setting. (New
45 HOD Policy)
46

1 RECOMMENDATION C:
2

3 Madam Speaker, your Reference Committee recommends
4 that the recommendations in Council on Medical Service
5 Report 4 be adopted as amended and the remainder of the
6 report be filed.
7

8 Council on Medical Service Report 4 recommends that our AMA reaffirm Policies H-
9 240.993, D-330.997, H-400.957 and H-400.966; support Medicare payment policies for
10 outpatient services that are site-neutral without lowering total Medicare payments;
11 support Medicare payments for the same service routinely and safely provided in
12 multiple outpatient settings (eg, physician offices, HOPDs, and ASCs) that are based on
13 sufficient and accurate data regarding the real costs of providing the service in each
14 setting; urge CMS to update the data used to calculate the practice expense component
15 of the Medicare physician fee schedule by administering a physician practice survey
16 (similar to the Physician Practice Information Survey administered in 2007-2008) every
17 five years, and that this survey collect data to ensure that all physician practice costs are
18 captured; encourage CMS to both: a) base disproportionate share hospital payments
19 and uncompensated care payments to hospitals on actual uncompensated care data;
20 and b) study the costs to independent physician practices of providing uncompensated
21 care; and collect data and conduct research both: a) to document the role that
22 physicians have played in reducing Medicare spending; and b) to facilitate adjustments
23 to the portion of the Medicare budget allocated to physician services that more
24 accurately reflects practice costs and changes in health care delivery.
25

26 Your Reference Committee heard supportive testimony on Council on Medical Service
27 Report 4. In introducing the report, a member of the Council on Medical Service outlined
28 amendments to the fifth and sixth recommendations of the report, after having spoken to
29 members of the Integrated Physician Practice Section (IPPS). Your Reference
30 Committee accepts the amendments and applauds the efforts done to unify the house of
31 medicine behind the recommendations of Council on Medical Service Report 4. Your
32 Reference Committee appreciates amendments that were offered to correct for
33 underpayments made to physicians through the potential use of Medicare Part A
34 savings, but agrees with the member of Council on Medical Service who stated that the
35 ninth recommendation of the report needs to be implemented before such an
36 amendment could be considered. The ninth recommendation of the report calls for our
37 AMA to collect data and conduct research both: a) to document the role physicians have
38 played in reducing Medicare spending; and b) to facilitate adjustments to the portion of
39 the Medicare budget allocated to physician services that more accurately reflects
40 practice costs and changes in care delivery. Your Reference Committee believes that
41 the recommendations of Council on Medical Service Report 4 recognize the high priority
42 placed on the issue of the site-of-service differential by the members of our AMA, and
43 recommends that the recommendations of Council on Medical Service Report 4 be
44 adopted as amended and the remainder of the report be filed.

1 (10) RESOLUTION 802 - DUE DILIGENCE FOR PHYSICIANS
2 AND PRACTICES JOINING AN ACO WITH RISK BASED
3 MODELS (UP SIDE AND DOWN SIDE RISK)

4
5 RECOMMENDATION A:

6
7 Madam Speaker, your Reference Committee recommends
8 that the second Resolve of Resolution 802 be amended by
9 addition and deletion to read as follows:

10
11 RESOLVED, That our AMA develop educational resources
12 and business tools analytics to help physicians complete
13 due diligence in evaluating the performance of physician-
14 led and hospital integrated systems before considering
15 consolidation. Specific attention should be given to the
16 evaluation of transparency on past savings results, system
17 finances, quality metrics, physician workforce stability and
18 physician job satisfaction, and the cost of clinical
19 documentation software (Directive to Take Action); and be
20 it further

21
22 RECOMMENDATION B:

23
24 Madam Speaker, your Reference Committee recommends
25 that the third Resolve of Resolution 802 be amended by
26 deletion as follows:

27
28 RESOLVED, That our AMA evaluate the characteristics of
29 successful physician owned MSSP ACOs and participation
30 in alternative payment models (APMs) to create a
31 framework of the resources and organizational tools
32 needed to allow smaller practices to form virtual ACOs that
33 would facilitate participation in MSSP ACOs and APMs.
34 (Directive to Take Action)

35
36 RECOMMENDATION C:

37
38 Madam Speaker, your Reference Committee recommends
39 that Resolution 802 be adopted as amended.

40
41 Resolution 802 asks that our AMA advocate for the continuation of up side only risk
42 Medicare Shared Savings ACO (MSSP ACO) program as an option from the Centers for
43 Medicare and Medicaid Services, particularly for physician owned groups; develop
44 educational resources and business analytics to help physicians complete due diligence
45 in evaluating the performance of hospital integrated systems before considering
46 consolidation. Specific attention should be given to the evaluation of transparency on
47 past savings results, system finances, quality metrics, physician workforce stability and
48 physician job satisfaction, and the cost of clinical documentation software; and evaluate
49 the characteristics of successful physician owned MSSP ACOs and participation in
50 alternative payment models (APMs) to create a framework of the resources and

1 organizational tools needed to allow smaller practices to form virtual ACOs that would
2 facilitate participation in MSSP ACOs and APMs.

3
4 Testimony on Resolution 802 was unanimously supportive. Your Reference Committee
5 notes that Resolution 802 coincides with ongoing AMA advocacy efforts seeking to
6 better define ACO accountability to match its capabilities to withstand risk. Specifically,
7 in our AMA's recent comment letter on the ACO proposed rule, our AMA urged the
8 Centers for Medicare and Medicaid Services to retain the Track 1 model instead of
9 forcing all ACOs into two-sided risk models and provided evidence that ACOs can
10 achieve savings for Medicare without downside risk. An amendment was offered
11 suggesting that our AMA develop educational information and a webinar directed
12 towards small physician practices to encourage their participation in these payment
13 model activities. However, your Reference Committee believes that the request to
14 develop educational resources in the second resolve clause satisfies this ask.
15 Additionally, your Reference Committee suggests several minor amendments to be
16 inclusive of all practice sizes and notes that definitions of a "smaller practice" are
17 variable. Moreover, your Reference Committee suggests calling for business tools
18 believing that this language is broader than the call for analytics and will provide the
19 AMA with more leeway in the business resources it makes available to physicians.
20 Therefore, your Reference Committee recommends that Resolution 802 be adopted as
21 amended.

22
23 (11) RESOLUTION 803 - INSURANCE COVERAGE FOR
24 ADDITIONAL SCREENING RECOMMENDED IN STATES
25 WITH LAWS REQUIRING NOTIFICATION OF "DENSE
26 BREASTS" ON MAMMOGRAM

27 RECOMMENDATION:

28
29
30 Madam Speaker, your Reference Committee recommends
31 that the following alternate resolution be adopted in lieu of
32 Resolution 803:

33
34 RESOLVED, That our American Medical Association
35 (AMA) reaffirm Policy H-525.993, which supports
36 insurance coverage for screening mammography (Reaffirm
37 HOD Policy); and be it further

38
39 RESOLVED, That our AMA reaffirm Policy H-525.977,
40 which opposes state requirements for mandatory
41 notification of breast tissue density to patients (Reaffirm
42 HOD Policy); and be it further

1 RESOLVED, That our AMA encourage research on the
2 benefits and harms of adjunctive screening for breast
3 cancer for women identified to have dense breasts on an
4 otherwise negative screening mammogram, in order to
5 guide appropriate and evidence-based insurance coverage
6 of the service (New HOD Policy); and be it further

7
8 RESOLVED, That our AMA support insurance coverage
9 for and adequate access to supplemental screening
10 recommended for patients with “dense breast” tissue
11 following a discussion between the patient and their
12 physician which integrates secondary risk characteristics.
13 (New HOD Policy)

14
15 Resolution 803 asks that our AMA support insurance coverage for supplemental
16 screening recommended for patients with “dense breast” tissue following a conversation
17 between the patient and their physician; and advocate for insurance coverage for and
18 adequate access to supplemental screening recommended for patients with “dense
19 breast” tissue following a conversation between the patient and their physician.

20
21 Your Reference Committee heard mixed testimony on Resolution 803. Amendments
22 were offered in support of insurance coverage for and adequate access to supplemental
23 screening recommended for patients with dense breast tissue, which your Reference
24 Committee incorporated in the alternate resolution. Based on testimony addressing the
25 evidence behind screening mammography and concerns regarding state requirements
26 for mandatory notification of breast tissue density to patients, your Reference Committee
27 is recommending the reaffirmation of applicable AMA policy. Finally, several speakers
28 stressed that AMA policy should not get ahead of the science on this issue, and as such
29 your Reference Committee is including a recommendation to encourage research on the
30 benefits and harms of adjunctive screening for breast cancer for women identified to
31 have dense breasts on an otherwise negative screening mammogram. Accordingly, your
32 Reference Committee recommends that the alternate resolution offered be adopted in
33 lieu of Resolution 803.

34
35 H-525.993 Screening Mammography
36 Our AMA: a. recognizes the mortality reduction benefit of screening
37 mammography and supports its use as a tool to detect breast cancer. b.
38 recognizes that as with all medical screening procedures there are small, but not
39 inconsequential associated risks including false positive and false negative
40 results and overdiagnosis. c. favors participation in and support of the efforts of
41 professional, voluntary, and government organizations to educate physicians and
42 the public regarding the value of screening mammography in reducing breast
43 cancer mortality, as well as its limitations. d. advocates remaining alert to new
44 epidemiological findings regarding screening mammography and encourages the
45 periodic reconsideration of these recommendations as more epidemiological data
46 become available. e. believes that beginning at the age of 40 years, all women
47 should be eligible for screening mammography. f. encourages physicians to
48 regularly discuss with their individual patients the benefits and risks of screening
49 mammography, and whether screening is appropriate for each clinical situation

1 given that the balance of benefits and risks will be viewed differently by each
2 patient. g. encourages physicians to inquire about and update each patient's
3 family history to detect red flags for hereditary cancer and to consider other risk
4 factors for breast cancer, so that recommendations for screening will be
5 appropriate. h. supports insurance coverage for screening mammography. i.
6 supports seeking common recommendations with other organizations, informed
7 and respectful dialogue as guideline-making groups address the similarities and
8 differences among their respective recommendations, and adherence to
9 standards that ensure guidelines are unbiased, valid and trustworthy. j. reiterates
10 its longstanding position that all medical care decisions should occur only after
11 thoughtful deliberation between patients and physicians. (CSA Rep. F, A-88;
12 Reaffirmed: Res. 506, A-94; Amended: CSA Rep. 16, A-99; Appended: Res. 120,
13 A-02; Modified: CSAPH Rep. 6, A-12)

14
15 H-525.977 Breast Density Notification

16 Our AMA supports the inclusion of breast tissue density information in the
17 mammography report when appropriate and education of patients about the
18 clinical relevance of such information, but opposes state requirements for
19 mandatory notification of breast tissue density to patients. (Res. 502, A-14)

20
21 (12) RESOLUTION 805 - PROMPT PAY

22
23 RECOMMENDATION:

24
25 Madam Speaker, your Reference Committee recommends
26 that the following alternate resolution be adopted in lieu of
27 Resolution 805:

28
29 RESOLVED, That our American Medical Association
30 continue to encourage regulators to enforce existing
31 prompt pay requirements. (Directive to Take Action)

32
33 Resolution 805 asks that Policy H-190.959 be amended by addition and deletion to seek
34 regulatory and legislative relief to ensure that all health insurance and managed care
35 companies pay for clean claims submitted electronically within three days instead of
36 fourteen days; and when electronic claims are deemed to be lacking information to make
37 the claim complete, the health insurance and managed care companies will be required
38 to notify the health care provider within one day instead of five business days to allow
39 prompt resubmission of a clean claim.

40
41 Testimony on Resolution 805 was supportive. A member of the Council on Medical
42 Service testified that existing AMA policy addresses the intent of Resolution 805 and that
43 the Council is unsure why our AMA would request to shorten the payment timeline when
44 we are still struggling to achieve conformance with our 14-day policy. Additionally, the
45 member expressed concern that asking this of payers may result in payers requesting
46 faster claims submission of providers. Recognizing the importance of Resolution 805
47 and the concerns expressed in testimony, your Reference Committee suggests an
48 alternate resolution for our AMA to continue to work with regulators to enforce existing
49 prompt pay requirements. Your Reference Committee believes that the issue lies not
50 with the exact number of days in which payment must be made but rather with the lack

1 of enforcement of current prompt pay regulations. Accordingly, your Reference
2 Committee recommends that the alternate resolution be adopted in lieu of Resolution
3 805.

4

5 (13) RESOLUTION 806 - TELEMEDICINE MODELS AND
6 ACCESS TO CARE IN POST-ACUTE AND LONG-TERM
7 CARE

8 RECOMMENDATION A:

9

10 Madam Speaker, your Reference Committee recommends
11 that the first Resolve of Resolution 806 be amended by
12 addition and deletion to read as follows:

13

14 RESOLVED, That our American Medical Association
15 advocate for removal of arbitrary limits on telemedicine
16 visits by medical practitioners in nursing facilities and
17 instead base them purely on medical necessity, and
18 collaborate with relevant national medical specialty
19 ~~societies AMDA – The Society for Post-Acute and Long-~~
20 ~~Term Care Medicine~~ to effect a change in Medicare's
21 policy regarding this matter under the provisions of
22 Physician Fee Schedule (PFS) and Quality Payment
23 Program (QPP) (New HOD Policy); and be it further

24

25 RECOMMENDATION B:

26

27 Madam Speaker, your Reference Committee recommends
28 that the second Resolve of Resolution 806 be amended by
29 addition and deletion to read as follows:

30

31 RESOLVED, That our AMA work with relevant national
32 medical specialty societies ~~AMDA – The Society for Post-~~
33 ~~Acute and Long-Term Care Medicine~~ and other
34 stakeholders to influence Congress to broaden the scope
35 of telemedicine care models in post-acute and long-term
36 care and authorize payment mechanisms for models that
37 are evidence based, relevant to post-acute and long-term
38 care and continue to engage primary care physicians and
39 practitioners in the care of their patients.

40

41 RECOMMENDATION C:

42

43 Madam Speaker, your Reference Committee recommends
44 that Resolution 806 be adopted as amended.

45

46 Resolution 806 asks that our AMA advocate for removal of arbitrary limits on
47 telemedicine visits by medical practitioners in nursing facilities and instead base them
48 purely on medical necessity, and collaborate with AMDA – The Society for Post-Acute
49 and Long-Term Care Medicine to effect a change in Medicare's policy regarding this

1 matter under the provisions of Physician Fee Schedule (PFS) and Quality Payment
2 Program (QPP); and work with AMDA-The Society for Post-Acute and Long-Term Care
3 Medicine and other stakeholders to influence Congress to broaden the scope of
4 telemedicine care models in post-acute and long-term care and authorize payment
5 mechanisms for models that are evidence based, relevant to post-acute and long-term
6 care and continue to engage primary care physicians and practitioners in the care of
7 their patients.

8
9 Your Reference Committee heard limited yet supportive testimony on Resolution 806.
10 Your Reference Committee is offering amendments to the resolution to ensure that our
11 AMA is able to work with all relevant national medical specialty societies to achieve the
12 objectives of the resolution. Accordingly, your Reference Committee recommends that
13 Resolution 806 be adopted as amended.

14
15 (14) RESOLUTION 808 - THE IMPROPER USE OF BEERS
16 OR SIMILAR CRITERIA AND THIRD-PARTY PAYER
17 COMPLIANCE ACTIVITIES (H-185.940)

18
19 RECOMMENDATION:

20
21 Madam Speaker, your Reference Committee recommends
22 that the following alternate resolution be adopted in lieu of
23 Resolution 808:

24
25 THE IMPROPER USE OF BEERS OR SIMILAR
26 CRITERIA

27
28 RESOLVED, That our American Medical Association
29 (AMA) reaffirm Policy H-185.940 (Reaffirm HOD Policy);
30 and be it further

31
32 RESOLVED, That our AMA educate and urge health
33 insurers, benefit managers, and other payers not to
34 inappropriately apply the Beers or similar criteria to quality
35 ratings programs in a way that may financially penalize
36 physicians. (New HOD Policy)

37
38 Resolution 808 asks that our AMA identify and establish a workgroup with insurers that
39 are inappropriately applying Beers or similar criteria to quality rating programs and work
40 with the insurers to resolve internal policies that financially penalize physicians; study
41 and report back to the House of Delegates the 2019 Interim Meeting, the potential
42 inappropriate use of Beers Criteria by insurance companies looking at which companies
43 are involved and the effect of the use of these criteria on physicians' practices; and
44 provide a mechanism for members to report possible abuses of Beers criteria by
45 insurance companies.

46
47 There was mixed testimony on Resolution 808. A member of the Council on Medical
48 Service called for reaffirmation of Policy H-185.940 stating that the Council believes
49 existing AMA policy satisfies Resolution 808. Moreover, the member questioned the
50 necessity of a workgroup and a report back because the American Geriatric Society

1 (AGS) and our AMA state that the criteria should not be used in a punitive manner and
2 the criteria is no longer used as part of the Medicare star ratings system. Your
3 Reference Committee notes that, effective in 2017, it is simply a “display measure.”
4 Moreover, while the American Geriatric Society states that the criteria be used as both
5 an educational tool and quality measure, it further states that the intent is not to apply
6 the criteria in a punitive manner (see <https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/Downloads/2017-Star-Ratings-Request-for-Comments.pdf>). A member of the Beers Panel and the AGS testified against adoption
7 stating that AGS published an article in 2015 about how to use the Beers Criteria and
8 stated that that the workgroup called for in the resolution is an ineffective use of AMA
9 resources and that instead our AMA should continue its work on the Beers Criteria and
10 Prior Authorization. Testimony further stated that our AMA does and should continue to
11 take advantage of comment periods relating to the Beers Criteria and that the next
12 comment period will begin in early 2019.
13

14
15 With respect to the underlying intent of the third resolve of the original resolution, your
16 Reference Committee notes that there already are a variety of forums in which members
17 of the Federation can seek AMA assistance, such as through the Specialty and Service
18 Society and the work of the Advocacy Resource Center. In addition, the AMA Advocacy
19 Group engages health insurers directly on systemic issues that involve national insurers
20 or cut across multiple health insurance markets, such as the AMA's current broad-based
21 efforts to reduce the patient and practice burdens associated with prior authorization.
22

23
24 Based on testimony, your Reference Committee believes that the problem may not be
25 the Beers Criteria itself but rather how payers are using clinical guidelines to financially
26 penalize physicians. This belief was echoed by the author who stated that they simply
27 wanted our AMA to assist in ensuring that insurers are not using the Beers Criteria in a
28 punitive manner and was open to amendment of Resolution 808. Accordingly, your
29 Reference Committee recommends adopting an alternate resolution that reaffirms Policy
30 H-185.940. Your Reference Committee believes that the alternate resolution achieves
31 the request of the authors and targets the source of the issue.
32

33 H-185.940 Beers or Similar Criteria and Third Party Payer Compliances Activities
34 Our AMA adopts policy: (1) discouraging health insurers, benefit managers, and
35 other payers from using the Beers Criteria and other similar lists to definitively
36 determine coverage and/or reimbursement, and inform health insurers and other
37 payers of this policy; and (2) clarifying that while it is appropriate for
38 the Beers Criteria to be incorporated in quality measures, such measures should
39 not be applied in a punitive or onerous manner to physicians and must recognize
40 the multitude of circumstances where deviation from the quality measure may be
41 appropriate, and inform health insurers and other payers of this policy. (BOT
42 Rep. 14, A-12)

1 (15) RESOLUTION 812 - ICD CODE FOR PATIENTS HARM
2 FROM PAYER INTERFERENCE

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that the following alternate resolution be adopted in lieu of
8 Resolution 812:

9
10 PRIOR AUTHORIZATION AND PATIENT HARM

11
12 RESOLVED, That our American Medical Association
13 support efforts to track and quantify the impact of health
14 plans' prior authorization and utilization management
15 processes on patient access to necessary care and patient
16 clinical outcomes, including the extent to which these
17 processes contribute to patient harm. (New HOD Policy)

18
19 Resolution 812 asks that our AMA support the creation and implementation of an ICD
20 code(s) to identify administrator or payer influence that affects treatment and leads to or
21 contributes to, directly or indirectly, patient harm.

22
23 Testimony was supportive of the intent of Resolution 812 and the importance of
24 supporting efforts to track the harm to patients caused by payer interference via prior
25 authorization requirements. A member of the Council on Medical Service proposed
26 substitute language and testified that the ICD-10 code requested by Resolution 812
27 would require physicians to clearly document the correlation between payer policies and
28 adverse clinical outcomes, which raises concerns about the appropriateness of
29 documenting this information in the clinical record, timing of when the code would be
30 reported during the patient's treatment, and potential repercussions to the physician for
31 what he/she did for the patient to prevent the harm. Additionally, the Council member
32 stated that this documentation burden would likely lead to underutilization of the code
33 and that there may be more suitable ways to obtain this data. Your Reference
34 Committee suggests that the Prior Authorization Physician Survey may be one way to
35 obtain this data. In last year's survey, 92 percent of physicians reported that prior
36 authorization can have a negative impact on patient clinical outcomes. And this year's
37 version of the survey, which will be conducted in December, includes more questions
38 addressing this point. Our AMA will have new data to report early next year. Taking into
39 account these considerations and believing that an ICD-10 code is not the appropriate
40 mechanism to address the issue, your Reference Committee recommends that the
41 alternate resolution be adopted in lieu of Resolution 812.

1 (16) RESOLUTION 814 - PRIOR AUTHORIZATION RELIEF IN
2 MEDICARE ADVANTAGE PLANS

3 RECOMMENDATION A:

4
5 Madam Speaker, your Reference Committee recommends
6 that the first resolve of Resolution 814 be amended by
7 addition and deletion as follows:

8
9 RESOLVED, That our American Medical Association
10 support legislation and/or regulations that would apply the
11 following ~~legislative~~ processes and parameters to prior
12 authorization (PA) for Medicaid and Medicaid managed
13 care plans and Medicare Advantage plans:

14 a. Listing services that require a PA on a website and
15 ensuring that patient informational materials include full
16 disclosure of any PA requirements.
17 b. Notifying providers of any changes at least 45 days
18 prior to change.
19 c. Improving transparency by requiring plans to report on
20 the scope of PA practices, including the list of services
21 subject to PA and corresponding denial, delay, and
22 approval rates.
23 d. Standardizing a PA request form.
24 e. Minimizing PA requirements as much as possible
25 within each plan and eliminating the application of PA
26 to services that are routinely approved.
27 f. Not denying payment for PA that has been approved
28 unless fraudulently obtained ~~or ineligible at time of~~
29 service.
30 g. Medications already being administered when a patient
31 changes health plans cannot be changed by the health
32 plan without discussion and approval of the ordering
33 physician.
34 h. Making an easily accessible and responsive direct
35 communication tool available to resolve disagreements
36 between health plan and ordering provider.
37 i. Defining a consistent process for appeals and
38 grievances, including to Medicaid and Medicaid
39 managed care plans (New HOD Policy). ; ~~and be it~~
40 ~~further~~

41
42 RECOMMENDATION B:

43
44 Madam Speaker, your Reference Committee recommends
45 that the second resolve of Resolution 814 be amended by
46 deletion as follows:

1 RESOLVED, That our AMA apply these same legislative
2 processes and parameters to prior authorization (PA) for
3 Medicaid and Medicaid managed care plans and Medicare
4 Advantage plans, to include:

- 5 a. Medications already working when a patient changes
6 health plans cannot be changed by the plan without
7 discussion and approval of the ordering physician.
- 8 b. Minimizing PA requirements as much as possible
9 within each plan.
- 10 c. Making an easily accessible and reasonably
11 responsive direct communication tool available to
12 resolve disagreements between plan and ordering
13 provider. (New HOD Policy)

14
15 RECOMMENDATION C:

16
17 Madam Speaker, your Reference Committee recommends
18 that Resolution 814 be adopted as amended.

19
20 Resolution 814 asks that our AMA support legislation that would apply the following
21 legislative processes and parameters to prior authorization (PA) for Medicaid and
22 Medicaid managed care plans and Medicare Advantage plans: 1) Listing services that
23 require a PA on a website, 2) Notifying providers of any changes at least 45 days prior to
24 change, 3) Standardizing a PA request form, 4) Not denying payment for PA that has
25 been approved unless fraudulently obtained or ineligible at time of service and 5)
26 Defining a consistent process for appeals and grievances, including to Medicaid and
27 Medicaid managed care plans; and apply these same legislative processes and
28 parameters to prior authorization (PA) for Medicaid and Medicaid managed care plans
29 and Medicare Advantage plans, to include: 1) Medications already working when a
30 patient changes health plans cannot be changed by the plan without discussion and
31 approval of the ordering physician, 2) Minimizing PA requirements as much as possible
32 within each plan and 3) Making an easily accessible and reasonably responsive direct
33 communication tool available to resolve disagreements between plan and ordering
34 provider.

35
36 A member of the Council on Medical Service testified that, at the 2017 Annual Meeting,
37 the Council presented a comprehensive report on prior authorization and utilization
38 management reform that recommended that our AMA continue its widespread prior
39 authorization advocacy and outreach, including promotion of the Prior Authorization and
40 Utilization Management Reform Principles, model state legislation, the Prior
41 Authorization Physician Survey, and our AMA Prior Authorization toolkit. The Council
42 believes that these tools, coupled with existing AMA prior authorization policy, address
43 the points outlined in Resolution 814. Policy H-320.939 supports prior authorization
44 advocacy and outreach, including promotion/adoption of the Prior Authorization and
45 Utilization Management Reform Principles and AMA model legislation aimed at reducing
46 PA burdens and improving access to care. Policy H-320.961 supports legislation or
47 regulations that prevent the retrospective denial of payment for services for which a
48 physician had previously received authorization. Additional testimony echoed that the
49 points raised in the resolution are addressed by numerous additional policies—including
50 Policies H-320.968, H-320.952, H-285.965, and D-190.974—as well as the

1 aforementioned Principles, the Consensus Statement on Improving the Prior
2 Authorization Process, and AMA model state legislation.

3
4 Amendments were offered to ensure that our AMA took action on PA both in the
5 legislative and regulatory spheres and to take out wording that PA be approved unless
6 ineligible at the time of service to reduce physician burden and inappropriate PA
7 determinations. Your Reference Committee accepts these amendments. Overall,
8 although your Reference Committee agrees with testimony stating that Resolution 814 is
9 largely addressed by current policy, it believes portions of Resolution 814 are consistent
10 and additive to current policy. Moreover, your Reference Committee understands the
11 burdens imposed on physicians by PA and wants to ensure that our AMA continues to
12 do all it can to reduce PA and its negative impacts on patients and physicians.
13 Accordingly, your Reference Committee recommends that Resolution 814 be adopted as
14 amended.

15
16 (17) RESOLUTION 820 - ENSURING QUALITY HEALTH
17 CARE FOR OUR VETERANS

18
19 RECOMMENDATION A:

20
21 Madam Speaker, your Reference Committee recommends
22 that Resolution 820 be amended by addition and deletion
23 to read as follows:

24
25 RESOLVED, That our American Medical Association
26 amend Policy H-510.986, "Ensuring Access to Care for our
27 Veterans," by addition to read as follows:

28
29 Ensuring Access to Safe and Quality Care for our Veterans
30 H-510.986

31 1. Our AMA encourages all physicians to participate, when
32 needed, in the health care of veterans.
33 2. Our AMA supports providing full health benefits to
34 eligible United States Veterans to ensure that they can
35 access the Medical care they need outside the Veterans
36 Administration in a timely manner.

37 3. Our AMA will advocate strongly: a) that the President of
38 the United States take immediate action to provide timely
39 access to health care for eligible veterans utilizing the
40 healthcare sector outside the Veterans Administration until
41 the Veterans Administration can provide health care in a
42 timely fashion; and b) that Congress act rapidly to enact a
43 bipartisan long term solution for timely access to entitled
44 care for eligible veterans.

45 4. Our AMA recommends that in order to expedite access,
46 state and local medical societies create a registry of
47 doctors offering to see our veterans and that the registry
48 be made available to the veterans in their community and
49 the local Veterans Administration.

1 5. Our AMA will strongly advocate that the Veterans Health
2 Administration and Congress develop and implement
3 necessary resources, protocols, and accountability to
4 ensure the Veterans Health Administration recruits, hires
5 and retains ~~first rate, competent, and ethical~~ physicians
6 and other health care professionals to deliver the safe,
7 effective and high-quality care that our veterans have been
8 promised and are owed.

9 6. Our AMA will engage the Veterans Health
10 Administration in dialogue on accreditation practices by the
11 Veterans Health Administration to align its practices with
12 external best practices assure they are similar to those of
13 hospitals, state medical boards, and insurance companies.
14 (Modify Current HOD Policy)

15 RECOMMENDATION B:

16 Madam Speaker, your Reference Committee recommends
17 that Resolution 820 be adopted as amended.

18 Resolution 820 asks that our AMA amend Policy H-510.986 by addition to state that our
19 AMA will strongly advocate that the Veterans Health Administration and Congress
20 develop and implement necessary resources, protocols, and accountability to ensure the
21 Veterans Health Administration recruits, hires and retains first-rate, competent, and
22 ethical physicians and other health care professionals to deliver the safe, effective and
23 high-quality care that our veterans have been promised and are owed; and engage the
24 Veterans Health Administration in dialogue on accreditation practices by the Veterans
25 Health Administration to assure they are similar to those of hospitals, state medical
26 boards, and insurance companies.

27 Your Reference Committee heard mixed testimony on Resolution 820. An amendment
28 was offered to remove language in Part 5 of the proposed policy addition because it is
29 potentially inflammatory, and your Reference Committee agrees. Moreover, though your
30 Reference Committee understands that while the VA is highly regulated on the federal
31 side, such regulations and practices may diverge from those of local hospitals and
32 states. Therefore, your Reference Committee believes that a dialogue with the VHA is
33 appropriate to explore these differences to ensure the continued quality care of our
34 veterans. Accordingly, your Reference Committee recommends that Resolution 820 be
35 adopted as amended.

36 (18) RESOLUTION 826 - DEVELOPING SUSTAINABLE
37 SOLUTIONS TO DISCHARGE OF CHRONICALLY-
38 HOMELESS PATIENTS

39 RECOMMENDATION:

40 Madam Speaker, your Reference Committee recommends
41 that Resolution 826 be referred.

1 Resolution 826 work with relevant stakeholders in developing sustainable plans for the
2 appropriate discharge of chronically-homeless patients from hospitals, and reaffirm
3 Policies H-270.962 and H-130.940.

4

5 Your Reference Committee heard mixed testimony on Resolution 826. Speakers
6 stressed that the resolution could have unintended consequences and amount to an
7 unfunded mandate. Your Reference Committee agrees and recommends referral of
8 Resolution 826.

9

10 (19) RESOLUTION 822 - BONE DENSITY REIMBURSEMENT

11

12 RECOMMENDATION:

13

14 Madam Speaker, your Reference Committee recommends
15 that Resolution 822 not be adopted.

16

17 Resolution 822 asks that our AMA advocate for the correction of the underpayment by
18 Medicare, Medicaid, and third-party payers to medical practices for office-based DXA
19 tests.

20

21 There was mixed testimony on Resolution 822. Several speakers were supportive of the
22 resolution and stated that inadequate reimbursement often results in access to care
23 issues. A member of the Council on Medical Service called for not adoption of
24 Resolution 822 explaining that current payment rates for bone density are largely based
25 off of Resource-Based Relative Value Scale Update Committee (RUC)
26 recommendations. Moreover, the DXA is a covered service when provided once every
27 two years as part of the Annual Wellness Visit, in addition to being part of the Welcome
28 to Medicare exam, and beneficiaries no longer have to pay copayments for this
29 preventive benefit. Additionally, an AMA representative to the RUC stated that the AMA
30 supports resource-based payment, and that, if payment is inadequate, it should be
31 nominated for a misvalued service and should go through the RUC process to be
32 remedied. The representative also urged the authors to work with colleagues in
33 radiology and other specialties for the best possible outcome. Numerous speakers
34 echoed this sentiment that the best and most appropriate course of action is to go
35 through the RUC process. Your Reference Committee strongly agrees and therefore
36 recommends that Resolution 822 be not adopted.

37

38 (20) RESOLUTION 807 - EMERGENCY DEPARTMENT
39 COPAYMENTS FOR MEDICAID BENEFICIARIES

40

41 RECOMMENDATION:

42

43 Madam Speaker, your Reference Committee recommends
44 that Policies H-290.965, H-130.970, H-385.921, and D-
45 290.977 be reaffirmed in lieu of Resolution 807.

46

47 Resolution 807 asks that our AMA oppose imposition of copays for Medicaid
48 beneficiaries seeking care in the emergency department. ESI triage level versus prudent
49 layperson standards – 1115 waivers for increasing amounts and to use for emergent
50 services.

1 There was mixed testimony on Resolution 807. Testimony indicated that the imposition
2 of Medicaid copayments for “nonemergent” emergency room care does not appear to
3 affect Medicaid beneficiary use of hospital emergency departments. Speakers stressed
4 the need to promote the use of preventive care and encourage appropriate treatment
5 settings by Medicaid beneficiaries. Some testimony also raised concerns that requiring
6 Medicaid copayments for emergency care could place hospitals at risk of EMTALA
7 violations.

8
9 The implied goal of imposing copays for Medicare beneficiaries seeking care in the
10 emergency department is to promote more appropriate utilization of the emergency
11 department by this segment of the population. Your Reference Committee believes that
12 Policy H-290.965 addresses the goal that imposing ED copayments is attempting to
13 achieve, while recognizing that other best practices may be more successful in
14 impacting avoidable ED visits among Medicaid beneficiaries. Policy H-130.970 responds
15 to testimony that raised concerns with state Medicaid policies that violate the “prudent
16 layperson” standard of determining when to seek emergency care. Finally, several
17 speakers stressed that steps need to be taken to ensure that Medicaid beneficiaries are
18 better able to access primary care services, and as such is recommending the
19 reaffirmation of Policies H-385.921, and D-290.977. To achieve the goal of ensuring
20 Medicaid beneficiary access to care while promoting appropriate ED utilization, your
21 Reference Committee recommends that Policies H-290.965, H-130.970, H-385.921, and
22 D-290.977 be reaffirmed in lieu of Resolution 807.

23
24 H-290.965 Affordable Care Act Medicaid Expansion

25 1. Our AMA encourages state medical associations to participate in the
26 development of their state's Medicaid access monitoring review plan and provide
27 ongoing feedback regarding barriers to access. 2. Our AMA will continue to
28 advocate that Medicaid access monitoring review plans be required for services
29 provided by managed care organizations and state waiver programs, as well as
30 by state Medicaid fee-for-service models. 3. Our AMA supports efforts to monitor
31 the progress of the Centers for Medicare and Medicaid Services (CMS) on
32 implementing the 2014 Office of Inspector General's recommendations to
33 improve access to care for Medicaid beneficiaries. 4. Our AMA will advocate that
34 CMS ensure that mechanisms are in place to provide robust access to specialty
35 care for all Medicaid beneficiaries, including children and adolescents.5. Our
36 AMA supports independent researchers performing longitudinal and risk-adjusted
37 research to assess the impact of Medicaid expansion programs on quality of
38 care. 6. Our AMA supports adequate physician payment as an explicit objective
39 of state Medicaid expansion programs. 7. Our AMA supports increasing
40 physician payment rates in any redistribution of funds in Medicaid expansion
41 states experiencing budget savings to encourage physician participation and
42 increase patient access to care. **8. Our AMA will continue to advocate that CMS**
43 provide strict oversight to ensure that states are setting and
44 maintaining their Medicaid rate structures at levels to ensure there is
45 sufficient physician participation so that Medicaid patients can have equal
46 access to necessary services. 9. Our AMA will continue to advocate that CMS
47 develop a mechanism for physicians to challenge payment rates directly to CMS.
48 10. Our AMA supports extending to states the three years of 100 percent federal
49 funding for Medicaid expansions that are implemented beyond 2016. 11. Our
50 AMA supports maintenance of federal funding for Medicaid expansion

1 populations at 90 percent beyond 2020 as long as the Affordable Care Act's
2 Medicaid expansion exists. 12. Our AMA supports improved communication
3 among states to share successes and challenges of their respective Medicaid
4 expansion approaches. **13. Our AMA supports the use of emergency**
5 **department (ED) best practices that are evidence-based to reduce**
6 **avoidable ED visits.** (CMS Rep. 02, A-16; Reaffirmation: A-17)

7
8 H-130.970 Access to Emergency Services

9 1. Our AMA supports the following principles regarding access to emergency
10 services; and these principles will form the basis for continued AMA legislative
11 and private sector advocacy efforts to assure appropriate patient access to
12 emergency services: (A) Emergency services should be defined as those health
13 care services that are provided in a hospital emergency facility after the sudden
14 onset of a medical condition that manifests itself by symptoms of sufficient
15 severity, including severe pain, that the absence of immediate medical attention
16 could reasonably be expected by a prudent layperson, who possesses an
17 average knowledge of health and medicine, to result in: (1) placing the patient's
18 health in serious jeopardy; (2) serious impairment to bodily function; or (3)
19 serious dysfunction of any bodily organ or part. (B) All physicians and health care
20 facilities have an ethical obligation and moral responsibility to provide needed
21 emergency services to all patients, regardless of their ability to pay. (Reaffirmed
22 by CMS Rep. 1, I-96) (C) All health plans should be prohibited from requiring
23 prior authorization for emergency services. (D) Health plans may require
24 patients, when able, to notify the plan or primary physician at the time of
25 presentation for emergency services, as long as such notification does not delay
26 the initiation of appropriate assessment and medical treatment. (E) All health
27 payers should be required to cover emergency services provided by physicians
28 and hospitals to plan enrollees, as required under Section 1867 of the Social
29 Security Act (i.e., medical screening examination and further examination and
30 treatment needed to stabilize an "emergency medical condition" as defined in the
31 Act) without regard to prior authorization or the emergency care physician's
32 contractual relationship with the payer. (F) Failure to obtain prior authorization for
33 emergency services should never constitute a basis for denial of payment by any
34 health plan or third party payer whether it is retrospectively determined that an
35 emergency existed or not. (G) States should be encouraged to enact legislation
36 holding health plans and third party payers liable for patient harm resulting from
37 unreasonable application of prior authorization requirements or any restrictions
38 on the provision of emergency services. (H) Health plans should educate
39 enrollees regarding the appropriate use of emergency facilities and the
40 availability of community-wide 911 and other emergency access systems that
41 can be utilized when for any reason plan resources are not readily available. (I)
42 In instances in which no private or public third party coverage is applicable, the
43 individual who seeks emergency services is responsible for payment for such
44 services. **2. Our AMA will work with state insurance regulators, insurance**
companies and other stakeholders to immediately take action to halt the
implementation of policies that violate the "prudent layperson" standard of
determining when to seek emergency care. (CMS Rep. A, A-89; Modified by
45 CMS Rep. 6, I-95; Reaffirmation A-97; Reaffirmed by Sub. Res. 707, A-98;
46 Reaffirmed: Res. 705, A-99; Reaffirmed: CMS Rep. 3, I-99; Reaffirmation A-00;
47 Reaffirmed: Sub. Res. 706, I-00; Amended: Res. 229, A-01; Reaffirmation and
48
49
50

1 Reaffirmed: Res. 708, A-02; Reaffirmed: CMS Rep. 4, A-12; Reaffirmed: CMS
2 Rep. 07, A-16; Appended: Res. 128, A-17; Reaffirmation: A-18)

3
4 H-385.921 Health Care Access for Medicaid Patients

5 It is AMA policy that to increase and maintain access to health care for all,
6 payment for physician providers for Medicaid, TRICARE, and any other publicly
7 funded insurance plan must be at minimum 100% of the RBRVS Medicare
8 allowable. (Res. 103, A-07; Reaffirmed: CMS Rep. 2, I-08; Reaffirmation A-12;
9 Reaffirmed: Res 132, A-14; Reaffirmed in lieu of Res. 808, I-14; Reaffirmation A-
10 15)

11
12 D-290.977 Medicaid Primary Care Payment Increases

13 Our AMA: (1) advocates that the Affordable Care Act's Medicaid primary care
14 payment increases for Evaluation and Management codes and vaccine
15 administration codes include obstetricians and gynecologists as qualifying
16 specialists, and support flexibility to achieve the best possible outcome; and (2)
17 advocates for the Affordable Care Act's Medicaid primary care payment
18 increases to continue past 2014 in a manner that does not negatively impact
19 payment for any other physicians. (CMS Rep. 7, I-14)

20
21 (21) RESOLUTION 818 - DRUG PRICING TRANSPARENCY

22
23 RECOMMENDATION:

24
25 Madam Speaker, your Reference Committee recommends
26 that Policies H-110.987, H-110.984, H-110.986 and H-
27 125.980 be reaffirmed in lieu of Resolution 818.

28
29 Resolution 818 asks that our AMA advocate to the U.S. Surgeon General for federal
30 legislation that investigates all drug pricing.

31
32 Your Reference Committee heard mixed testimony on Resolution 818. In introducing the
33 resolution, the sponsor offered an amendment to advocate for federal legislation to
34 promote drug pricing transparency for essential medications. Members of the Council on
35 Medical Service and Council on Legislation testified that even with the amendment,
36 existing policy and advocacy efforts already address the intent of the resolution. First, a
37 member of the Council on Medical Service stated that Policy H-110.987 already
38 supports: (a) drug price transparency legislation that requires pharmaceutical
39 manufacturers to provide public notice before increasing the price of any drug by 10% or
40 more each year or per course of treatment and provide justification for the price
41 increase; and (b) legislation that authorizes the Attorney General and/or the FTC to take
42 legal action to address price gouging by pharmaceutical manufacturers and increase
43 access to affordable drugs for patients.

44
45 A member of the Council on Legislation stated that through its legislative and regulatory
46 efforts on the federal level, development and dissemination of model state legislation
47 and working with interested state medical societies, our AMA is supporting requiring
48 pharmaceutical supply chain transparency – among pharmaceutical manufacturers,
49 pharmacy benefit managers and health plans. In particular, the AMA submitted a letter to
50 Secretary Azar regarding the Trump Administration's drug pricing blueprint, which

1 highlighted our policy priorities addressing drug price transparency and promoting and
2 ensuring fair competition in the pharmaceutical marketplace. Also, our AMA has been
3 active in testifying before Congress on the issue. Finally, our AMA also submitted letters
4 of support of relevant federal legislation and amendments, including H.R. 6733, Know
5 the Cost Act of 2018; S. 2554, The Patients Right to Know Drug Prices Act of 2018; and
6 a bipartisan amendment to require pharmaceutical manufacturers to provide an
7 appropriate disclosure of pricing information for their product in direct-to-consumer
8 (DTC) advertisements.

9
10 Another amendment was offered that was more focused on addressing insulin pricing. A
11 member of the Council on Medical Service testified that the Council just presented a
12 report at the 2018 Annual Meeting on insulin pricing, which established Policy H-110.984
13 that states that our AMA will encourage the FTC and the Department of Justice to
14 monitor insulin pricing and market competition and take enforcement actions as
15 appropriate. Relevant to encouraging the use of value-based contracts, Policy H-
16 110.986 outlines principles to guide the support of our AMA for value-based pricing
17 programs, initiatives and mechanisms for pharmaceuticals. Addressing anticompetitive
18 patent reforms, Policy H-110.987 states that our AMA will continue to support an
19 appropriate balance between incentives based on appropriate safeguards for innovation
20 on the one hand and efforts to reduce regulatory and statutory barriers to competition as
21 part of the patent system. The policy also states that our AMA encourages FTC actions
22 to limit anticompetitive behavior by pharmaceutical companies attempting to reduce
23 competition from generic manufacturers through manipulation of patent protections and
24 abuse of regulatory exclusivity incentives. Policy H-125.980 supports an abbreviated
25 pathway for biosimilar approval.

26
27 Your Reference Committee believes that our AMA must continue to place a high priority
28 on promoting prescription drug price transparency. However, your Reference Committee
29 believes that Resolution 818 and all amendments offered are already addressed by
30 existing AMA policy and ongoing advocacy efforts. As such, your Reference Committee
31 recommends that Policies H-110.987, H-110.984, H-110.986 and H-125.980 be
32 reaffirmed in lieu of Resolution 818.

33
34 H-110.987 Pharmaceutical Costs
35 1. Our AMA encourages Federal Trade Commission (FTC) actions to limit
36 anticompetitive behavior by pharmaceutical companies attempting to reduce
37 competition from generic manufacturers through manipulation of patent
38 protections and abuse of regulatory exclusivity incentives. 2. Our AMA
39 encourages Congress, the FTC and the Department of Health and Human
40 Services to monitor and evaluate the utilization and impact of controlled
41 distribution channels for prescription pharmaceuticals on patient access and
42 market competition. 3. Our AMA will monitor the impact of mergers and
43 acquisitions in the pharmaceutical industry. 4. Our AMA will continue to monitor
44 and support an appropriate balance between incentives based on appropriate
45 safeguards for innovation on the one hand and efforts to reduce regulatory and
46 statutory barriers to competition as part of the patent system. 5. Our AMA
47 encourages prescription drug price and cost transparency among pharmaceutical
48 companies, pharmacy benefit managers and health insurance companies. 6. Our
49 AMA supports legislation to require generic drug manufacturers to pay an
50 additional rebate to state Medicaid programs if the price of a generic drug rises

1 faster than inflation. 7. Our AMA supports legislation to shorten the exclusivity
2 period for biologics. 8. Our AMA will convene a task force of appropriate AMA
3 Councils, state medical societies and national medical specialty societies to
4 develop principles to guide advocacy and grassroots efforts aimed at addressing
5 pharmaceutical costs and improving patient access and adherence to medically
6 necessary prescription drug regimens. 9. Our AMA will generate an advocacy
7 campaign to engage physicians and patients in local and national advocacy
8 initiatives that bring attention to the rising price of prescription drugs and help to
9 put forward solutions to make prescription drugs more affordable for all patients.
10. Our AMA supports: (a) drug price transparency legislation that requires
11 pharmaceutical manufacturers to provide public notice before increasing the
12 price of any drug (generic, brand, or specialty) by 10% or more each year or per
13 course of treatment and provide justification for the price increase; (b) legislation
14 that authorizes the Attorney General and/or the Federal Trade Commission to
15 take legal action to address price gouging by pharmaceutical manufacturers and
16 increase access to affordable drugs for patients; and (c) the expedited review of
17 generic drug applications and prioritizing review of such applications when there
18 is a drug shortage, no available comparable generic drug, or a price increase of
19 10% or more each year or per course of treatment. 11. Our AMA advocates for
20 policies that prohibit price gouging on prescription medications when there are no
21 justifiable factors or data to support the price increase. 12. Our AMA will provide
22 assistance upon request to state medical associations in support of state
23 legislative and regulatory efforts addressing drug price and cost transparency.
24 (CMS Rep. 2, I-15; Reaffirmed in lieu of: Res. 817, I-16; Appended: Res. 201, A-
25 17; Reaffirmed in lieu of: Res. 207, A-17; Modified: Speakers Rep. 01, A-17;
26 Appended: Alt. Res. 806, I-17; Reaffirmed: BOT Rep. 14, A-18; Appended: CMS
27 Rep. 07, A-18)

28
29 H-110.984 Insulin Affordability

30 Our AMA will: (1) encourage the Federal Trade Commission (FTC) and the
31 Department of Justice to monitor insulin pricing and market competition and take
32 enforcement actions as appropriate; and (2) support initiatives, including those by
33 national medical specialty societies, that provide physician education regarding
34 the cost-effectiveness of insulin therapies. (CMS Rep. 07, A-18)

35
36 H-110.986 Incorporating Value into Pharmaceutical Pricing

37 1. Our AMA supports value-based pricing programs, initiatives and mechanisms
38 for pharmaceuticals that are guided by the following principles: (a) value-based
39 prices of pharmaceuticals should be determined by objective, independent
40 entities; (b) value-based prices of pharmaceuticals should be evidence-based
41 and be the result of valid and reliable inputs and data that incorporate rigorous
42 scientific methods, including clinical trials, clinical data registries, comparative
43 effectiveness research, and robust outcome measures that capture short- and
44 long-term clinical outcomes; (c) processes to determine value-based prices of
45 pharmaceuticals must be transparent, easily accessible to physicians and
46 patients, and provide practicing physicians and researchers a central and
47 significant role; (d) processes to determine value-based prices of
48 pharmaceuticals should limit administrative burdens on physicians and patients;
49 (e) processes to determine value-based prices of pharmaceuticals should
50 incorporate affordability criteria to help assure patient affordability as well as limit

1 system-wide budgetary impact; and (f) value-based pricing of pharmaceuticals
2 should allow for patient variation and physician discretion. 2. Our AMA supports
3 the inclusion of the cost of alternatives and cost-effectiveness analysis in
4 comparative effectiveness research. 3. Our AMA supports direct purchasing of
5 pharmaceuticals used to treat or cure diseases that pose unique public health
6 threats, including hepatitis C, in which lower drug prices are assured in exchange
7 for a guaranteed market size. (CMS Rep. 05, I-16; Reaffirmed in lieu of: Res.
8 207, A-17; Reaffirmed: CMS-CSAPH Rep. 01, A-17; Reaffirmed: CMS Rep. 07,
9 A-18)

10
11 H-125.980 Abbreviated Pathway for Biosimilar Approval

12 Our AMA supports FDA implementation of the Biologics Price Competition and
13 Innovation Act of 2009 in a manner that 1) places appropriate emphasis on
14 promoting patient access, protecting patient safety, and preserving market
15 competition and innovation; 2) includes planning by the FDA and the allocation of
16 sufficient resources to ensure that physicians understand the distinctions
17 between biosimilar products that are considered highly similar, and those that are
18 deemed interchangeable. Focused educational activities must precede and
19 accompany the entry of biosimilars into the U.S. market, both for physicians and
20 patients; and 3) includes compiling and maintaining an official compendium of
21 biosimilar products, biologic reference products, and their related
22 interchangeable biosimilars as they are developed and approved for marketing
23 by the FDA. (Res. 220, A-09; Reaffirmation A-11; Modified: CSAPH Rep. 1, I-11;
24 Modified: CSAPH Rep. 4, A-14)

25
26 (22) RESOLUTION 823 - MEDICARE CUTS TO RADIOLOGY
27 IMAGING

28 RECOMMENDATION:

29
30 Madam Speaker, your Reference Committee recommends
31 that Policy D-390.969 be reaffirmed in lieu of Resolution
32
33 823.

34 Resolution 823 asks that our AMA advocate for elimination of the Medicare differential
35 imaging payments for small practices versus facility payments, and for elimination of the
36 Medicare computed radiography (CR) payment reductions.

37
38 Your Reference Committee heard mixed testimony on Resolution 823. While testimony
39 was generally supportive of the first Resolve of the resolution, several speakers stressed
40 that existing policy, as well as Council on Medical Service Report 4 being considered at
41 this meeting, addresses its intent. Several speakers raised concerns with the second
42 Resolve of Resolution 823. Namely, a member of the Council on Medical Service
43 underscored that the time to weigh in on Medicare computed radiography payment
44 reductions has passed, since these reductions were set in statute two years ago
45 (Consolidated Appropriations Act of 2016). Also, testimony raised concerns that the
46 second Resolve has the potential to adversely affect other specialties, because if the
47 payment reductions to Medicare computed radiography were overturned, it would
48 require a pay-for, which would likely be a reduction to all physician services via the
49 Medicare conversion factor.

1 Your Reference Committee believes that both Resolves of Resolution 823 are already
2 addressed by existing policy, as well as Council on Medical Service Report 4 being
3 considered at this meeting. As such, your Reference Committee recommends the
4 reaffirmation of Policy D-390.969 in lieu of Resolution 823.

5

6 D-390.969 Parity in Medicare Reimbursement

7 Our AMA will continue its comprehensive advocacy campaign to: (1) repeal the
8 reductions in Medicare payment for imaging services furnished in physicians'
9 offices, as mandated by the Deficit Reduction Act of 2005; (2) pass legislation
10 allowing physicians to share in Medicare Part A savings that are achieved when
11 physicians provide medical care that results in fewer in-patient complications,
12 shorter lengths-of-stays, and fewer hospital readmissions; and (3) advocate for
13 other mechanisms to ensure adequate payments to physicians, such as balance
14 billing and gainsharing. (BOT Action in response to referred for decision Res.
15 236, A-06; Reaffirmation I-08; Modified: BOT Rep. 09, A-18)

16

1 Madam Speaker, this concludes the report of Reference Committee J. I would like to
2 thank Timothy Beittel, MD, Nitin Damle, MD, Florence Jameson, MD, Steve Lee, MD,
3 Adam Panzer, Susan Strate, MD, and all those who testified before the Committee. I
4 would also like to thank AMA staff: Courtney Perlino, MPP, Andrea Preisler, JD, and
5 Jane Ascroft, MPA.

Timothy Beittel, MD (Alternate)
North Carolina

Steve Lee, MD (Alternate)
American Society of Clinical Oncology

Nitin Damle, MD
American College of Physicians

Adam Panzer
Colorado

Florence Jameson, MD
Nevada

Susan Strate, MD (Alternate)
College of American Pathologists

Steven Chen, MD
American Society of Breast Surgeons
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (I-18)

Report of Reference Committee K

Darlyne Menscer, MD, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:

2 **RECOMMENDED FOR ADOPTION**

3

4

5 1. Resolution 901 – Support for Preregistration in Biomedical Research

6 2. Resolution 906 – Increased Access to Identification Cards for the Homeless

7 Population

8 3. Resolution 908 – Increasing Accessibility to Incontinence Products

9 4. Resolution 927 – Oppose FDA's Decision to Approve Primatene Mist HFA for

10 Over the Counter Use

11 **RECOMMENDED FOR ADOPTION AS AMENDED OR SUBSTITUTED**

12

13

14 5. Board of Trustees Report 12 – Information Regarding Animal-Derived

15 Medications

16 6. Council on Science and Public Health Report 1 – Improving Screening and

17 Treatment Guidelines for Domestic Violence Against Lesbian, Gay, Bisexual,

18 Transgender, Queer/Questioning, and Other Individuals

19 7. Council on Science and Public Health Report 2 – Improving FDA Expedited

20 Approval Pathways

21 8. Resolution 902 – Increasing Patient Access to Sexual Assault Nurse Examiners

22 9. Resolution 903 – Regulating Front-of-Package Labels on Food Products

23 10. Resolution 904 – Support for Continued 9-1-1 Modernization and the National

24 Implementation of Text-to-911 Service

25 11. Resolution 905 – Support Offering HIV Post Exposure Prophylaxis to all

26 Survivors of Sexual Assault

27 12. Resolution 911 – Regulating Tattoo and Permanent Makeup Inks

28 13. Resolution 912 – Comprehensive Breast Cancer Treatment

29 14. Resolution 913 – Addressing the Public Health Implications of Pornography

30 15. Resolution 916 – Ban on Tobacco Flavoring Agents with Respiratory Toxicity

31 16. Resolution 917 – Protect and Maintain the Clean Air Act

32 17. Resolution 918 – Allergen Labeling on Food Packaging

33 18. Resolution 920 – Continued Support for Federal Vaccination Funding

34 19. Resolution 921 – Food Environments and Challenges Accessing Healthy Food

35 20. Resolution 924 – Utilizing Blood from “Therapeutic” Donations

36 21. Resolution 926 – E-Cigarettes, Revisited

37 **RECOMMENDED FOR REFERRAL**

38

39

40 22. Resolution 915 – Mandatory Reporting

41 23. Resolution 919 – Opioid Mitigation

1 **RECOMMENDED FOR NOT ADOPTION**

2
3 24. Resolution 914 – Common Sense Strategy for Tobacco Control and Harm
4 Reduction

5

6 **RECOMMENDED FOR REAFFIRMATION IN LIEU OF**

7
8 25. Resolution 922 – Full Information on Generic Drugs
9 26. Resolution 923 – Scoring of Medication Pills

Resolutions not considered:

Resolution 907 – Developing Diagnostic Criteria and Evidence-Based Treatment Options for Problematic Pornography Viewing

Resolution 909 – Use of Person-Centered Language

Resolution 910 – Shade Structures in Public and Private Planning and Zoning Matters

1 (1) RESOLUTION 901 – SUPPORT FOR
2 PREREGISTRATION IN BIOMEDICAL RESEARCH

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 901 be adopted.

8
9 Resolution 901 asks that our American Medical Association support preregistration in order
10 to mitigate publication bias and improve the reproducibility of biomedical research.
11 (New HOD Policy)

12
13 Your Reference Committee heard testimony largely in support of this resolution, including on
14 behalf of the National Institutes of Health. Many who testified noted the need for negative data
15 and results to be published in journals for a complete picture of an evidence-base. These
16 results are not commonly published or made available because of the bias to publish positive
17 results. Many peer-reviewed journals have already adopted pre-registration. Additionally,
18 several noted that the pre-registration of research study protocols would ensure that
19 researchers maintain research integrity, and do not alter study design for more favorable
20 results. Some sentiment was expressed for broadening the concept beyond randomized
21 controlled trials. Your Reference Committee believes the current language is sufficient and
22 recommends that Resolution 901 be adopted.

23
24 (2) RESOLUTION 906 – INCREASED ACCESS TO
25 IDENTIFICATION CARDS FOR THE HOMELESS
26 POPULATION

27
28 RECOMMENDATION:

29
30 Madam Speaker, your Reference Committee recommends
31 that Resolution 906 be adopted.

32
33 Resolution 906 asks that our American Medical Association (AMA) recognize that among the
34 homeless population, a lack of identification card serves as a barrier to accessing medical
35 care as well as and fundamental services that support health and that our AMA support
36 legislative and policy changes that streamline, simplify, and reduce or eliminate the cost of
37 obtaining identification cards for the homeless population. (New HOD Policy)

38
39 Your Reference Committee heard testimony in strong support of this resolution. It was noted
40 that many persons who are homeless lack photo identification due to the difficulty of
41 maintaining important documents while homeless. People without photo identification have
42 difficulty accessing critical services and benefits, including health care. A proposed
43 amendment called for the development of model state legislation on this issue, but your
44 Reference Committee believes that because the policy changes relate to simplifying existing
45 processes and reducing or eliminating costs, this is not necessary. Therefore, your Reference
46 Committee recommends that Resolution 906 be adopted.

1 (3) RESOLUTION 908 – INCREASING ACCESSIBILITY TO
2 INCONTINENCE PRODUCTS

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 908 be adopted.

8
9 Resolution 908 asks that our American Medical Association support increased access to
10 affordable incontinence products. (New HOD Policy)

11
12 Your Reference Committee heard mostly supportive testimony for this item, emphasizing lack
13 of access to incontinence products as an important issue for patient health and safety. Some
14 support was offered for referral and for broadening the therapeutic target to include “bowel
15 and bladder management.” In order to focus on the most common condition and terminology,
16 your Reference Committee recommends that Resolution 908 be adopted as written.

17
18 (4) RESOLUTION 927 – OPPOSE FDA'S DECISION TO
19 APPROVE PRIMATENE MIST HFA FOR OVER THE
20 COUNTER USE

21
22 RECOMMENDATION A:

23
24 Madam Speaker, your Reference Committee recommends
25 that Resolution 927 be adopted in lieu of Policy H-115.972.

26
27 Resolution 927 asks that our American Medical Association send a letter to the US Food and
28 Drug Administration (FDA) expressing: 1) our strong opposition to FDA making the decision
29 to allow inhaled epinephrine to be sold as an over-the-counter medication without first soliciting
30 public input, and 2) our opposition to the approval of over-the-counter sale of inhaled
31 epinephrine as it is currently not a recommended treatment for asthma. (Directive to Take
32 Action).

33
34 Testimony voiced strong support for this resolution, opposing the return of an over-the-counter
35 formulation of an epinephrine inhaler for the treatment of mild, intermittent asthma. Comments
36 were directed to the belief that epinephrine is a potentially dangerous substance and its use
37 is not endorsed in any treatment guidelines for asthma. Many noted that inexpensive, over-
38 the-counter medications for asthma are a risk to patient safety. Your Reference Committee
39 agrees and recommends that Resolution 927 be adopted. Policy H-115.972 is in conflict with
40 this resolution. Therefore, we recommend that it be rescinded.

41
42 H-115.972, “Over-the-Counter Inhalers in Asthma”

43 Our AMA: (1) supports strengthening the product labeling for over-the-counter (OTC)
44 epinephrine inhalers to better educate users about patterns of inappropriate use; to include
45 clear statements that the use of OTC inhalers can be dangerous; to urge users to seek
46 medical care if symptoms do not improve or if they meet criteria for the presence of persistent
47 disease; and to encourage explicit discussions with physicians about dosage when these
48 products are used; (2) encourages the FDA to reexamine whether OTC epinephrine inhalers
49 should be removed from the market; and (3) In the event that these products continue to be
50 marketed OTC, further information should be obtained to determine whether OTC availability
51 is a risk factor for asthma morbidity and mortality.

1 (5) BOARD OF TRUSTEES REPORT 12 – INFORMATION
2 REGARDING ANIMAL-DERIVED MEDICATIONS

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that the recommendations in Board of Trustees Report 12
8 be amended by deletion to read as follows:

9
10 Animal-Derived Ingredients

11 Our AMA:

12 1. Urges ~~the U.S. Food and Drug Administration to require~~
13 manufacturers to include all ingredients and
14 components present in medical products on the product
15 label, including both active and inactive ingredients, and
16 denote any derived from an animal source. (New HOD
17 Policy)

18 2. Encourages cultural awareness regarding patient
19 preferences associated with medical products
20 containing active or inactive ingredients or components
21 derived from animal sources. (New HOD Policy)

22
23 RECOMMENDATION B:

24
25 Madam Speaker, your Reference Committee recommends
26 that the recommendations in Board of Trustees Report 12
27 be adopted as amended and the remainder of the report be
28 filed.

29
30 Board of Trustees Report 12, in response to Resolution 515-A-18, summarizes the issue of
31 animal-derived ingredients and current evidence related to animal-derived components of
32 medical products. Some chemical products used as inactive excipients for prescription drugs,
33 as well as some active prescription medications and also some surgical implants, dressings,
34 and mesh, are derived from animal sources. The consumption or use of such products may
35 be objectionable to certain religions or based on consumer choice. The Board of Trustees
36 recommends the following be adopted in lieu of Resolution 515-A-18, and the remainder of
37 the report be filed:

38 Animal-Derived Ingredients

39 Our AMA:

40 1. Urges the U.S. Food and Drug Administration to require manufacturers to
41 include all ingredients and components present in medical products on the
42 product label, including both active and inactive ingredients, and denote any
43 derived from an animal source. (New HOD Policy)

44 2. Encourages cultural awareness regarding patient preferences associated with
45 medical products containing active or inactive ingredients or components
46 derived from animal sources. (New HOD Policy)

47
48 Your Reference Committee heard limited and mixed testimony regarding this report
49 developed by the Board of Trustees. The FDA noted that it would require an enormous
50 undertaking for them to require manufacturers to include this information on product labels
51 and suggested urging manufacturers to include more informative labeling. Additional

1 testimony noted that determining the make-up of sourced inactive ingredients is a difficult task,
2 as was noted in the report. Your Reference Committee agrees that asking the FDA to take on
3 this issue is overly-burdensome. Therefore, your Reference Committee
4 recommends that the recommendations in Board of Trustees Report 12 be adopted as
5 amended.

6

7 (6) COUNCIL ON SCIENCE AND PUBLIC HEALTH REPORT
8 1 – IMPROVING SCREENING AND TREATMENT
9 GUIDELINES FOR DOMESTIC VIOLENCE AGAINST
10 LESBIAN, GAY, BISEXUAL, TRANSGENDER,
11 QUEER/QUESTIONING, AND OTHER INDIVIDUALS

12 RECOMMENDATION A:

13 Madam Speaker, your Reference Committee recommends
14 that recommendation 1 in Council on Science and Public
15 Health Report 1 be amended by addition and deletion to
16 read as follows:

17 Policy D-515.980, "Improving Screening and Treatment
18 Guidelines for ~~Domestic Intimate Partner~~ Violence Against
19 Lesbian, Gay, Bisexual, Transgender, Queer/Questioning,
20 and Other Individuals"

21 Our AMA will: (1) ~~study recent domestic violence data and~~
22 ~~the unique issues faced by the LGBTQ population; and (2)~~
23 promote crisis resources for LGBTQ patients that cater to
24 the specific needs of LGBTQ ~~victims~~ survivors of domestic
25 violence, (2) ~~encourage physicians to familiarize~~
26 ~~themselves with resources available in their communities for~~
27 ~~LGBTQ survivors of intimate partner violence (IPV), and (3)~~
28 ~~advocate for federal funding to support programs and~~
29 ~~services for survivors of IPV~~ ~~intimate partner violence that~~
30 ~~do not discriminate against underserved communities,~~
31 ~~including on the basis of sexual orientation and gender~~
32 ~~identity, and (4) encourage the dissemination of research to~~
33 ~~educate physicians and the community regarding the~~
34 ~~prevalence of IPV in the LGBTQ population, the accuracy of~~
35 ~~screening tools, effectiveness of early detection and~~
36 ~~interventions, as well as the benefits and harms of~~
37 ~~screening.~~ (Modify Current HOD policy)

38 RECOMMENDATION B:

39 Madam Speaker, your Reference Committee recommends
40 that the recommendations in Council on Science and Public
41 Health Report 1 be adopted as amended and the remainder
42 of the report be filed.

1 Council on Science and Public Health Report 1 is in response to Policy D-515.980 and notes
2 that the lifetime prevalence of IPV in the LGBTQ community is estimated to be comparable to
3 or higher than that among heterosexual couples. There is limited information available on the
4 aspects of IPV that are unique to same-sex relationships and the effects on LGBTQ survivors'
5 mental and physical health. Despite the limited research available on this topic, physicians
6 should be alert to the possibility of IPV among their LGBTQ patients and should familiarize
7 themselves with resources available in their communities for LGBTQ survivors of IPV. The
8 Council on Science and Public Health recommends that the following statements be adopted
9 and the remainder of the report be filed:

10 1. That Policy D-515.980, "Improving Screening and Treatment Guidelines for Domestic
11 Violence Against Lesbian, Gay, Bisexual, Transgender, Queer/Questioning, and Other
12 Individuals" be amended by addition and deletion to read as follows:

13 Our AMA will: (1) ~~study recent domestic violence data and the unique issues faced by~~
14 ~~the LGBTQ population; and (2) promote crisis resources for LGBTQ patients that~~
15 ~~cater to the specific needs of LGBTQ victims survivors of domestic violence, (2)~~
16 ~~encourage physicians to familiarize themselves with resources available in their~~
17 ~~communities for LGBTQ survivors of intimate partner violence, and (3) advocate for~~
18 ~~federal funding to support programs and services for survivors of intimate partner~~
19 ~~violence that do not discriminate against underserved communities, including on the~~
20 ~~basis of sexual orientation and gender identity.~~ (Modify Current HOD policy)

21 2. Our AMA encourages research on intimate partner violence in the LGBTQ community to
22 include studies on the prevalence, the accuracy of screening tools, effectiveness of early
23 detection and interventions, as well as the benefits and harms of screening. (New HOD
24 Policy)

25 3. That Policy H-160.991, "Health Care Needs of Lesbian, Gay, Bisexual, Transgender and
26 Queer Populations," be reaffirmed.

27 Our AMA will collaborate with our partner organizations to educate physicians
28 regarding: (i) the need for sexual and gender minority individuals to undergo regular
29 cancer and sexually transmitted infection screenings based on anatomy due to their
30 comparable or elevated risk for these conditions; and (ii) the need for comprehensive
31 screening for sexually transmitted diseases in men who have sex with men; (iii)
32 appropriate safe sex techniques to avoid the risk for sexually transmitted
33 diseases; and (iv) that individuals who identify as a sexual and/or gender minority
34 (lesbian, gay, bisexual, transgender, queer/questioning individuals) experience
35 intimate partner violence, and how sexual and gender minorities present with intimate
36 partner violence differs from their cisgender, heterosexual peers and may have unique
37 complicating factors. (Reaffirm HOD Policy)

38
39 Your Reference Committee heard testimony in strong support of this Council on Science and
40 Public Health report and its recommendations. While the Council found limited research on
41 this topic, the available data suggests that IPV in the LGBTQ community is comparable to or
42 higher than that among heterosexual couples. Physicians should be aware of the possibility
43 of IPV in their LGBTQ patients. Testimony called for an amendment to support education in
44 addition to research on this topic. CSAPH supported the amendment. Your Reference
45 Committee felt this amendment was more appropriate in the existing directive rather than in
46 the research policy. Therefore, your Reference Committee recommends adoption of the
47 report's recommendations as amended.

1 (7) COUNCIL ON SCIENCE AND PUBLIC HEALTH REPORT
2 – FDA EXPEDITED REVIEW PROGRAMS AND
3 PROCESSES

4
5 RECOMMENDATION A:

6
7 Madam Speaker, your Reference Committee recommends
8 that the recommendation in Council on Science and Public
9 Health Report 2 be amended by addition and deletion to
10 read as follows:

11
12 1(b) ~~the~~is evidence for drug approval should be evaluated
13 by the FDA, in consultation with its Advisory Committees
14 and expert extramural advisory bodies, as appropriate;

15
16 1(d) ~~confirmatory trials for drugs approved under expedited~~
17 ~~programs accelerated approval~~ should be planned and
18 underway at the time of expedited approval;

19
20 1(g) ~~FDA should make the annual summary of drugs~~
21 ~~approved under expedited programs more readily available~~
22 ~~and consider adding information on confirmatory clinical~~
23 ~~trials for such drugs to the drugs trials snapshot a simple~~
24 ~~system to assign a grade for each approval of prescription~~
25 ~~drugs occurring via expedited programs in order to signal~~
26 ~~and provide in a transparent manner, the quality of clinical~~
27 ~~trial evidence used to establish safety and effectiveness~~,
28 ~~and whether confirmatory trials are required for labeled~~
29 ~~indications~~.

30
31 RECOMMENDATION B:

32
33 Madam Speaker, your Reference Committee recommends
34 that the recommendation in Council on Science and Public
35 Health Report 2 be adopted as amended and the remainder
36 of the report be filed.

37
38 Council on Science and Public Health Report 2 is in response to Resolution 201-I-17 and
39 examines expedited FDA drug approval programs or processes in place in the United States,
40 including so-called fast track, accelerated approval, designated breakthrough therapies, and
41 “priority review” for drugs and biologics, and whether the operation of such programs needs
42 to be re-examined or modified. The Council on Science and Public Health recommends that
43 Policy H-100.992 be amended by addition and deletion to read as follows in lieu of Res-201-
44 I-17, and the remainder of the report be filed:

45 (1) Our AMA ~~reaffirms its supports~~ for the principles that:

46 (a) an FDA decision to approve a new drug, to withdraw a drug's approval, or to change
47 the indications for use of a drug must be based on sound scientific and medical
48 evidence derived from controlled trials and/or postmarket incident reports as provided
49 by statute;

50 (b) ~~the~~is evidence for drug approval should be evaluated by the FDA, in consultation
51 with its Advisory Committees and expert extramural advisory bodies;

1 (c) expedited programs for drug approval serve the public interest as long as sponsors
2 for drugs that are approved based on surrogate endpoints or limited evidence conduct
3 confirmatory trials in a timely fashion to establish the expected clinical benefit and
4 predicted risk-benefit profile;

5 (d) confirmatory trials for drugs approved under expedited programs should be
6 planned and underway at the time of expedited approval;

7 (e) the FDA should pursue having in place a systematic process to ensure that
8 sponsors adhere to their obligations for confirmatory trials, and Congress should
9 establish a firmer threshold to trigger expedited withdrawal when sponsors fail to fulfill
10 their postmarketing study obligations;

11 (f) any risk-benefit analysis or relative safety or efficacy judgments should not be
12 grounds for limiting access to or indications for use of a drug unless the weight of the
13 evidence from clinical trials and postmarket reports shows that the drug is unsafe
14 and/or ineffective for its labeled indications; and,

15 (g) FDA should consider a simple system to assign a grade for each approval of
16 prescription drugs occurring via expedited programs in order to signal, and provide in
17 a transparent manner, the quality of clinical trial evidence used to establish safety and
18 effectiveness, and whether confirmatory trials are required for labeled indications.

19 (2) The AMA believes that social and economic concerns and disputes per se should not
20 be permitted to play a significant part in the FDA's decision-making process in the
21 course of FDA devising either general or product specific drug regulation.

22 (3) It is the position of our AMA that the Food and Drug Administration should not permit
23 political considerations or conflicts of interest to overrule scientific evidence in making
24 policy decisions; and our AMA urges the current administration and all future
25 administrations to consider our best and brightest scientists for positions on advisory
26 committees and councils regardless of their political affiliation and voting history.
27 (Modify Current HOD Policy)

28
29 Generally supportive testimony was offered on Council on Science and Public Health Report
30 2 and the Council was thanked for developing an informative report. Testimony noted that
31 FDA labeling guidance is not supportive of using letters, or other grades to signify levels of
32 evidence, and that drugs approved under expedited programs or processes are ultimately
33 held to the same evidentiary standard for determining safety and effectiveness. The Council
34 offered amendments to reflect concerns expressed by the FDA and others. Your Reference
35 Committee agrees with amending the recommendation to reflect those viewpoints.

1 (8) RESOLUTION 902 – INCREASING PATIENT ACCESS
2 TO SEXUAL ASSAULT NURSE EXAMINERS

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 902 be amended by addition to read as
8 follows:

9
10 RESOLVED, That our American Medical Association
11 advocate for increased post-pubertal patient access to
12 Sexual Assault Nurse Examiners, and other trained and
13 qualified clinicians, in the emergency department for
14 medical forensic examinations. (New HOD Policy)

15
16 RECOMMENDATION B:

17
18 Madam Speaker, your Reference Committee recommends
19 that Resolution 902 be adopted as amended.

20
21 RECOMMENDATION C:

22
23 Madam Speaker, your Reference Committee recommends
24 that the title of Resolution 902 be changed to read as
25 follows:

26
27 INCREASING PATIENT ACCESS TO SEXUAL ASSAULT
28 MEDICAL FORENSIC EXAMINATIONS

29
30 Resolution 902 asks that our American Medical Association advocate for increased patient
31 access to Sexual Assault Nurse Examiners in the emergency department. (New HOD Policy)

32
33 Your Reference Committee heard testimony largely in support of this resolution. Many noted
34 that the registered nurses who have completed specialized education and clinical preparation
35 in the medical forensic care of an individual who has experienced sexual assault or abuse are
36 an important resource for these survivors. Additionally, several comments noted that other
37 clinicians, in addition to nurses, are trained and qualified to perform medical forensic
38 examinations. It was also stated that a medical forensic examination in a pre-pubertal patient
39 could unintentionally induce additional trauma and an amendment was offered to specify this
40 examination is optimal for post-pubertal patients. Your Reference Committee agrees that both
41 nurses and other clinicians who are trained and qualified to perform medical forensic
42 examinations are important for patient care and that the examination could be problematic for
43 pre-pubertal patients, who should receive specialized care, and therefore recommends that
44 Resolution 902 be adopted as amended.

1 (9) RESOLUTION 903 – REGULATING FRONT-OF-
2 PACKAGE LABELS ON FOOD PRODUCTS

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that the following alternate Resolution be adopted in lieu of
8 Resolution 903.

9
10 FRONT-OF-PACKAGE LABELS FOR FOOD PRODUCTS
11 WITH ADDED SUGARS

12
13 RESOLVED, That our AMA encourage the FDA to: (1)
14 develop front-of-package warning labels for foods that are
15 high in added sugars based on the established
16 recommended daily value and (2) limit the amount of added
17 sugars permitted in a food product containing front-of-
18 package health or nutrient content claims. (New HOD
19 Policy)

20
21 Resolution 903 asks that our American Medical Association support additional U.S. Food and
22 Drug Administration criteria that limit the amount of added sugar a food product can contain if
23 it carries any front-of-package label advertising nutritional or health benefits and that our AMA
24 support the use of front-of-package warning labels on foods that contain excess added sugar.
25 (New HOD Policy)

26
27 Your Reference Committee heard testimony supporting the intent of this resolution. Concerns
28 were raised regarding the lack of a standard for excess added sugar. The sponsor addressed
29 this issue by referencing the recommended daily value for added sugars. Testimony also
30 noted there are several initiatives underway at FDA related to this issue including: the revised
31 nutrition facts label requirements for added sugars that take effect in 2020 or 2021 depending
32 on the company's annual food sales, and the final proposed rule to update the regulatory
33 definition of the nutrient content claim "healthy" and how to depict "healthy" on the package.
34 Your Reference Committee believes that expressing support for increased transparency for
35 consumers related to high added sugars in food products is needed, but suggests alternate
36 language to streamline the policy.

1 (10) RESOLUTION 904 – SUPPORT FOR CONTINUED 9-1-1
2 MODERNIZATION AND THE NATIONAL
3 IMPLEMENTATION OF TEXT-TO-911 SERVICE

4
5 RECOMMENDATION A:

6
7 Madam Speaker, your Reference Committee recommends
8 that Resolution 904 be amended by addition and deletion,
9 to read as follows:

10
11 RESOLVED, That our American Medical Association
12 support the funding of ~~for the~~ ~~modernization of the~~ ~~for and modernization of~~ 9-1-1
13 infrastructure, including incorporation of text-to-911
14 technology. (New HOD Policy)

15
16 RECOMMENDATION B:

17
18 Madam Speaker, your Reference Committee recommends
19 that Resolution 904 be adopted as amended.

20
21 Resolution 904 asks that our American Medical Association support the funding of federal
22 grant programs for modernization of the 9-1-1 infrastructure, including incorporation of text to
23 911 technology. (New HOD Policy)

24
25 Your Reference Committee heard testimony largely in support of Resolution 904. Your
26 Reference Committee discussed that other funding, beyond federal grant programs, is likely
27 also needed. Therefore, your Reference Committee suggests a minor amendment to also
28 include support for additional avenues of funding and recommends adoption as amended.

29
30 (11) RESOLUTION 905 – SUPPORT OFFERING HIV POST
31 EXPOSURE PROPHYLAXIS TO ALL SURVIVORS OF
32 SEXUAL ASSAULT

33
34 RECOMMENDATION A:

35
36 Madam Speaker, your Reference Committee recommends
37 that first Resolve of Resolution 905 be amended by addition
38 and deletion to read as follows:

39
40 RESOLVED, That our American Medical Association (AMA)
41 ~~advocate for support~~ education of physicians about the
42 effective use of HIV Post-Exposure Prophylaxis (PEP) and
43 the U.S. PEP Clinical Practice Guidelines; (New HOD
44 Policy), and be it further

45
46 RECOMMENDATION B:

47
48 Madam Speaker, your Reference Committee recommends
49 that the second Resolve of Resolution 905 be amended by
50 addition and deletion to read as follows:

1 RESOLVED, That our AMA support increased access to,
2 and coverage for, PEP for HIV and, as well as enhanced
3 public education on its about the effective use of Post-
4 Exposure Prophylaxis for HIV; (New HOD Policy) and be it
5 further

6
7 RECOMMENDATION C:

8
9 Madam Speaker, your Reference Committee recommends
10 that the third Resolve of Resolution 905 be amended by
11 addition and deletion to read as follows:

12 RESOLVED, That our AMA amend policy H-20.900 by
13 insertion as follows:

14 H-20.900, "HIV, Sexual Assault, and Violence"
15 Our AMA believes that HIV testing and Post-Exposure
16 Prophylaxis (PEP) should be offered to all victims survivors
17 of sexual assault, who present within 72 hours of a
18 substantial exposure risk, that these victims survivors
19 should be encouraged to be retested in six months if the
20 initial test is negative, and that strict confidentiality of test
21 results be maintained. (Modify Current HOD Policy)

22
23 RECOMMENDATION D:

24
25 Madam Speaker, your Reference Committee recommends
26 that Resolution 905 be adopted as amended.

27 Resolution 905 asks that our American Medical Association (AMA) advocate for education of
28 physicians about the effective use of HIV Post-Exposure Prophylaxis (PEP) and the U.S. PEP
29 Clinical Practice Guidelines; that our AMA support increased public education about the
30 effective use of Post-Exposure Prophylaxis for HIV; and that our AMA amend policy H-20.900
31 by insertion as follows:

32 H-20.900, "HIV, Sexual Assault, and Violence"
33 Our AMA believes that HIV testing and Post-Exposure Prophylaxis (PEP) should be
34 offered to all victims survivors of sexual assault, that these victims survivors should be
35 encouraged to be retested in six months if the initial test is negative, and that strict
36 confidentiality of test results be maintained. (Modify Current HOD Policy)

37 Testimony strongly supported the intent of the resolution and the need to enhance education
38 and provide HIV prophylaxis in a timely fashion to survivors of sexual assault. Postexposure
39 prophylaxis (PEP) should be used only in emergency situations and must be started within 72
40 hours after a recent possible exposure to HIV. "Updated Guidelines for Antiretroviral
41 Postexposure" are available from the CDC along with an informational leaflet for patients
42 (Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—
43 United States). The importance of improving treatment in this area is based on available data
44 indicating a significant proportion of such victims are not offered treatment. Amendments were
45 suggested on enhancing public education, improving access and coverage, and clarifying that
46 treatment must be started within 72 hours to be effective. Your Reference Committee agrees
47 and recommends adoption with those amendments.

1 (12) RESOLUTION 911 – REGULATING TATTOO AND
2 PERMANENT MAKEUP INKS

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Policy H-440.909 be amended by addition to read as
8 follows:

9
10 1. The AMA encourages the state regulation of tattoo
11 artists and tattoo facilities to ensure adequate
12 procedures to protect the public health; and encourages
13 tattoo artists, tattoo facilities, and physicians to report all
14 adverse reactions associated with tattooing to the Food
15 and Drug Administration MedWatch program.

16
17 2. The AMA encourages manufacturers of tattoo inks to
18 provide a list of their ingredients to protect public health;

19
20 3. The AMA encourages tattoo artists and tattoo facilities
21 to obtain informed consent from their clients, that
22 includes potential risks, prior to performing a tattooing
23 procedure;

24
25 4. The AMA, in consultation with relevant stakeholders,
26 develop model state legislation for regulation of tattoo
27 artists and tattoo facilities to ensure adequate
28 procedures to protect the public health and safety.
29 (Modify HOD Policy)

30
31 RECOMMENDATION B:

32
33 Madam Speaker, your Reference Committee recommends
34 that Policy H-440.909, as amended, be adopted in lieu of
35 Resolution 911.

36
37 Resolution 911 asks that our American Medical Association encourage the Food and Drug
38 Administration to adopt regulatory standards for tattoo and permanent makeup inks that
39 include at minimum the disclosures expected for injectable drugs and cosmetics and mandate
40 that this information be available to both the body licensed to perform the tattoo and to the
41 person receiving the tattoo and that our AMA study the safety of any chemical in tattoo and
42 permanent makeup inks. (Directive to Take Action)

43
44 Your Reference Committee heard limited and mixed testimony regarding this Resolution.
45 Some stated that this is a critical need and others noted that the oversite of tattoo facilities is
46 regulated by states and this is not necessary. Still others noted that the agencies that regulate
47 the practice of tattooing need assistance. The authors of the resolution stated that informed
48 consent was an important component that was misunderstood in their originally submitted
49 resolution and submitted an alternate resolution that amends current policy; additional
50 testimony was supportive of this alternate resolution. Your Reference Committee agrees that

1 the alternate resolution amending current policy is appropriate and recommends that Policy
2 H-440.909 be adopted as amended.

3
4 (13) RESOLUTION 912 – COMPREHENSIVE BREAST
5 CANCER TREATMENT

6
7 RECOMMENDATION A:

8
9 Madam Speaker, your Reference Committee recommends
10 that Resolution 912 be amended by addition and deletion to
11 read as follows:

12
13 RESOLVED, That our American Medical Association
14 amend Policy H-55.973, "Breast Reconstruction," by
15 addition and deletion as follows:

16 Our AMA: (1) believes that reconstruction of the breast for
17 post-treatment rehabilitation of patients the postmastectomy
18 cancer post treatment patient with in situ or invasive breast
19 neoplasm should be considered reconstructive surgery
20 rather than aesthetic surgery; (2) supports education for
21 physicians and breast cancer patients on breast
22 reconstruction and its availability; (3) recommends that third
23 party payers provide coverage and reimbursement for
24 medically necessary breast cancer treatments including but
25 not limited to prophylactic contralateral mastectomy and/or
26 salpingo-oophorectomy; and (4) recognizes the validity of
27 contralateral breast procedures needed for the achievement
28 of symmetry in size and shape, and urges recognition of
29 these ancillary procedures by Medicare and all other third
30 parties for reimbursement when documentation of medical
31 necessity is provided. (Modify Current HOD Policy)

32
33 RECOMMENDATION B:

34
35 Madam Speaker, your Reference Committee recommends
36 that Resolution 912 be adopted as amended.

37
38 Resolution 912 asks that our American Medical Association amend Policy H-55.973, "Breast
39 Reconstruction," by addition and deletion as follows:

40 Our AMA: (1) believes that reconstruction of the breast for rehabilitation of the
41 postmastectomy cancer post treatment patient with in situ or invasive breast neoplasm
42 should be considered reconstructive surgery rather than aesthetic surgery; (2)
43 supports education for physicians and breast cancer patients on breast reconstruction
44 and its availability; (3) recommends that third party payers provide coverage and
45 reimbursement for medically necessary breast cancer treatments including but not
46 limited to prophylactic contralateral mastectomy and/or oophorectomy; and (4)
47 recognizes the validity of contralateral breast procedures needed for the achievement
48 of symmetry in size and shape, and urges recognition of these ancillary procedures by
49 Medicare and all other third parties for reimbursement when documentation of medical
50 necessity is provided. (Modify Current HOD Policy)

1 Your Reference Committee heard extensive supportive testimony for this resolution and a
2 minor amendment that was proposed. Your Reference Committee supports the amendments
3 and has also chosen to alter the policy slightly to use person-first language. Therefore, your
4 Reference Committee recommends that Resolution 912 be adopted as amended.

5
6 (14) RESOLUTION 913 – ADDRESSING THE PUBLIC
7 HEALTH IMPLICATIONS OF PORNOGRAPHY

8
9 RECOMMENDATION A:

10
11 Madam Speaker, your Reference Committee recommends
12 that Resolution 913 be amended by deletion to read as
13 follows:

14
15 RESOLVED, That our American Medical Association
16 support efforts to mitigate the negative public health impacts
17 of pornography as it relates to vulnerable populations,
18 ~~including but not limited to women and children.~~ (New HOD
19 Policy)

20
21 RECOMMENDATION B:

22
23 Madam Speaker, your Reference Committee recommends
24 that Resolution 913 be adopted as amended.

25
26 Resolution 913 asks that our American Medical Association support efforts to mitigate the
27 negative public health impacts of pornography as it relates to vulnerable populations, including
28 but not limited to women and children. (New HOD Policy)

29
30 A concern was expressed about use of the term “vulnerable” and whether it could be
31 considered limiting and some sentiment was offered for referral. Otherwise, testimony was
32 broadly supportive and noted the need to address the links between pornography, behavior,
33 and sex trafficking. Your Reference Committee concurs with the general support offered for
34 this resolution, but believes that truncating the language after populations allows for a more
35 inclusive approach.

1 (15) RESOLUTION 916 – BAN ON TOBACCO FLAVORING
2 AGENTS WITH RESPIRATORY TOXICITY

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Policy H-495.971 be amended to read as follows:

8
9 H-495.971 Opposition to Addition of Flavors to Cigarettes
10 Tobacco Products

11 Our AMA: (1) supports state and local legislation to prohibit
12 the sale or distribution of flavored tobacco products; and (2)
13 urges local and state medical societies and federation
14 members to support state and local legislation to prohibit the
15 sale or distribution of flavored tobacco products; and (3)
16 encourages the FDA to prohibit the use of flavoring agents
17 in tobacco products, which includes electronic nicotine
18 delivery systems.

19
20 RECOMMENDATION B:

21
22 Madam Speaker, you Reference Committee recommends
23 that Policy H-495.971 be adopted as amended in lieu of
24 Resolution 916.

25 Resolution 916 asks that our American Medical Association call for the immediate ban on
26 flavoring agents in electronic nicotine delivery systems (ENDS) and other tobacco products
27 that have known respiratory toxicity including but not limited to diacetyl, 2,3 pentanedione,
28 acetoin, cinnamaldehyde, benzaldehyde, eugenol, vanillin/ethyl vanillin, and menthol and that
29 the AMA urge the U.S. Food and Drug Administration (FDA) to require comprehensive testing
30 of flavoring agents used in ENDS and other tobacco products to assess the potential negative
31 health effects of chronic exposure to these flavoring agents. (Directive to Take Action)

32
33 Your Reference Committee heard testimony both in support of and in opposition to Resolution
34 916. While the intent of the resolution was supported, it was noted that existing policy broadly
35 supports banning flavors in electronic cigarettes, particularly those that appeal to youth. It was
36 felt by some that focusing on eliminating flavors with known respiratory toxicity would be taking
37 a step backwards, as not all toxicity is known or can be easily assessed. Your Reference
38 Committee agreed that a strong statement calling for a ban on the use of flavoring agents in
39 tobacco products was warranted. Therefore, your Reference Committee recommends
40 amending existing policy as outlined.

1 (16) RESOLUTION 917 – PROTECT AND MAINTAIN THE
2 CLEAN AIR ACT

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 917 be amended by addition and deletion to
8 read as follows:

9
10 RESOLVED, That our American Medical Association (AMA) oppose legislative or regulatory changes provisions of the Affordable Clean Energy proposed rule that would allow power plants to avoid complying with new source review requirements to install air pollution control equipment when annual pollution emissions increase (New HOD Policy); and be it further

11
12
13
14
15
16
17
18 RESOLVED, That our AMA ~~send a letter to the Environmental Protection Agency (EPA) work with other organizations to promote a public relations campaign, strongly expressing our opposition to EPA's Affordable Clean Energy rule and its proposed amendments of the New Source Review requirements under the Clean Air Act.~~ (Directive to Take Action)

19
20
21
22
23
24
25 RECOMMENDATION B:

26
27
28 Madam Speaker, your Reference Committee recommends
29 that Resolution 917 be adopted as amended.

30
31 Resolution 917 asks that our American Medical Association (AMA) oppose provisions of the Affordable Clean Energy proposed rule that would allow power plants to avoid complying with new source review requirements to install air pollution control equipment when annual pollution emissions increase and that our AMA send a letter to the Environmental Protection Agency (EPA) expressing our opposition to EPA's Affordable Clean Energy rule and its proposed amendments of the New Source Review requirements under the Clean Air Act. (Directive to Take Action)

32
33
34
35
36
37
38
39 Testimony strongly supported the intent of this resolution. The value of a letter was questioned given the deadline has passed for submission of comments on the Affordable Clean Energy rule, and the AMA has already signed on to such a letter as part of its participation in the Federation-based Climate Change Consortium. Instead, it was suggested that some sort of public campaign was necessary, a concept that received considerable support. A suggestion also was made to broaden the policy to express more general opposition to potential legislative or regulatory efforts intended to weaken provisions in the Clean Energy Act. Your Reference Committee agrees with the suggested amendments.

1 (17) RESOLUTION 918 – ALLERGEN LABELING ON FOOD
2 PACKAGING

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 918 be amended by addition and deletion to
8 read as follows:

9
10 RESOLVED, That our American Medical Association
11 ~~petition the Food and Drug Administration encourage food~~
12 ~~manufacturers to pursue more obvious labeling on food~~
13 ~~packaging distinctions between products that contains~~
14 ~~the eight most common food allergens identified in the Food~~
15 ~~Allergen Labeling and Consumer Protection Act and~~
16 ~~products that do not contain these allergens : milk, eggs,~~
17 ~~peanuts, tree nuts, wheat, soy, fish and crustacean shellfish.~~
18 (Directive to Take Action)

19
20 RECOMMENDATION B:

21
22 Madam Speaker, your Reference Committee recommends
23 that Resolution 918 be adopted as amended.

24
25 Resolution 918 asks that our American Medical Association petition the Food and Drug
26 Administration to pursue more obvious labeling on food packaging containing the eight most
27 common food allergens: milk, eggs, peanuts, tree nuts, wheat, soy, fish and crustacean
28 shellfish. (Directive to Take Action)

29
30 Your Reference Committee heard limited testimony in support of this resolution. The FDA
31 already enforces the Food Allergen Labeling and Consumer Protection Act, which requires
32 food labels to clearly identify the food source names of any ingredients that are one of the
33 major food allergens. However, product packaging developed by food manufacturers could
34 be improved to ensure that similar products that contain and do not contain common food
35 allergens are not confused by consumers. Your Reference Committee removed the specific
36 list of allergens should the FDA update that list in the future to include additional allergens (i.e.
37 sesame). Therefore, your Reference Committee recommends that Resolution 918 be adopted
38 as amended.

1 (18) RESOLUTION 920 – CONTINUED SUPPORT FOR
2 FEDERAL VACCINATION FUNDING

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Policy H-440.928 (3) be amended in lieu of Resolution
8 920 to read as follows:

9
10 H-440.928 Update on Immunizations and Vaccine
11 Purchases

12
13 Our AMA: (3) supports will release a public statement and
14 actively advocate for increased federal funding for vaccines,
15 including activities funded through Section 317 of the Public
16 Health Service Act, which supports purchasing vaccines
17 and implementing the national vaccine strategy, and
18 includes monies for education of the American public
19 about the importance of immunization, education and
20 training for health professionals, and for support to state and
21 local governments to remove barriers to effective
22 immunization.

23
24 RECOMMENDATION B:

25
26 Madam Speaker, your Reference Committee recommends
27 that Policy H-440.928, as amended, be adopted in lieu of
28 Resolution 920.

29
30 Resolution 920 asks that our American Medical Association release a public statement of
31 support for federal vaccination funding efforts such as Section 317, and actively advocate for
32 sustained funding. (Directive to Take Action)

33
34 Your Reference Committee heard testimony in strong support of federal funding for vaccines
35 through Section 317 of the Public Health Service Act. It was asked that the resolution be
36 amended to define the Section 317 Immunization Program. Since existing policy addresses
37 funding for vaccines and the activities funded through the Section 317 immunization program,
38 your Reference Committee believes that amending this policy was the best course of action.
39 Therefore, your Reference Committee recommends adopting existing policy as amended.

1 (19) RESOLUTION 921 – FOOD ENVIRONMENTS AND
2 CHALLENGES ACCESSING HEALTHY FOOD

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 921 be amended by addition and deletion to
8 read as follows:

9
10 RESOLVED, That our American Medical Association ~~work~~
11 ~~with encourage the U.S. Department of Agriculture and~~
12 ~~appropriate stakeholders to advocate for the study of the~~
13 ~~national prevalence, and impact, and solutions to the~~
14 ~~problems~~ of food mirages, food swamps, and food oases as
15 food environments distinct from food deserts. (Directive to
16 Take Action)

17
18 RECOMMENDATION B:

19
20 Madam Speaker, your Reference Committee recommends
21 that Resolution 921 be adopted as amended.

22
23 Resolution 921 asks that our American Medical Association work with appropriate
24 stakeholders to advocate for the study of the national prevalence and impact of food mirages,
25 food swamps, and food oases as food environments distinct from food deserts. (Directive to
26 Take Action)

27
28 Your Reference Committee heard testimony in strong support of this resolution. Food
29 environments include the food available in our day-to-day environments and are a determinant
30 of what we eat. Differences in income, education, and nutritional knowledge are major factors
31 that shape our eating habits and impact our health. While many resources are available
32 addressing access and affordability of healthy food, the U.S. Department of Agriculture's most
33 recent report on "Access to Affordable and Nutritious Food: Measuring and Understanding
34 Food Deserts and their Consequences" was from 2009. Your Reference Committee believes
35 that an update of this report is warranted and that the United States Department of Agriculture
36 is in the best position to conduct this study with input from stakeholders. The sponsor offered
37 an amendment to include the identification of solutions to this problem. Your Reference
38 Committee supports this amendment.

1 (20) RESOLUTION 924 – UTILIZING BLOOD FROM
2 "THERAPEUTIC" DONATIONS

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 924 be amended by addition and deletion to
8 read as follows:

9
10 RESOLVED, that our American Medical Association
11 encourage advocate for CMS the U.S. Food and Drug
12 Administration to engage in dialogue with the American
13 Association of Blood Banks and relevant stakeholders~~Red~~
14 ~~Cross to reanalyze their therapeutic phlebotomy policies on~~
15 ~~variances, donor eligibility criteria, to accept blood from a~~
16 ~~broader category of individuals, including but not limited to~~
17 ~~hereditary hemochromatosis. (New HOD Policy)~~

18
19 RECOMMENDATION B:

20
21 Madam Speaker, your Reference Committee recommends
22 that Resolution 924 be adopted as amended.

23
24 Resolution 924 asks that our American Medical Association advocate for CMS to engage in
25 dialogue with Red Cross to reanalyze their donor eligibility criteria, to accept blood from a
26 broader category of individuals, including but not limited to hereditary hemochromatosis.
27 (Directive to Take Action)

28
29 Your Reference Committee heard testimony largely in support of the intent of this resolution.
30 Testimony noted that CMS is not the appropriate organization to undertake this ask; the FDA
31 is the agency responsible for regulations regarding blood donation. Testimony also noted that
32 there are several other organizations besides the American Red Cross who perform
33 therapeutic blood donations, and this should be reflected in the statement. Those who testified
34 overwhelmingly noted that the ability to utilize blood donations from a larger cohort of
35 individuals would aid in the alleviation of blood shortages. Your Reference Committee agrees
36 and recommends that Resolution 924 be adopted as amended.

1 (21) RESOLUTION 926 – E-CIGARETTES, REVISITED
2

3 RECOMMENDATION A:
4

5 Madam Speaker, your Reference Committee recommends
6 that Resolution 926 be amended by addition and deletion to
7 read as follows:

8 RESOLVED, That our American Medical Association
9 recognize the use of e-cigarettes and vaping as an urgent
10 public health crisis epidemic and actively work with the Food
11 and Drug Administration and other relevant stakeholders to
12 counteract the marketing and use of addictive e-cigarette
13 and vaping devices, including but not limited to bans and
14 strict restrictions on marketing to minors under the age of
15 21. (Directive to Take Action)

16 RECOMMENDATION B:
17

18 Madam Speaker, your Reference Committee recommends
19 that Resolution 926 be adopted as amended.

20 RECOMMENDATION C:
21

22 Madam Speaker, your Reference Committee recommends
23 that the title of Resolution 924 be changed to read as
24 follows:

25 ADDRESSING THE PUBLIC HEALTH EPIDEMIC OF E-
26 CIGARETTES
27

28 Resolution 926 asks that our American Medical Association recognize the use of e-cigarettes
29 and vaping as an urgent public health crisis and actively work with the Food and Drug
30 Administration and other relevant stakeholders to counteract the marketing and use of
31 addictive e-cigarette and vaping devices, including but not limited to bans and strict restrictions
32 on marketing to minors under the age of 21. (Directive to Take Action)

33 Your Reference Committee heard testimony unanimously supportive of this resolution. A
34 minor amendment was offered changing the terminology from “public health crisis” to “public
35 health epidemic.” Your Reference Committee agrees with this change as the FDA has recently
36 recognized the use of e-cigarettes among teens as an epidemic. Therefore, your Reference
37 Committee recommends that Resolution 926 be adopted as amended.

1 (22) RESOLUTION 915 – MANDATORY REPORTING
2

3 RECOMMENDATION:

5 Madam Speaker, your Reference Committee recommends
6 that Resolution 915 be referred.

8 Resolution 915 asks that our American Medical Association oppose mandated reporting of
9 entire classes of patients and specific diagnoses unless compelling evidence exists to
10 demonstrate that a serious public health and/or safety risk will be mitigated as a result of such
11 reporting. (New HOD Policy)

13 Testimony on Resolution 915 was strongly in support of referral. It was noted that public health
14 surveillance is an essential public health function that has traditionally relied on health care
15 providers, hospitals, and laboratories to report to public health agencies specific conditions or
16 outbreaks that may impact the broader population. It was also noted that efforts are underway
17 to implement electronic case reporting, by which cases of reportable conditions are
18 automatically generated from EHRs and transmitted to public health agencies for review and
19 action. It was clear that the benefits of public health reporting need to be balanced against the
20 burden that mandatory reporting places on physicians. Due to the complex nature of this
21 issue, your Reference Committee agrees with referral.

22 (23) RESOLUTION 919 – OPIOID MITIGATION
23

24 RECOMMENDATION:

27 Madam Speaker, your Reference Committee recommends
28 that Resolution 919 be referred.

30 Resolution 919 asks that our American Medical Association review the following opioid
31 mitigation strategies based on their effectiveness in Huntington, WV, and Clark County, IN,
32 and provide feedback concerning their utility in dealing with opioids:

- 33 (1) The creation of an opioid overdose team that decreases the risk of future overdose
34 and overdose death, increases access to opioid-related services and increases the
35 likelihood that an individual will pursue drug rehabilitation.
- 36 (2) A needle exchange program that is open multiple days a week and is mobile offers not
37 only a source for needles but also Narcan, other supplies, health care and information.
- 38 (3) The creation of a drug court that allows a judge to have greater flexibility in determining
39 the legal consequences of an arrest for an opioid-related crime. It also allows for the
40 judicial patience necessary to deal with the recidivism of this population.
- 41 (4) Offering more acute-care inpatient drug rehab beds, although those ready for
42 treatment need to be willing to travel significant distances to get to a treatment bed.
- 43 (5) Make available Narcan intranasal spray OTC through pharmacies and the syringe
44 exchange, overdose team, etc.
- 45 (6) Encourage prevention education in K-12 programs that uses multiple media with anti-
46 drug messaging delivered in the school system but also in the home. (Directive to Take
47 Action)

48 Extensive testimony reflected the continuing concerns about opioid-related morbidity and
49 mortality and the fact that numerous community, state, federal, hospital and healthcare
50 system, and other private and public initiatives have been undertaken or are underway to

1 combat the epidemic, including many that are aligned with the focus areas noted in this
2 resolution. The AMA has already evaluated many of these approaches in reports to the House
3 of Delegates and has extensive policy related to opioids, overdose, pain management,
4 naloxone, drug courts, needle exchange, safe injection facilities, and education on risk
5 mitigation and pain care. The AMA also has formed a federation-based Opioid Task Force
6 and more recently a Pain Care Task Force. The AMA also hosts an end-the-opioid-epidemic
7 website that maintains a repository of state and medical specialty society resources at the
8 intersection of pain, opioids, and addiction. These activities will continue for the foreseeable
9 future. Because of the multitude of parallel efforts, strong sentiment was expressed for a need
10 to evaluate effective mitigation approaches and to provide practical guidance on best
11 practices around the nation. Ultimately, because of the complexity of this issue your Reference
12 Committee recommends referral, which would allow for a coordinated AMA
13 effort to be implemented.

14

15 (24) RESOLUTION 914 – COMMON SENSE STRATEGY FOR
16 TOBACCO CONTROL AND HARM REDUCTION

17

18 RECOMMENDATION:

19

20 Madam Speaker, your Reference Committee recommends
21 that Resolution 914 not be adopted.

22

23 Resolution 914 asks that our American Medical Association advocate for a “protect adult choice
24 and youth’s health” “common sense” tobacco strategy (with a report back to the House of
25 Delegates annually) under which:

- 26 • Current educational, promotional and policy initiatives (e.g. taxation) to reduce the use
27 of tobacco products by inhalation and orally would continue, including advocating for
28 the prohibition of the sale of ALL nicotine containing products to individuals under 21
29 years unless via prescription for medical purposes.
- 30 • E-cigarettes (non-tobacco products containing nicotine) would be accessible at an
31 affordable price to adults who wish to use them, and would be available to individuals
32 below 21 years of age only as part of state sanctioned tobacco cessation activities.
33 States and local jurisdictions would be free to require vendors to post warnings
34 regarding the possible health risks of the use of nicotine inhalation products.
- 35 • Non-nicotine, non-drug containing vaping and other inhalation products would not be
36 considered tobacco products, but would be monitored by state and local jurisdictions
37 as any other personal use product regarding safety and public accommodation. (New
38 HOD Policy)

39

40 Your Reference Committee heard testimony mostly in opposition to Resolution 914. The
41 Council on Science and Public Health testified that based on a recent review of the evidence,
42 their report adopted by the House of Delegates at A-18 concluded that the use of electronic
43 cigarettes is not harmless and significant concerns exist that novel, non-combustible products
44 may pose a significant threat to tobacco cessation and prevention efforts. Furthermore,
45 electronic cigarettes use among youth and young adults is a public health concern. Available
46 data suggest that youth who use electronic cigarettes are more likely to smoke combustible
47 cigarettes. While there was support for prohibiting the sale of nicotine products to individuals
48 under the age of 21, that is existing policy. Therefore, your Reference Committee
49 recommends that Resolution 914 not be adopted.

1 (25) RESOLUTION 922 – FULL INFORMATION ON GENERIC
2 DRUGS

3 RECOMMENDATION:

4
5 Madam Speaker, your Reference Committee recommends
6 that Policies H-125.981 and H-125.984 be reaffirmed in lieu
7
8 of Resolution 922.

9
10 Resolution 922 asks that American Medical Association advocate that generic drugs have an
11 FDA-approved package insert available when dispensed that discloses active and inactive
12 ingredients and clear language with bio-equivalent data as compared to parent branded drug.
13 (Directive to Take Action)

14
15 Limited testimony was offered on this resolution. Testimony from the Council on Science and
16 Public health emphasized the two previous reports authored by the Council on this topic, and
17 the fact that a common misconception exists that the average serum values between the
18 brand and generic equivalents can vary by a factor of -20 to +25%, which could lead to large
19 differences between multisource products. When evaluating the bioequivalence of a generic
20 product for approval, results are analyzed according to whether the generic or "test" product,
21 when substituted for the brand-name or "reference product," is significantly less bioavailable,
22 and alternatively, whether the brand-name product, when substituted for a generic product, is
23 significantly less bioavailable (that is, compared by using the two 1-sided tests). By
24 convention, all data are expressed as a ratio of the average response (area under the curve
25 and serum concentration maximum) for test versus the reference product, so the limit
26 expressed in the second analysis is 125% (the reciprocal of 80%). Tests are carried out using
27 an analysis of variance and calculating a 90% confidence interval (CI) for the average of each
28 pharmacokinetic parameter, which must be entirely within the 80% to 125% boundaries. The
29 width of the Confidence Interval reflects, in part, the within-subject variability of the test and
30 reference products. When applying the required statistical criteria to bioequivalence studies,
31 generic products whose mean arithmetic bioavailability parameters differ by more than ~5%
32 from the reference product begin failing the Confidence Interval requirement. Accordingly,
33 your Reference Committee does not believe the asks of this resolution would provide
34 meaningful information and recommends reaffirmation of existing policy.

35
36 Policies recommended for reaffirmation:

37
38 H-125.981, "Generic Medications"

39 Our AMA encourages the Food and Drug Administration to maintain standards and criteria
40 used for approving generic medications to ensure bioequivalence under various conditions
41 and in relevant patient populations.

1 H-125.984, "Generic Drugs"

2 Our AMA believes that:

- 3 (1) Physicians should be free to use either the generic or brand name in prescribing drugs for
4 their patients, and physicians should supplement medical judgments with cost
5 considerations in making this choice.
- 6 (2) It should be recognized that generic drugs frequently can be less costly alternatives to
7 brand-name products.
- 8 (3) Substitution with Food and Drug Administration (FDA) "B"-rated generic drug products
9 (i.e., products with potential or known bioequivalence problems) should be prohibited by
10 law, except when there is prior authorization from the prescribing physician.
- 11 (4) Physicians should report serious adverse events that may be related to generic
12 substitution, including the name, dosage form, and the manufacturer, to the FDA's
13 MedWatch program.
- 14 (5) The FDA, in conjunction with our AMA and the United States Pharmacopoeia, should
15 explore ways to more effectively inform physicians about the bioequivalence of generic
16 drugs, including decisional criteria used to determine the bioequivalence of individual
17 products.
- 18 (6) The FDA should fund or conduct additional research in order to identify the optimum
19 methodology to determine bioequivalence, including the concept of individual
20 bioequivalence, between pharmaceutically equivalent drug products (i.e., products that
21 contain the same active ingredient(s), are of the same dosage form, route of
22 administration, and are identical in strength).
- 23 (7) The Congress should provide adequate resources to the FDA to continue to support an
24 effective generic drug approval process.

25
26 (26) RESOLUTION 923 – SCORING OF MEDICATION PILLS

27
28 RECOMMENDATION:

29
30 Madam Speaker, your Reference Committee recommends
31 that Policy H-115.973 be reaffirmed in lieu of Resolution
32 923.

33
34 Resolution 923 asks that our American Medical Association advocate that the FDA require
35 scoring of all tablets and pills depending on their composition, so that the patient may be able
36 to dose adjust their medication number requirement as prescribed by their physician at a lower
37 cost to the patient. (Directive to Take Action)

38
39 Your Reference Committee heard mixed testimony on this resolution. Several spoke in
40 support and noted that cost issues necessitate the scoring of medications. Others spoke in
41 opposition noting that some medications cannot be split because of safety reasons or because
42 of composition, for example oral contraceptives. The Council on Science and Public Health
43 noted that the FDA currently considers medication splitting during the drug approval process
44 for the evaluation of safety issues and has also provided guidance for manufacturers
45 regarding what criteria should be met when evaluating and labeling tablets that have been
46 scored. Because the FDA already has a framework for manufacturers in place on this issue
47 and because AMA has policy urging manufacturers to score medications when appropriate,
48 your Reference Committee feels that reaffirmation of current AMA policy H-115.973 in lieu of
49 this resolution is appropriate.

1 Policy recommended for reaffirmation:
2
3 H-115.973, "Medication Scoring"
4 Our AMA:
5 (1) recommends to pharmaceutical manufacturers that, when appropriate, tablets be
6 scored on both sides and so constructed that they will more readily divide in half and not
7 fragment upon attempts at division; and
8 (2) opposes third party policies that mandate the use of pill-splitting or pill-breaking to
9 reduce pharmaceutical or healthcare costs without proper input from the pharmaceutical
10 manufacturers and practicing physicians.

1 Madam Speaker, this concludes the report of Reference Committee K. I would like to thank
2 Robert L. Allison, MD, Daniel B. Kimball, Jr, MD, Sarah Marsicek, MD, Daniel M. Meyer, MD,
3 Reid Orth, MD, William S. Pease, MD, and all those who testified before the Committee.
4 Additionally, I would like to thank our AMA staff, especially Barry Dickinson, who is serving on
5 his 44th and final Reference Committee.

Robert L. Allison, MD (Alternate)
South Dakota State Medical Association

Dan M. Meyer, MD
American Association for Thoracic
Surgery

Daniel B. Kimball, Jr, MD
Pennsylvania Medical Society

Reid Orth, MD (Alternate)
American College of Emergency
Physicians

Sarah Marsicek, MD
Sectional Resident and Fellow

William S. Pease, MD
American Association of Neuromuscular
& Electrodiagnostic Medicine

Darlyne Menscer, MD
North Carolina Medical Society
Chair